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Abstract 
 
 
This study describes the cloning, expression, purification, biophysical 
characterisation and crystallisation of DR_1146; a putative general stress protein 
from the extremophilic bacterium Deinococcus radiodurans (R1).  
The extraordinary ability of D. radiodurans to resist mutation or apoptosis on 
exposure to high does of ionising radiation has formed the basis of a structural 
genomics project underway at the European Synchrotron Radiation Facility 
(ESRF), Grenoble, France. The work presented in this study forms part of the 
ESRF’s D. radiodurans initiative, and was funded by the Biotechnology and 
Biological Sciences Research Council (BBSRC) and the ESRF as an Industrial 
Cooperative Award in Science and Engineering (CASE) PhD studentship. A period 
of one year was spent on secondment at the ESRF, working within the 
Macromolecular Crystallography Group.  
Several constructs of the dr_1146 gene have been successfully overexpressed in 
E. coli cells to give high yields of target protein. Purification by immobilised 
metal affinity chromatography (IMAC) was facilitated by the incorporation of a 
6xHis tag and supplemented by a final gel filtration step. Although high purity 
levels were achieved, imaging by SDS PAGE analysis identified that DR_1146 was 
susceptible to stringent proteolysis. It is thought that initial crystallisation trials 
were unsuccessful due to inhomogeneity of the sample caused by reported 
degradation of the target protein. 
Biophysical characterisation of DR_1146 by isothermal titration calorimetry (ITC) 
and fluorescence spectroscopy (FS) identified a moderate affinity of 4 11  M for 
the flavin molecules, riboflavin, flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD). Differential scanning calorimetry (DSC) and circular 
dichroism (CD) experiments demonstrated an increase in chemical and thermal 
stability of the protein on binding to the flavin molecule, FMN.  
Analytical ultracentrifugation (AUC) and Nuclear magnetic resonance (NMR) 
spectroscopy were employed to investigate the solution behaviour of DR_1146 in 
the presence of FMN. AUC results uncovered a monomer dimer equilibrium; with 
DR_1146 self associating to form a dimer at a concentration of 7.67  M. NMR    
  - v -   
spectroscopy depicted that global changes occur within the structure of DR_1146 
on binding to FMN. The high quality of spectra obtained showed potential for 3 D 
structure determination by NMR if ordered crystals could not be obtained for X 
ray diffraction. Interestingly, analysis of NMR spectra proved to be integral to 
identifying a homogenous sample for successful crystallisation of DR_1146. By 
monitoring chemical shifts it was possible to determine the time needed for 
degradation of DR_1146 to cease, and the amount of FMN needed to ensure 
saturation of binding sites. From this particular sample, a stable 28 kDa 
fragment was isolated by gel filtration. Automated sitting drop vapour diffusion 
experiments resulted in the growth of yellow DR_1146 FMN crystals for which, 
although poor in quality, X ray diffraction was obtained. Overall this study 
reflects the importance and advantage of incorporating information gained from 
biophysical characterisation into the strategies employed for successful protein 
crystallisation. 
The characterisation of DR_1146 as a flavoprotein points towards a possible role 
in electron transfer due to the extensive redox capacity of flavin. This could 
implicate the protein in the production of damaging reactive oxygen species 
(ROS) as a result of irradiation, contributing to oxidative stress levels. 
Alternatively, if DR_1146 is identified as a FMN binding pyridoxine 5' phosphate 
oxidase (PNPOx) enzyme, as sequence homology suggests, it could play a role in 
detoxification and stress response through production of pyridoxal 5' phosphate 
(PLP), a known scavenger of ROS. Only further characterisation and elucidation 
of a 3 D structure would confirm or dispel these functional hypotheses and 
ultimately provide a greater understanding of how D. radiodurans is able to deal 
with such oxidising conditions.  
Simultaneously, experiments were carried out on other soluble and membrane 
protein targets from D. radiodurans and their corresponding homologues from 
Streptococcus pneumoniae (TIGR4). The aim of comparable studies was to 
identify key structural or functional differences between the two Gram positive 
bacterial strains. Identification of features unique to D. radiodurans, but 
unconserved in S. pneumoniae, could contribute to further understanding of 
bacterial radioresistance.     
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SP_1651 is a thiol peroxidase which forms part of the Mn ABC transport system in 
S. pneumonia. Its homologue from D. radiodurans, DR_2242 is a putative thiol 
specific antioxidant protein, the structure of which has been solved by Dr. Dave 
Hall as part of the ESRF’s structural genomics project (unpublished). The aim of 
this part of the project was to elucidate the structure of SP_1651 so that a 
comparison with DR_2242 could be made.  
The sp_1651 gene (psaD) was successfully expressed and purified to homogeneity 
by IMAC and gel filtration. After the proteolytic removal of a 6xHis tag, the 
purified protein was crystallised by sitting drop vapour diffusion. Preliminary 
diffraction with a resolution limit of 3.2 Å was obtained, however data showed 
high mosaic spread. Unfortunately, attempts to reproduce initial crystals failed 
and hence, structural comparisons with DR_2242 could not be made. 
DR_0463 is a 108 kDa maltooligosyltrehalose synthase (MTSase) which has been 
shown to catalyse the breakdown of maltooligosaccharide (or starch) into the 
disaccharide, trehalose. The full length gene was expressed in BL21(DE3)pLysS 
cells, producing large yields of insoluble target protein. DR_0463 was solubilised 
with 8 M Urea and then purified by IMAC in the presence of the denaturant. The 
low affinity of DR_0463 for the Ni
2+ matrix of the HisTrap column proved to be 
problematic when trying to obtain homogeneity. However, by sequentially 
repeating IMAC purification up to three times with the same protein sample, a 
large proportion of impurities were removed.   
SP_1648 (PsaB) is an ATP binding protein that forms part of the Mn ATP transport 
system in S. pneumoniae and its homologue from D. radiodurans, DR_2284 is 
predicted to share similar function. Purification of soluble SP_1648, expressed in 
B834(DE3) cells, was complicated by an inability to bind the protein to the 
column matrix for IMAC. In the case of DR_2284, expression trials yielded only a 
minute amount of insoluble protein in BL21 AI competent cells. The bottlenecks 
in early expression and purification stages provided valuable experience in 
dealing with problematic proteins.  
As an introduction to molecular cloning, two genes predicted to encode integral 
membrane proteins from D. radiodurans, were cloned for preliminary expression 
trials. This work was carried out at the ESRF and contributed to an extension of    
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the structural genomics project, to incorporate membrane protein targets from 
D. radiodurans. Full length forms of the genes thought to encode an 
undecaprenyl diphosphatase (UDP) and a diacylglycerol kinase (DGKA) were 
successfully cloned in to pET 28b, with incorporation of separate N  and C  
terminal 6xHis tags.     
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1  Introduction 
1.1 Deinococcus radiodurans R1 
1.1.1 Structural genomics 
Deinococcus radiodurans (Strain R1) is a non pathogenic, red pigmented, gram 
positive bacterium [1] with an exceptional ability to survive acute exposure to 
oxidising, DNA damaging conditions such as ionising radiation, desiccation, UV 
radiation and cellular H2O2 [2]. 
This study is part of a structural genomics project underway at the European 
Synchrotron Radiation Facility (ESRF), Grenoble, which aims to elucidate the 3 D 
crystal structures of proteins encoded from the genome of D. radiodurans in 
order to gain further understanding of the mechanisms employed by this 
extremophillic bacterium. The essence of this project is to progress from the 
gene sequence through to structure via production, purification and 
crystallisation of the target protein. The challenge then is to assign biochemical 
and biological function of that protein within the organism [3]. It is the hope 
that structures of target proteins will reveal functions relevant to the defence of 
D. radiodurans against mutation and cell death that will provide basis for 
radiation recovery targets. 
The publication of the complete genome sequence of D. radiodurans R1 [4, 5], 
which is annotated on the Comprehensive Microbial Resource (CMR) database [6, 
7], has enabled the ESRF’s structural genomic initiative to take place. It is 
reported that the 3.28 Mb chromosome of D. radiodurans is segmented into a 
2.64 Mb chromosome (chromosome I), a 0.41 Mb chromosome (chromosome II), a 
0.18 Mb megaplasmid and a 0.045 Mb plasmid [8]. Each cell has between 4 to 10 
genome copies, depending on the phase of bacterial growth [9] and the 
chromosome has an unusual ring like structure [10].   Chapter 1 Introduction   
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All of the gene targets investigated in this study belong to chromosome 1 of the 
D. radiodurans genome [6, 7]. 
1.1.2 General characteristics and morphology 
D. radiodurans was discovered in 1956 by A. W. Anderson whilst trying to find a 
method of sterilising food using γ radiation. This novel vegetative bacterium, 
found on samples of ground meat, survived exposure to 4000 Gray (Gy) of 
irradiation [1], a dose hundreds of times higher than that deemed fatal for most 
other organisms.  
Since its initial discovery, D. radiodurans has been isolated from contrasting 
locations worldwide including nutrient rich environments such as soil and animal 
faeces, in addition to nutrient depleted environments including dry Antarctic 
valleys and arid desert soil [5, 11 13]. 
D. radiodurans belongs to the Deinococcaceae family which is comprised of 11 
members, all with the genus name Deinococcus [14 16]. All of the Deinococci are 
non motile, do not form spores and are mostly spherical, existing as single cells, 
pairs or tetrads. Figure 1.1 illustrates the tetrad morphology of D. radiodurans.  
          
Figure 1.1: Electron micrographic image of D. radiodurans displaying tetrad morphology. 
Taken from the web page of M.J. Daly (http://www.usuhs.mil/pat/deinococcus/index_20.htm) [17]. 
In contrast to its thermophilic relatives, D. geothermalis and D. murrayi [18], D. 
radiodurans is a mesophile which exhibits optimum cellular growth between 30 
37°C [19].    Chapter 1 Introduction   
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The origin of this fascinating species and its evolution to possess such abnormal 
levels of radioresistance remains unknown although many speculative theories 
have been proposed. Pavlov et al. (2006) [20] postulated that D. radiodurans 
could be of extra terrestrial origin, transported through space to earth by debris 
from Mars. Although exciting, this arguably eccentric theory is unlikely, as the 
species shows genetic and biochemical characteristics similar to terrestrial 
bacteria.        
1.1.3 Repair of cellular damage caused by oxidising conditions 
Like other microorganisms, the genome of D. radiodurans is shattered into 
hundreds of short DNA fragments on high exposure to oxidising conditions. 
However, researchers claim that it is the unique ability of this bacterium to 
accurately reassemble into a functional genome, which differentiates it from 
others [2, 21, 22]. 
The most severe form of genomic damage [23] double strand breaks (DSBs) occur 
as a result of oxidative stress [22]. This condition is caused by a build up of 
reactive oxygen species (ROS) to levels which exceed the capacity of the 
scavengers needed to neutralise them; leaving the cell susceptible to damage 
[24, 25]. DNA damaging hydroxyl radicals (OH) are generated by radiolysis of 
water by direct γ irradiation and by energy metabolism during recovery from 
radiation [24, 25].   
ROS cause damaging DSBs in the DNA of both E. coli and D. radiodurans at 
comparable rates [10, 26]. However, D. radiodurans is able to tolerate 30 times 
more DSBs before cell death compared to E. coli [23, 27]. In fact, DR shows 
resistance up to 5000 Gy without loss of viability or cell death [22, 28]. This 
confirms that DR is not able to prevent cellular damage occurring, but that it has 
a novel method of preventing the lethal effects of DSBs by effectively repairing 
the damage [19].  
Although extensively researched, the mechanisms by which D. radiodurans is 
able to avoid cell death after damage caused by oxidising conditions are not 
wholly understood. It is thought that such extremophillic behaviour can be 
attributed to a combination of non enzymatic and enzymatic defences which   Chapter 1 Introduction   
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allow conventional pathways, present in other bacteria, to function more 
efficiently [10].  New methodologies are regularly developed and dismissed as 
the search for the true pathways continue. Two recently proposed mechanisms 
include: (a) an enzymatic dependent DNA repair system involving a two stage 
process for genomic reassembly [29] and (b) non enzymatic protection from 
protein oxidation by detoxification of ROS by cellular Mn(II) [10, 30]. In addition, 
the genome of DR has unusually high numbers of detoxification genes, such as 
superoxide dismutases (SODs) and catalases [31, 32], whose levels of expression 
are greatly increased after irradiation [33]. 
1.1.3.1  DNA repair by extended synthesis-dependent strand annealing 
(ESDSA)   
A study by Zahradka et al. (2006) [29] claims to exclude previously identified 
mechanisms of genome reassembly in favour of a two stage DNA repair pathway 
consisting of extended synthesis dependent strand annealing (ESDSA) followed 
and completed by crossovers. To allow this process to occur effectively, two 
copies of the genome with random DNA breakages are required. EDSA involves a 
nucleotide rich polymerase chain reaction (PCR), using chromosomal fragments 
(with overlapping homologies) as both primers and template DNA. This 
polymerase I dependent amplification reaction produces new complementary 
single stranded extensions that then anneal with high precision to form double 
stranded intermediates. These intermediates then undergo homologous 
recombination into circular chromosomes, facilitated by the protein RecA. The 
final result is a ‘double stranded patchwork’ of DNA blocks synthesised before 
radiation, connected by DNA blocks synthesised after radiation [29]. 
1.1.3.2  Protection from protein oxidation by high cellular Mn(II) levels 
Research carried out by Daly et al. (2007) [30] shifts focus away from DNA repair 
mechanisms by relating the high radioresistance of D. radiodurans with its ability 
to prevent radiation induced protein damage. It has been proposed that the 
capacity to protect cellular proteins from oxidation is equally or more critically 
important for maintaining viability than DNA repair. This hypothesis could 
explain why other organisms, with similar repair genes to D. radiodurans, are   Chapter 1 Introduction   
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susceptible to apoptosis on low levels of radiation and low instances of DSBs [30, 
34, 35].  
Protein damage is caused by oxidation of amino acid side chains by ROS and 
H2O2, which are generated during irradiation, desiccation [22] and energy 
metabolism [24]. The extent of protein damage is established by the level of 
irreversible and irreparable carbonyl group production, which occurs as a result 
of amino acid oxidation [36, 37]. Resistant bacteria, like Gram positive D. 
radiodurans, show lower levels of protein oxidation in comparison with radiation 
sensitive bacteria like Gram negative Shewanella oneidensis.  
Such resistance to oxidative radiation and desiccation has been quantifiably 
liked with high levels of Mn(II) and low levels Fe(II) in the cell [30]. For example, 
D. radiodurans has a relatively high Mn(II)/Fe(II) concentration ratio of 0.24 and 
is susceptible to 10 % cell death on exposure to 10 12 kGy of ionising radiation 
and more than 30 days of desiccation [10, 38]. In contrast, highly sensitive S. 
oneidensis has a much lower Mn(II)/Fe(II) ratio of less than 0.001 and undergoes 
10 % cell death with only 0.07 kGy of ionising radiation and 1 day of desiccation 
[10, 38]. This suggests that the potential antioxidant capability of Mn(II) could 
play a role in protein protection. The link between radiosensitivity and high 
Fe(II) levels is thought to lie in the Fe(II) dependence of damaging ROS produced 
during metabolic recovery. As Fe(II) is released from proteins as a result of 
irradiation, Fe(II) rich bacteria are particularly susceptible to Fe(II) induced 
oxidative stress [38].   
Although the mechanism of protein protection remains unknown, it has been 
proposed that a non enzymatic Mn(II) based protection system, existent in 
radioresistant bacteria like D. radiodurans, facilitates survival by scavenging 
Fe(II) dependent ROS [10, 39]. While Mn(II) has no influence on DNA damaging 
OH (primary product of radiolysis), it is able to scavenge endogenously induced 
peroxyl radicals
 which may minimise protein damage by preventing propagation 
of secondary reactions that ultimately damage proteins [24, 40, 41]. It is thought 
that this may protect other enzymatic detoxifying and repair systems allowing 
them to survive and function with greater efficiency [30, 38]. The impact of 
Mn(II) in the stress response of D. radiodurans is corroborated by an observed   Chapter 1 Introduction   
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increase in radiation sensitivity and protein oxidation on restriction of Mn(II) 
during growth [10, 26, 42]. 
Interestingly, there is also a positive correlation between high cellular 
Mn(II)/Fe(II) concentration ratios and capacity to survive desiccation [10, 38]. 
This adds to the debate that mechanisms contributing to radioresistance and 
control of oxidative stress may be an evolutionary consequence of the robustness 
needed to survive desiccation [22, 43].  
1.1.4 Current and proposed applications 
It is thought that a more complete understanding of the repair and protection 
systems employed by D. radiodurans may lead to the discovery of novel 
mechanisms that could aid understanding of responses in higher organisms 
providing an insight that could be utilised clinically. For example, by 
understanding how Mn(II)/Fe(II) levels contribute to radiation resistance, 
approaches could be developed to control recovery from radiation injury [44]. In 
addition, further understanding of the ability of D. radiodurans to regain 
integrity by supply of water and ions, after extensive desiccation [45], could 
inspire research into anti ageing and regenerative medicine [29]. 
A current application of DR has been investigated by the US Department of 
Energy, who have funded work into using genetically modified forms of the 
bacterium as a bioremediation agent, in an effort to address the problem of 
highly toxic radioactive nuclear waste sites which are leaking into the 
surrounding areas [46]. Such sites contaminated with radionucleotides, heavy 
metals and harmful solvents [47], would require billions of dollars to clean up by 
physiochemical methods [48] and thus bioremediation technologies are highly 
favourable to avoid such expense. Many of the experiments carried out with 
other possible bacterial [49 52] and plant candidates [53, 54], have failed due to 
their sensitivity to ionising radiation. As a solvent tolerant, soil bacterium, which 
can grow and express foreign genes in the presence of radiation levels typical of 
toxic waste sites [47, 55], D. radiodurans has proved to be a good target for such 
studies. Researchers have generated strains of D. radiodurans that can express a 
cloned mercury resistant gene merA [56] which could be used to reduce toxic Hg 
(II) to less toxic, more volatile, elemental mercury in problematic areas [57].     Chapter 1 Introduction   
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1.1.5 Putative general stress protein, DR_1146  
The primary focus of this study is the expression, purification and crystallisation 
of an un characterised gene from D. radiodurans, with the locus name dr_1146. 
It is annotated on the CMR database [6, 7] as putative general stress protein 26 
and is predicted to exhibit the characteristics listed in Table 1.1. The nucleotide 
and amino acid sequence of DR_1146 are included in Appendix 1. 
Locus name  DR_1146 
Putative identification  General stress protein 26, putative 
Coordinates  1155760 1156341 
Gene length  582 bp 
Protein length  193 aa 
Molecular weight  21,043.23 Da 
PI  4.58 
% GC content  61.14 
TIGR cellular role category  Cellular processes: adaptations to atypical conditions 
Table 1.1: Predicted characteristics of the dr_1146 gene as annotated on the CMR database 
[6, 7]. 
A NCBI BLAST search [58, 59], using the amino acid sequence of DR_1146, 
identified sequence homology with other bacterial proteins putatively associated 
with cellular general stress responses. In addition, the search identified close 
sequence homology (43 58 %) with putative pyridoxamine 5' phosphate oxidase 
(PMPOx) related FMN binding proteins, including a protein from Deinococcus 
geothermalis, another member of the Deinococcaceae family.    
1.1.5.1  Pyridoxamine 5'-phosphate oxidases 
The PNPOx family of enzymes have been shown to catalyse the terminal step in 
the de novo biosynthesis of the cofactor pyridoxal 5' phosphate (PLP) in 
microorganisms and plants. They also function as a constituent in the recycling 
of PLP in higher organisms that require vitamin B6 [60]. Failure to provide 
adequate supplies of PLP in mammals is usually manifested as neurological 
disorders [61]. PNPOx enzymes have been identified and characterised in 
bacteria [62], humans [63], animals [60, 64, 65], yeast [66] and plants [67]. The 
3 D crystal structures for human and E. coli PNPOx have been determined along 
with probable mechanistic pathways [61, 68].  
PLP, the biochemically active form of Vitamin B6, is known as one of the most 
versatile cofactors in nature, necessary for over 100 enzymatic reactions, the   Chapter 1 Introduction   
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majority of which are involved in the metabolism of amino acids [69 71]. 
Recently, PLP was uncovered as an antioxidant, with potency equivalent to that 
of vitamins C and E [72 74]. As an effective singlet oxygen quencher [75] it may 
play a role in D. radiodurans cellular response to oxidative stress. 
In E. coli, PLP has been shown to be produced by the FMN dependent oxidation 
of the substrates, PNP (pyridoxine 5'  phosphate) or PMP (pyridoxamine 5'  
phosphate) whilst associated to PNPOx [61, 68].  This reaction requires that the 
FMN cofactor maintains strict structural requirements with only a few alterations 
in the isoalloxazine ring being permitted [76]. A pair of electrons are transferred 
from C4' of PNP (or PMP) to the N5' of a tightly bound molecule of FMN, forming 
FMNH2. This is thought to occur by either direct hydride transfer or by removal 
of a proton by a basic amino acid to form a C4' carbanion which attacks N5' of 
FMN. The high potential electrons are then transferred to molecular oxygen, 
thus regenerating FMN and forming H2O2 [77] (Figure 1.2).  
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Figure 1.2: Schematic diagram illustrating the involvement of FMN in the PNPOx catalysed 
conversion of PNP into PLP in E. coli. From Safo et al. (2000) [61].   Chapter 1 Introduction   
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In addition to its production by PNPOx, PLP has been shown as an effective 
reaction inhibitor when complexed with the enzyme. It has greater affinity for 
the active site than either PNP or PMP substrates suggesting that product 
inhibition is a mode of regulation for the reaction [60, 76]. Although this 
reaction results in the production of H2O2, it has been proposed that D. 
radiodurans is able to deal with this strong oxidant by exhibiting extremely high 
catalase activity [10, 78]. 
The PNPOx enzymes are the smallest members of the flavin containing oxidase 
class with molecular weights between 22 29 kDa. They are normally found as a 
dimer and have highly conserved motifs that include amino acids involved in FMN 
and PLP binding [61]. 
1.1.5.2  Putative general stress protein (COG3871) from Nostic punctiforme  
A search of the Protein Data Bank [79, 80] using the amino acid sequence of 
DR_1146, found homology (32 % identity) with a structure of an uncharacterised 
putative general stress protein (COG3871) from Nostic punctiforme PCC 73102 
(PDB ID: 2I02) [81]. Like PNPOx, this dimeric protein was crystallised in the 
presence of a single FMN molecule. Interestingly, the crystal structure of this 
homologue does not include any bound PLP cofactors in contrast to those of the 
PNPOx enzymes including E. coli PNPOx.  
The FMN binding ability of the homologues discussed, fuelled investigation into 
the possible flavin binding capacity of DR_1146 and the subsequent effects on 
protein stabilisation, structure and crystallisation. 
1.1.6 Flavin chemistry and flavoproteins 
Since their discovery in the 1930s, flavins have been labelled one of the most 
important cofactors involved in enzymatic functions [82 87]. Flavoproteins are 
ubiquitous proteins that are tightly complexed with one or more flavin 
prosthetic groups [88]. A large number of flavoproteins have been characterised 
over the past 60 years, with the researcher Vincent Massey at the forefront of 
this work [89].         Chapter 1 Introduction   
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The two most commonly occurring flavins, flavin mononucleotide (FMN) and 
flavin adenine dinucleotide (FAD) [90], are derivatives of riboflavin, otherwise 
known as vitamin B1. The structures of FMN and FAD are based upon the 
heterocyclic isoalloxazine ring system of riboflavin, from which extends either a 
ribityl phosphate prosthetic group (FMN) or a ribityl adenine diphosphate 
prosthetic group (FAD) (Figure 1.3) [90]. 
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Figure 1.3: Structures of riboflavin, FMN and FAD in their oxidised state [90]. 
In vivo synthesis occurs via ATP phosphorylation of the ribityl chain of riboflavin 
to produce riboflavin 5' phosphate (FMN), followed by the transfer of an 
additional AMP moiety to form FAD [78]. This two step process is facilitated by 
the enzymes riboflavin kinase [91, 92] and FAD synthase [93].  
The conjugated isoalloxazine ring component of flavins is accountable for many 
of their unique physical and chemical properties [85]. It gives rise to a bright 
yellow colour and a characteristic absorption spectrum consisting of two peaks 
between 300 500 nm when in an oxidised redox state [94]. The aromatic ring 
system is a centre for extensive redox chemistry [85], which enables flavin 
molecules to catalyse a wide variety of biochemical and biological activities 
when complexed with proteins [95, 96]. Flavins are perhaps best known for their   Chapter 1 Introduction   
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role in aerobic metabolism [85], however, their activities extend to include cell 
apoptosis [97, 98], detoxification [99, 100] and light driven DNA repair [101, 
102].  
The determination of over 40 flavoprotein crystal structures has given insight 
into the nature of interactions between the flavin cofactor and the protein [85]. 
In most flavoproteins, the flavin prosthetic group is non covalently bound. 
However, there are some reports of the flavin molecule being covalently 
attached to the polypeptide chain [103]. The majority of flavin protein 
intermolecular interactions, independent of nature, are with the ribityl side 
chain and prosthetic groups of either FMN or FAD [85]. Although many 
flavoproteins show specificity for either FMN or FAD, some contain both FMN and 
FAD binding domains [88], which is the case for the enzyme NADPH cytochrome 
P450 reductase [104]. Interestingly, characterisation of PNPOx enzymes shows 
high affinity and specificity for FMN [105], however the literature does not 
describe or quantify binding affinities for FAD. The affinity of flavoproteins for 
flavin molecules has been facilitated by the evolution of various binding folds 
[84, 106, 107]. Structural motifs within these characteristic folds, including the 
TIM barrel and the Rossmann fold, interact with specific moieties of the flavin 
prosthetic group [88].    
Flavins can exist in three different redox states; an oxidised state, a 
semiquinone radical intermediate, and a fully reduced state [83]. Changes in 
their oxidation state are reflected in absorbance spectra as demonstrated in 
Figure 1.4 which illustrates spectral changes for the flavoprotein, glucose 
oxidase, on gaining electrons to form a reduced state [85, 108].    Chapter 1 Introduction   
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Figure 1.4: Absorbance spectra of the flavoprotein, glucose oxidase, in the oxidised, 
semiquinone (neutral and ionic) and fully reduced states. Figure taken from Massey 2000 [85], 
based on data from Massey 1996 [108]. 
The versatility of flavoproteins is shown by the capability to undergo both one  
and two electron transfer processes [85]. This is demonstrated by the role of the 
FMN in the multi redox oxidation of NADH during cellular respiration [78] (Figure 
1.5).   Chapter 1 Introduction   
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Figure 1.5: FMN facilitated single-electron transfer for the oxidation of NADH in the 
respiratory chain [78]. 
During this process, NADH binds to a dehydrogenase, which in turn has FMN 
bound. Two high potential electrons are transferred from NADH to FMN to give 
reduced FMNH2 (Figure 1.5a c). This two electron dehydrogenation, involves the 
formation of a semiquinone radical intermediate (FMNH) (Figure 1.5b). The 
electrons are then transferred, via a series of single electron steps, to iron 
sulfur clusters; a process by which the reduced FMNH2 is re oxidised to FMN [85]. 
Reduced flavins show high reactivity with molecular oxygen, upon which a one 
electron reaction takes place. This results in the reduction of O2, yielding a   Chapter 1 Introduction   
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flavin radical and superoxide [85]. Subsequently, these two radicals become 
involved in several chemical pathways [109 113] which include the formation of 
hydroxyl radicals through reaction of superoxide with peroxide [114]. The 
production of hydroxyl radicals is commonly believed to be one of the major 
sources of DNA and protein damage [24, 25, 85].  
It has been proposed that there is a relationship between the amount of ROS 
producing intracellular flavins and the proclivity of cells to generate oxidative 
stress. This in turn, leads to a correlation between the number of flavins and the 
ability to survive radiation and other oxidising conditions [115]. For example, 
radioresistant D. radiodurans encodes only 39 flavoproteins [5, 10] in comparison 
with the radiosensitive bacterium S. oneidensis, which encodes 59 [10, 116]. 
Also, the rates at which different flavins react with oxygen to produce ROS, vary 
over several orders of magnitude depending on the extent of flavin exposure 
[38].  
The ability of DR_1146 to bind flavins could implicate this protein in the 
production of metabolic ROS as a result of irradiation. Characterisation and 
elucidation of a 3 D structure may contribute to a greater understanding of how 
D. radiodurans is able to deal with such oxidising conditions in order to maintain 
viability and prevent cell death.  
Alternatively, if DR_1146 is identified as a PNPOx enzyme, as sequence homology 
suggests, it may play a role in stress response through scavenging of superoxide 
by its reaction product PLP. Such action may prevent the production of cell 
damaging hydroxyl radicals and thus contribute to the radioresistance of 
Deinococcus radiodurans.     
1.1.7 DR_1146 project aims 
The primary focus of this study was to express and purify DR_1146 in order to 
gain diffraction quality crystals for 3 D structure determination using 
crystallographic methods. Elucidation of the structure would enable comparison 
of fold [117, 118] and structural motifs [119] with structural databases, which 
could reveal similarities, from which information about biochemical and 
biological function could be inferred [3].    Chapter 1 Introduction   
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It is well documented that crystallisation is a major bottleneck in X ray 
crystallographic structure determination [120, 121] and that there are no 
systematic methods to ensure that ordered 3 D crystals will be obtained. 
It is however, believed that a critical factor for success is the homogeneity, 
monodispersity and stability of the protein preparation itself [120]. This study 
utilises biophysical methods of characterisation to aid protein preparation and as 
a result produce protein crystals that are well ordered and will subsequently 
generate a high resolution structure. In particular, the capacity of DR_1146 to 
bind flavin molecules is investigated. Structural information gained from 
protein ligand complexes are often very useful in gaining functional insight as 
they show the nature of the ligand, where and how it is bound and which 
residues form the active site from which a catalytic mechanism could be 
postulated [3]. In the absence of a structure, information about cofactor binding 
can aid efforts to grow crystals as saturation of protein binding sites may 
produce a homogenous sample favourable for crystallisation.    
1.1.8 Maltooligosyltrehalose synthase (DR_0463) 
D. radiodurans encodes a large 108 kDa enzyme known as maltooligosyltrehalose 
synthase (MTSase) from the gene treY (locus name dr_0463) [6, 7]. The putative 
characteristics of the gene and protein, as annotated on the CMR database, are 
summarised in Table 1.2. 
Locus name  DR_0463 
Putative identification  Maltooligosyltrehalose synthase 
Gene symbol  Trey 
Coordinates  461679 458743 
Gene length  2937 bp 
Protein length  978 aa 
Molecular weight  108,738.59 Da 
pI  6.34 
% GC content  68.75 % 
TIGR cellular role category  Cell envelope: Biosynthesis and degradation of 
surface polysaccharides and lipopolysaccharides  
Table 1.2: Predicted characteristics of the treY gene as annotated on the TIGR CMR 
database [6, 7]. 
MTSase forms one half of the two step metabolism of trehalose in D. 
radiodurans. Together with its partner protein, maltooligosyltrehalose   Chapter 1 Introduction   
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trehalohyrdolase (MTHase), they catalyse the breakdown of 
maltooligosaccharide (or starch) into trehalose [122].  
Trehalose, or α D glucopyranosyl  1,1 α D glucopyranose, is a non reducing 
disaccharide which contains an α 1,1 linkage between two glucose molecules. 
The sugar has been shown to protect cell membranes and proteins against 
oxidative stresses including drought, heat and osmotic changes [123 126] by 
serving as a carbohydrate reserve, water substitute [127] and a free radical 
scavenger [128]. It can therefore be postulated that for D. radiodurans, 
trehalose may facilitate protection or recovery from the desiccating conditions 
of arid dessert environments. In addition, trehalose has many industrial 
applications including use as a sweetener, preservative or stabiliser in food, 
cosmetics, vaccines and medicine [129].  
The process by which MTSase and MTHase produce trehalose is summarised in 
Figure 1.6 [122].  
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Figure 1.6: Two-step breakdown of maltopentaose into trehalose and maltotriose catalysed 
by MTSase and MTHase [122].  
Firstly, MTSase converts the glycosidic bond, between the last two glucose 
moieties of starch, from an α 1,4 linkage to an α 1,1 linkage, thus producing a 
glycosyl trehaloside. MTHase then cleaves the α 1,4 linkage adjacent to the α 
1,1  glycosidic bond to release free trehalose and maltotriose as a side product 
[122].  Solution of the 3 D structure of MTHase from D. radiodurans has given   Chapter 1 Introduction   
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some insight into the mechanism by which the second part of the enzymatic 
reaction occurs including the involvement of active site amino acids. Elucidation 
of the structure of MTSase would complete understanding and thus may uncover 
a vital role in stress response through trehalose production. 
This study reports the expression of treY in the insoluble fraction of E. coli cells 
and the subsequent solubilisation and purification of MTSase by immobilised 
metal affinity chromatography (IMAC). 
1.2 Streptococcus pneumoniae TIGR4 
Like D. radiodurans, Streptococcus pneumoniae is a Gram positive, non motile 
bacterium [130] which exhibits some resistance to oxidative stress [131 133]. 
However, where D. radiodurans is a relatively harmless microorganism, S. 
pneumoniae has earned a reputation as a major human pathogen associated with 
life threatening diseases such as meningitis and pneumonia [134, 135]. 
Pneumococcal infection is most prevalent in young, elderly and 
immunocompromised populations [136 138], with high mortality rates 
maintained by acquired resistance to widely used antibiotics, including penicillin 
[139]. In 1997, nearly half of the elderly population of the United States were 
immunised with a 23 valent polysaccharide vaccine [140]. Although the 
efficiency of this vaccine has been extensively proven [141, 142], over 60,000 
cases of pneumococcal disease continue to be diagnosed every year in the US 
[143]. Hence, the search continues to find novel vaccine candidates and to 
understand fully, the pathogenic mechanisms employed by S. pneumonia.   
1.2.1 Manganese ABC transport system in S. pneumoniae  
S. pneumoniae has been shown to encode an ABC type transport system from the 
gene locus, psaBCA. There is strong evidence to suggest that this system 
facilitates the transfer of divalent manganese across the cytoplasmic membrane 
[144]. The ABC transport complex in S. pneumonia consists of three protein 
components: PsaA, an extracellular solute binding protein, PsaC, a hydrophobic 
transmembrane protein responsible for solute transport [145], and PsaB, a 
cytoplasmic ATP binding protein. Immediately downstream of the psaBCA operon   Chapter 1 Introduction   
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is psaD, a gene which encodes a periplasmic thiol peroxidase protein [144]. 
Although not strictly part of the Mn(II) transport system, psaD is thought to be 
cotranscribed by the psaBCA Promoter [139]. 
The most extensively studied component of the pneumococcal Mn(II) ABC 
permease is the surface protein PsaA which has been identified as a potential 
drug target and vaccine candidate [134]. The solute binding protein has been 
shown to play an indirect role in pathogenesis as psaA
  mutants are unable to 
produce important virulence factors like adhesins. It is proposed that reduced 
levels of Mn(II) importation in the absence of PsaA could prevent the manganese 
regulated expression of proteins associated with virulence [134].  
As discussed earlier, the essential role of Mn(II) in detoxification and stress 
response in D. radiodurans has been reported in depth [30, 38]. It is hence not 
surprising that compromised Mn(II) influx has also been associated with oxidative 
stress and growth retardation in S. pneumoniae [132, 139]. Individual psaA
 , 
psaD
 , psaB
  and psaC
  pneumococcal mutants have shown requirement for added 
manganese to maintain cell growth rates. In addition, psaA
  and psaD
  mutants 
show significant susceptibility to oxidative conditions in comparison to wild type 
strains [131]. This has lead to the postulation that regulation of Mn(II) transport 
by PsaA and PsaD in S. pneumoniae could influence the response of this 
bacterium to oxidative stress [131]. 
The 3 D crystal structure of PsaA from S. pneumoniae presents major differences 
in domain architecture and folding topology on comparison with Gram negative 
ABC type proteins [146]. This could infer a novel mode of Mn(II) uptake and 
release in Gram positive bacteria like S. pneumonia and D. radiodurans. Hence, 
structural elucidation and comparison of the other ABC components from the 
two bacteria could contribute to further understanding of the role of manganese 
transport in pathogenesis and response to oxidative stress. 
1.2.2 Putative thiol peroxidase, SP_1651 
This study presents the conditions for recombinant expression of psaD from S. 
pneumonia (Strain TIGR4), and reports subsequent purification and 
crystallisation of the encoded protein SP_1651. The initial aim of experiments   Chapter 1 Introduction   
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was to solve the 3 D crystal structure of SP_1651 so that a comparison could be 
made with a homologue from D. radiodurans. DR_2242 is a putative thiol specific 
antioxidant protein, which exhibits 26 % sequence homology with SP_1651. The 
structure of DR_2242 has been solved by Dr. Dave Hall as part of the ESRF’s 
structural genomics project but remains unpublished and uncharacterised to 
date. Although Mn(II) is known to play a pivotal role in preventing oxidative 
protein damage in D. radiodurans [10, 30, 38], research into the structure of the 
Mn ABC transport system remains undocumented. Hence, structural comparison 
with SP_1651 could provide information about the biochemical function of 
DR_2242, and perhaps aid understanding of the importance of Mn(II) ABC type 
transfer in D. radiodurans.     
1.2.3  ATP-binding protein involved in Mn(II) transport, SP_1648 
This study describes the recombinant expression of psaB and purification of the 
encoded protein SP_1648 from S. pneumoniae. The homologue from D. 
radiodurans (DR_2284) shares 34 % identity with SP_1648 and hence is thought to 
display similar function through ATP binding. Again, investigations were carried 
out in the hope of producing purified protein for comparable studies of SP_1648 
and DR_2284.   
- 20 - 
2  Materials and methods 
Chemicals, biochemicals and materials of the highest quality were purchased 
from Sigma Aldrich Company, Gillingham, UK or Fisher Scientific, Loughborough, 
UK unless stated otherwise. 
General techniques were carried out as described in Sambrook et al. (1989) 
[147] unless stated otherwise. 
2.1 Provided constructs for gene expression 
2.1.1 Full length dr_1146 gene in pDEST17 
A clone of the full length dr_1146 gene in a pDEST™17 vector (Table 2.1) was 
kindly provided by Protein’eXpert, Grenoble, France. This plasmid DNA was used 
in the PCR step of the cloning of a full length and an N terminal truncated form 
of the dr_1146 gene into expression vector pET 15b. 
Vector  Key features  Manufacturer & References 
pDEST™17  T7 promoter for expression in E. coli. 
Ampicillin/carbenicillin resistance. 
Non cleavable 6xHis tag.  
Invitrogen™ Gateway® 
Cloning 
Rosenberg et al., 1987 [148] 
Studier & Moffat, 1986 [149] 
Studier et al., 1990 [150] 
 
POPINF  T7 promoter for expression in E. coli. 
Ampicillin/carbenicillin resistance. 
HRV 3C protease cleavable N terminal 
6xHis tag. 
Developed by Oxford 
Protein Production Facility 
using In Fusion™ enzyme 
(Clontech) 
 
pET 15b  T7 promoter for expression in E. coli. 
Ampicillin/carbenicillin resistance. 
Thrombin cleavable N terminal 6xHis tag 
GSH – remaining residues after cleavage. 
Novagen® (Merck 
Biosciences) 
Rosenberg et al., 1987 [148] 
Studier & Moffat, 1986 [149] 
Studier et al., 1990 [150] 
 
PET151/D TOPO® 
 
T7 promoter for expression in E. coli. 
TEV cleavable N terminal 6xHis tag. 
Ampicillin resistance. 
 
Rosenberg et al., 1987 [148] 
Studier & Moffat, 1986 [149] 
Studier et al., 1990 [150] 
pcR® Blunt II TOPO®  Linearised cloning vector. 
Kanamycin resistance. 
Direct insertion of blunt ended PCR 
products. 
 
Invitrogen TOPO® cloning 
Shuman, 1991 [151] 
PLysS  Encodes T7 lysozyme.  
Chloramphenicol resistance. 
Grodberg & Dunn, 1988[152] 
Moffat & Studier, 1987[153] 
Table 2.1: Summary of vectors for cloning and expression   Chapter 2 Materials and methods   
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2.1.2 Full length sp_1651 gene in pOPINF 
A clone of the full length sp_1651 gene in the pOPINF vector (Table 2.1) was 
kindly provided by Dr. Alan Riboldi Tunnicliffe, University of Glasgow, Glasgow, 
UK. Cloning was carried out at the Oxford Protein Production Facility (OPPF), 
Oxford, UK. 
2.2 Molecular cloning using restriction enzymes 
Full length and N terminal truncated versions of the dr_1146 gene were cloned 
into the vector pET 15b (Table 2.1) using restrictions enzymes. 
2.2.1 Oligonucleotide primers 
Oligonucleotide primers were designed by hand with a preferential length of 22 
30 bp, a melting temperature of 55 80°C and a GC content between 50 60 %. 
Appropriate restriction sites were incorporated at the 5' terminals. 
Oligonuclotides were synthesised by Sigma Proligo and were provided at a 
concentration of 100  M and stored at –20°C. Oligonuclotides for full length and 
truncated constructs are depicted in Table 2.2. 
Primer name  Sequence  Comment 
Full length DR_1146 fwd  5' CAT ATG TGT GGT CTG 
GCC CAT TCT CCG GA 3' 
NdeI (CAÑ TATG) restriction 
site including  
ATG start codon. 
 
Full length DR_1146 rev  5' GGA TCC TTA GAG ATT 
AAC CGT G 3' 
BamHI (GÑ GATCC) 
restriction site and stop 
codon. 
 
N term truncated DR_1146 fwd  5' CATATG AGC CGT GAC GAA 
GCC GTG 3' 
NdeI (CAÑ TATG) restriction 
site including  
ATG start codon. 
 
N term truncated DR_1146 rev  5' GGA TCC TTA GAG ATT 
AAC CGT G 3' 
BamHI (GÑ GATCC) 
restriction site and stop 
codon. 
 
N+C term truncated DR_1146 fwd  5' AA GTT CTG TTT CAG GGC 
CCG AGC CGT GAC GAA GCC 
GTG AAG ACG 3' 
5' AA GTT CTG TTT CAG 
GGC CCG ……3' extension 
corresponding to pOPINF. 
 
N+C term truncated DR_1146 rev  5' ATG GTC TAG AAA GCT 
TTA GCC GCT CTC CCA GTA 
TTC GGC GCC 3' 
5' ATG GTC TAG AAA GCT 
TTA ..…3' extension 
corresponding to pOPINF. 
Table 2.2: Oligonucleotide primers for PCR   Chapter 2 Materials and methods   
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2.2.2 Enzymes 
BamHI and NdeI restriction enzymes and their corresponding buffers were 
purchased from New England Biolabs, Hitchin, UK. Pfu DNA polymerase (with10x 
MgSO4 buffer) was purchased from Promega, Southampton, UK. T4 DNA Ligase 
was purchased from New England Biolabs. All enzymes were stored at –20°C. 
2.2.3 Polymerase Chain Reaction (PCR) 
PCR was carried out using a Techgene PCR machine (Techne) and 200  L thin 
wall PCR tubes. The reaction master mix was composed on ice with reagents 
added in the order listed in Table 2.3. The reaction was initiated with a 2 min 
initial denaturing step at 95°C. The cycle consisting of a denaturing step at 95°C 
for 30 s, an annealing step at 68°C for 30 s and an extension step at 72°C for 1 
min, was repeated 30 times. A final extension step was carried out at 72°C for 5 
mins and the reaction was held at 4°C. The annealing temperature was varied 
depending on the melting temperature of the primers. PCR products were 
separated by agarose gel electrophoresis. 
Reagent  Volume of stock solution 
used 
Final Concentration 
dNTP mix  5  L of 2 mM stock   200  M each dNTP 
Forward primer  2.5  L from 10  M stock   0.5  M 
Reverse primer  2.5  L from 10  M stock   0.5  M 
Genomic DNA  1  L of 50 ng/ L stock  1 ng/ L (50 ng in 50  L) 
10 x Pfu buffer with MgSO4  5  L  1 x 
Sterile deionised H2O  33.5  L    
Pfu DNA Polymerase  0.5  L of 3 units/ L stock  1.25 units/50  L 
Total reaction volume  50  L   
Table 2.3: Master mix for PCR 
2.2.4 Agarose gel electrophoresis and gel purification 
Gels of between 0.5 – 2.0 % (w/v) agarose in 1x TAE buffer (Table 2.4), 
supplemented with 0.1  g/mL ethidium bromide were used for the analysis, 
separation and purification of linear and circular DNA. DNA samples were diluted 
5:1 with Blue/Orange 6x loading Dye (Promega) and ran alongside a 1 kb DNA 
ladder (Promega) in order to estimate band size. Gels were run at 100 V for 40 
minutes and imaged under UV light using an Alphalimager™ System (Alpha 
Innotech). If needed, the desired DNA fragment was excised from the gel and   Chapter 2 Materials and methods   
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purified using a QIAquick Gel Extraction Kit (Qiagen) [154] following the 
manufacturer’s protocol.  
Buffer  Composition  Preparation 
50 x TAE  2M Tris Base 
50 mM EDTA pH 8 
5.71% (v/v) glacial acetic acid 
 
pH should be approx 8.5. 
Diluted to 1x for use. 
1 x TE  10 mM Tris HCl pH 7.5 
1 mM EDTA 
 
pH adjusted to 8.0 before use.  
5 x M9 salt solution  33.9 g Na2HPO4 
15.0 g KH2PO4 
2.5 g NaCl 
Make up to 1 L with deionised H2O and 
autoclaved. 
Used at 1x concentration 
Table 2.4: Molecular biology buffers 
2.2.5 Blunt ended insertion of PCR products into pCR
® -Blunt II-
TOPO
® vector 
1  L of pCR
®  Blunt II TOPO
® vector and 2  L sterile H2O was added to 3  L of 
purified PCR product. The reaction was mixed gently and incubated for 5 
minutes at room temperature then quenched on ice. 
2.2.6 Transformation of DH5α competent cells  
1 2 µL of plasmid DNA was used to transform E. coli Library Efficiency® DH5a  ™ 
competent cells (Invitrogen) following the manufacturer’s protocol [155 157]. 
DH5a  cells were used for plasmid storage and maintenance.  The transformed 
cells were then plated onto LB Agar plates with appropriate antibiotic selection 
(Table 2.1) and incubated overnight (20 hrs) at 37°C. The desired result would 
be an even spread of single colonies. 
2.2.7 Isolation of plasmid DNA   
A 5 mL culture of Luria Bertani (LB) media (Table 2.5) containing appropriate 
antibiotic selection was inoculated with a single colony of the desired strain. 
This was incubated overnight at 37°C with shaking. Plasmid extraction and 
purification was carried out using a QIAprep® Spin Miniprep Kit (Qiagen) 
following the manufacturer’s protocol [158]. The concentration and yield of DNA 
was estimated by A260 in conjunction with the Online DNA Concentration 
Calculator available at http://www.pubquizhelp.com/other/dnacalculator.html.   Chapter 2 Materials and methods   
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Media  Composition  Comment 
Luria Bertani (LB) media  10 g/L tryptone 
10 g/L NaCl 
5 g/L yeast extract 
 
Sterilised by autoclaving before 
use. 
LB Agar  LB media  
1.5% (w/v) micro agar 
 
Sterilised by autoclaving before 
use. 
SOC  20 g/L tryptone 
5 g/L yeast extract 
10 mM NaCl 
2.5 mM KCl 
20 mM MgCl2 
20 mM glucose 
 
Purchased from Invitrogen®. 
Stored at 4°C. 
Overnight Express™ Autoinduction 
media 
 
 
Purchased from Novagen® (Merck 
Biosciences) 
 
M9 Minimal media  1 x M9 salt solution  
2 mM MgSO4 
0.1 mM CaCl2 
0.4% glucose solution 
20 mg/L thiamine 
2  M FeCl2 
1 g/L 
15NH4SO4 
1 x M9 salts were prepared from 
5x stock (Table 2 5). Other 
components were made from 
filtered stock solutions. 1 g/L 
15NH4SO4 was added directly. 
Solution was made up in 500 mL 
volumes using sterile deionised 
H2O. 
Table 2.5: Growth media composition 
2.2.8 Double restriction digestion 
Approximately 200 ng of DNA (10 µL) was digested using 10 units (1 µL) of BamHI 
and 10 units (1 µL) of NdeI with the addition of 2 µL buffer D and 6 µL sterile 
H2O. The 20 µL reaction mixture was mixed gently and incubated at 37°C for 3 
hrs. When digesting vector DNA the reaction was incubated overnight at 37°C. 
The resulting product was analysed by agarose gel electrophoresis and purified 
as described in Section 2.2.4.  
2.2.9 Ligation 
T4 DNA Ligase (New England Biolabs) was used to ligate the digested vector and 
insert DNA in a molar ration of 7:1. A typical reaction mixture comprised 1 µL 
vector, 7 µL insert, 1 µL 10 x T4 DNA Ligase Reaction Buffer and finally 1 µL (40 
units) of T4 DNA Ligase. The 10 µL reaction was incubated overnight (20 hrs) at 
16°C. The resulting plasmid DNA was used to transform DH5a  cells and was 
isolated as described in Section 2.2.7.  The concentration and yield of plasmid 
DNA was estimated by A260.   Chapter 2 Materials and methods   
  - 25 -   
2.2.10  DNA sequencing 
Final plasmid DNA was sequenced using T7 forward and reverse primers by The 
Sequencing Service, University of Dundee, UK.  
2.3 Molecular cloning by In-Fusion™ Reaction 
An attempt to clone an N and C terminal truncated form of dr_1146 into a 
pOPINF vector was made using the In Fusion ™ PCR Reaction system (Clontech). 
2.3.1 Deinococcus radiodurans genomic DNA 
Deinococcus radiodurans R1 genomic DNA at a concentration of 250 ng/ L       
was kindly provided by the Macromolecular Crystallography Group, ESRF, 
Grenoble, France. 
2.3.2 pOPINF vector 
The Linearised pOPINF vector was kindly provided by the OPPF, Oxford, UK at a 
stock concentration of 100 ng/ L.  
2.3.3 Oligonucleotides 
Oligonucleotide primers were designed as described in Section 2.2.1. The primer 
extensions required for insertion into pOPINF are shown in Table 2.2. Primers 
were synthesised by Sigma Genosys in a pelleted form. They were reconstituted 
with sterile H2O to a concentration of 100 mM and stored at –20°C. 
2.3.4 In-Fusion™ PCR cloning reaction  
The required DNA insert was amplified by PCR as described in Section 2.2.3. A 
reaction mixture containing 100 ng purified insert, 100 ng linearised and purified 
pOPINF vector was made up to 10  L with sterile H2O and added to a well of the 
dry down In Fusion™ plate. The contents were mixed briefly, sealed and 
incubated for 30 minutes at 42°C. The reaction was immediately quenched with   Chapter 2 Materials and methods   
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40  L TE buffer (Table 2.4). 5  L was used to transform a vial of DH5a  
competent cells.    
2.4 Gene Expression 
2.4.1 Bacterial cell lines 
A summary of the cell lines used is given in Table 2.6. When investigating the 
optimum conditions for gene expression, the desired plasmid DNA was 
transformed into several cell lines.  
Cell line  Genotype  Manufacturer/ reference 
Library Efficiency® DH5a ™  F  φ80lacZ M15  .(lacZYA 
argF)U169 recA1 endA1 hsdR17(r
k
 
, 
m
k
+
) phoA supE44 thi 1 gyrA96 
relA1 λ
 
 
Invitrogen™ 
Hanahan, 1983[155] 
Tartof & Hobbs, 1987[157] 
BL21 Star™(DE3)  F  ompT hsdSB (rB
 , mB
 ) gal dcm 
rne131 (DE3)  
 
Invitrogen™ 
Studier & Moffat, 1986[149] 
Grodberg & Dunn, 1988[152] 
Grunberg Manago, 1999[159] 
 
BL21(DE3)pLysS  F  ompT hsdSB (rB
 , mB
 ) gal dcm 
(DE3) pLysS (Cam
R)  
 
Invitrogen™ 
Studier & Moffat, 1986[149] 
Grodberg & Dunn, 1988[152] 
Moffatt & Studier, 1987[153] 
 
BL21 AI™  F  ompT hsdSB(rB
 , mB
 ) gal dcm 
araB::T7 RNAP tetA  
Invitrogen™ 
Studier & Moffat, 1986[149] 
Grodberg & Dunn, 1988[152] 
Miyada et al., 1984[160] 
Lee, 1980[161] 
Lee et al.,[162] 
 
Rosetta™(DE3)pLysS  F– ompT hsdSB(rB
– mB
–) gal dcm 
(DE3) pLysSRARE (Cam
R) 
 
Novagen® (Merck Biosciences) 
Studier & Moffat, 1986[149] 
Grodberg & Dunn, 1988[152] 
Novy et al., 2001[163] 
Moffatt & Studier, 1987[153] 
Baca & Hol, 2000[164] 
 
Rosetta™ 2(DE3)  F
  ompT hsdSB(rB
  mB
 ) gal dcm 
(DE3) pRARE2 (Cam
R) 
 
Novagen® (Merck Biosciences) 
Studier & Moffat, 1986[149] 
Grodberg & Dunn, 1988[152] 
Novy et al., 2001[163] 
Baca & Hol, 2000[164] 
 
B834(DE3)  F– ompT hsdSB(rB
– mB
–) gal dcm met 
 
Novagen® (Merck Biosciences) 
Wood, W.B., 1966[165] 
Leahy et al., 1992[166] 
Table 2.6: Summary of bacterial cell lines   Chapter 2 Materials and methods   
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2.4.2 Antibiotics 
Antibiotics were selected depending on choice of vector and cell line (Tables 2.1 
and 2.6). 1000 x stock solutions were created at the appropriate strength, with 
the appropriate solvent as outlined in Table 2.7. All stock solutions were filter 
sterilised (0.2  m filter) and stored at  20°C until needed.  
Antibiotic  Stock concentration  Final concentration  Solvent 
Ampicillin  50 mg/mL  50  g/mL  H2O 
Carbenicillin  50 mg/mL  50  g/mL  H2O 
Chloramphenicol  32 mg/mL  32  g/mL  EtOH 
Kanamycin  50 mg/mL  50  g/mL  H2O 
Table 2.7: Antibiotic stock solutions and preparation 
2.4.3 Isopropyl-β-D-thiogalactopyranoside (IPTG) 
A 0.4M stock (1000 x final concentration) of IPTG was filter sterilised (0.2  m 
filter), divided into 1 mL aliquots and stored at –20°C until needed.  
2.4.4 Small scale expression trials in LB media 
A 200 mL culture of LB media (Table 2.5) with the appropriate antibiotic 
selection (Tables 2.1 and 2.7) was inoculated with a single colony from the 
transformation of an E. coli cell line. This was done for each cell line 
transformed. The inoculated culture was incubated at 37°C, with shaking, until 
an A600 of 0.6 was reached. A 0.5 mL sample was taken for SDS PAGE analysis 
(Section 2.4.8) and the culture divided into two equal 100 mL portions. Protein 
production was induced by the addition of 0.4 mM (final concentration) IPTG. 
One flask was incubated, with shaking, at 22°C and the other, with shaking, at 
37°C for 20 hours. 0.5 mL samples of each culture were taken throughout 
incubation and were analysed by SDS PAGE to monitor the expression of soluble 
protein. In the case of low expression or inconclusive SDS PAGE, a western blot 
(Section 2.4.9) was used to identify and analyse the expression of target protein.     Chapter 2 Materials and methods   
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2.4.5 Large scale expression in LB media 
The variables (cell line and temperature) resulting in the largest amount of 
soluble protein were selected for large scale experiments in order to gain 
sufficient yields for crystallisation experiments and biophysical characterisation. 
A 60 mL starter culture, with appropriate antibiotic selection, was inoculated 
with a single colony from a transformation of the successful cell line from initial 
trials. The starter culture was incubated, with shaking, for 20 hours at 37°C until 
an A600 of approximately 3.5 was reached. 5 mL volumes of the starter culture 
were used to inoculate 10 x 0.5 L of LB media (Table 2.5) held in 2 L baffled 
flasks with the appropriate antibiotic selection. The 2 L flasks were incubated, 
with shaking, at 37°C. When an A600 of 0.6 was reached, protein production was 
induced by the addition of 0.4 mM IPTG (final concentration). The temperature 
was adjusted to the optimum setting and the cultures were incubated for 20 hrs 
or for the optimum time established by initial trials.   
2.4.6 Small scale expression trials and large scale expression in 
autoinduction media 
Recombinant expression of sp_1651 was carried out using Overnight Express™ 
Autoinduction media (Novagen) (Table 2.5). Experiments were carried out in the 
same way as those described for LB media (Sections 2.4.4 and 2.4.5) with 
exception of incubation and induction of protein production by the addition of 
IPTG. After inoculation of cultures with either single colonies or starter culture, 
the cultures were incubated at 4 hours at 37°C, with shaking. The temperature 
was then adjusted to the optimum setting and cultures were incubated for 20 
hrs or for the optimum time established by initial trials. 
2.4.7 Harvesting and storage of cells 
E. coli cells were harvested by centrifugation at 5000 rcf for 20 minutes. The 
resulting pellets were weighed and then stored at  80°C until needed. Typically 
batches of cell pellet harvest from 2 L of cells would be used to gain enough 
protein for further experiments but this varied depending on the construct used.   Chapter 2 Materials and methods   
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2.4.8 SDS-PAGE analysis of whole cell pellets 
0.5 mL time point samples taken during initial expression trials were analysed 
using the NuPAGE
® Pre Cast Gel System based on the Laemmli SDS PAGE method 
[167, 168] to establish the presence of expressed target protein. The samples 
were pelleted by centrifugation at 10,000rpm for 10 mins. The LB media was 
removed and the soluble and insoluble cell fractions were isolated and 
normalised using B PER
® Bacterial Protein Extraction Reagent (PIERCE), following 
the manufacturer’s protocol [169]. 20  L aliquots of both the soluble and 
insoluble cell fractions were added to 6 x LDS loading buffer (1 x final 
concentration) and 0.3 mM DTT (final concentration). The resulting samples 
were incubated at 70°C for 10 minutes then briefly centrifuged before loading. 
20  L of each sample were loaded on to a 10 well NuPAGE
® Novex Bis Tris gel 
(Invitrogen) alongside SeeBlue Plus2 Pre Stained Standard (Invitrogen) to 
estimate the molecular weight of the resulting bands. Gels were run at 200V in 
the presence of 1 x MES running buffer (Invitrogen) for 42 minutes. After 
separation, gels were washed briefly with deionised H2O then stained with 
Coomassie Brilliant Blue R250 (0.1 % in 50 % Ethanol, 10 % acetic acid) for 20 
minutes. Gels were destained by brief incubation in destain (40 % Ethanol, 10% 
acetic acid), followed by overnight shaking in deionised H2O.        
2.4.9 Western blot analysis 
If results of SDS PAGE analysis were inconclusive, as was often the case with 
whole cell pellets or poorly expressing proteins, further analysis by western 
blotting was carried out to establish target protein presence and purity 
After running a fresh SDS PAGE gel as described in Section 2.4.8, the protein was 
transferred from the gel onto Immobilon Polyvinylidene difluoride (PVDF) 
membrane (Millipore) following the NuPAGE® Novex Bis Tris Gel Western 
Transfer Protocol (Invitrogen) [167]. This involved the use of the Xcell II™ Blot 
Module and 1x NuPAGE
® Transfer Buffer (Invitrogen). Detection of the 6xHis 
tagged protein was carried out using the SuperSignal
® West HisProb™ Kit (Pierce) 
following the manufacturer’s protocol [170]. When following the SuperSignal
®   Chapter 2 Materials and methods   
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West HisProb™ Kit protocol, film (Kodak) was developed using a X OMAT SRX 
101A system (Konica Minolta).  
2.5 Protein purification 
2.5.1 Buffer preparation  
The pH of buffers was measured and adjusted using a Corning pH meter 240 and 
the appropriate acid or base. The pH meter was calibrated before use according 
to the manufacturer’s instructions using standard buffers of pH 4.0, 7.0 and 
10.0. The pH of buffers for purification was varied depending on the isoelectric 
point (pI) of the target protein but was typically pH 7.5. 
All purification buffers were filter sterilised (0.2  m filter) and degassed under 
vacuum before use. The composition of all buffers used is shown in Table 2.8. 
Buffer  Composition 
Cell lysis buffer  50 mM Tris HCl pH 7.5 
500 mM NaCl 
20 mM imidazole pH 7.5 
5 mM MgCl2 
DNase 
1 Complete EDTA Free Protease Inhibitor Cocktail tablet 
 
Solubilisation buffer  50 mM Tris HCl pH 7.5 
500 mM NaCl 
8 M urea or 6 M guanidine hydrochloride 
 
IMAC wash buffer  50 mM Tris HCl pH 7.5 
500 mM NaCl 
20 mM imidazole pH 7.5 
 
IMAC elution buffer  50 mM Tris HCl pH 7.5 
500 mM NaCl 
500 mM imidazole pH 7.5 
 
IEX buffer A  20 mM Tris HCl pH 7.5 
 
IEX buffer B  20 mM Tris HCl pH 7.5 
1M NaCl 
 
Gel filtration buffer  50 mM Tris HCl pH 7.5 
200 mM NaCl 
Optional addition of 0.01% NaN3, BME or DTT  
Table 2.8: Composition of purification buffers   Chapter 2 Materials and methods   
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2.5.2 Preparation for dialysis 
10 kDa MWCO dialysis membrane (Medicell International Ltd) was boiled in 
deionised H2O for 3 minutes then rinsed with chilled deionised H2O. Typically, a 
protein sample would be dialysed overnight at 4°C against 5 L of the desired 
buffer.  
2.5.3 Mechanical cell lysis 
The required volume of cell pellet was thawed in a 25°C water bath and then re 
suspended in lysis buffer (Table 2.8) with the addition of 1 Complete EDTA Free 
Protease Inhibitor Cocktail Tablet (Roche Applied Science). Typically 5 mL of 
lysis buffer was used per 1 g of cell pellet. The resuspended pellet was 
homogenised then mechanically lysed using either the French Press Cell 
disrupter (Thermo), with 3 passes at 950 psi, or the Constant Cell Disruption 
System, with 2 passes at 20 kpsi, depending on equipment availability and 
sample volume. Throughout cell lysis, the sample was kept on ice in an attempt 
to minimise proteolysis. The resulting lysate was centrifuged at 5700 rcf for 20 
minutes followed by 34,900 rcf for 40 minutes at 4°C. The soluble supernatant 
and insoluble pellet were separated and the soluble supernatant was filtered 
(0.2  m filter).  
If required for purification, the insoluble pellet was solubilised with 
solubilisation buffer (typically 20 mL), which contained 8 M urea (Table 2.8). 
This procedure required continuous stirring at 4°C for 1 hour after which the 
sample was centrifuged for a further 30 minutes at 34,900 rcf. The solubilised 
supernatant was then separated from remaining cell debris and filtered (0.2  m 
filter).  
2.5.4 Immobilised metal affinity chromatography (IMAC) 
The cell lysate was loaded onto a 5 mL HisTrap HR column (GE Healthcare) 
which was pre equilibrated with IMAC wash buffer (Table 2.8). This was done 
using a peristaltic pump at a speed of 3 mL/min at 4°C. The column was 
connected to an AKTA Purifier FPLC (GE Healthcare) and the unbound lysate was 
eluted with IMAC wash buffer at 3 mL/min until A280 reached zero. The protein   Chapter 2 Materials and methods   
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was eluted using a step gradient program which was run at 3 mL/min at 4°C, 
collecting 5 mL fractions. The program included 8 14 column volume steps of 
increasing imidazole concentrations, typically 10, 20 and 100 % IMAC elution 
buffer (Table 2 8). The presence and purity of the target protein was established 
by SDS PAGE analysis of fractions collected. 
2.5.5 Concentration and yield measurement by UV  
Protein concentration and subsequent protein yields were estimated using the 
Beer Lambert Law. To do this, protein molecular weights and extinction 
coefficient values were estimated using the ProtParam tool [171] from the 
ExPASy proteomics server [172]. The absorbance of a purified protein solution in 
a 1cm quartz cuvette was measured using a Lambda 40 spectrophotometer 
(Perkin Elmer). The estimated protein concentration was then used to estimate 
the yield of purified protein depending on the volume eluted after purification. 
Extinction coefficients (ε ), molecular weights (MW) and isoelectric point (pI) 
values estimated for the proteins studied, including vector residues and tags are 
listed in Table 2.9. 
Construct  pI  MW (Da)  ε  (cm
 1 M
 1) 
Full length DR_1146 in pDEST17 with 6xHis tag 
 
5.49  23,400.90  28,420 
Full length DR_1146 in pET 15b with 6xHis tag 
 
5.57  23,206.60  23,590 
Full length DR_1146 in pET 15b without 6xHis tag 
 
4.90  21,324.55  23,590 
N term truncated DR_1146 in pET 15b with 6xHis tag 
 
5.72  20,319.57  23,470 
N term truncated DR_1146 in pET 15b without 6xHis tag 
 
4.97  18,437.52  23,470 
SP_1651 in pOPINF with 6xHis tag 
 
5.27  21,336.10  18,575 
SP_1651 in pOPINF without 6xHis tag 
 
4.73  19,349.90  18,575 
DR_0463 in pDEST17 with 6xHis tag 
 
6.13  111,096.50  150,245 
SP_1648 in pOPINF with 6xHis tag  
 
6.90  28,984.60  16,055 
DR_2284 in pET151/D TOPO with 6xHis tag  7.17  29,954.10  36,565 
Table 2.9: pI, MW and extinction coefficient values for target constructs including 
contributions by tag and expression vector residues. Calculated using ProtParam tool [171] 
available on the ExPASy proteomics server [172].   Chapter 2 Materials and methods   
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2.5.6 Ion exchange chromatography (IEX) 
The IMAC purified target protein was dialysed against 5 L of IEX buffer A (Table 
2.8) to remove NaCl and Imidazole before IEX. A 5 mL QTrap HP anion exchange 
column was equilibrated with IEX buffer A and the dialysed protein sample 
loaded by peristaltic pump at 3 mL/min at 4°C. The column was attached to the 
AKTA Purifier FPLC and the protein was eluted with a linear gradient between 0 
70% IEX buffer B (Table 2 8) over 30 column volumes. 5 mL fractions were 
collected and analysed by SDS PAGE. The resulting purified target protein was 
dialysed against 5 L of gel filtration buffer (Table 2.8) and was then 
concentrated by centrifugation using 10 kDa MWCO concentrators (Vivascience) 
to 10 mg/mL before loading onto a gel filtration column for size exclusion 
chromatography (SEC). 
2.5.7 Size exclusion chromatography (SEC) 
A S200 10/300 HR global gel filtration column (GE Healthcare) attached to an 
AKTA Purifier FPLC at 4°C was equilibrated with gel filtration buffer (Table 2 8). 
The concentrated target protein sample was centrifuged for 10 minutes at 
13,000 rpm and a volume of 500  L (or less depending on the amount of protein 
available) was injected onto the column. The protein was eluted with 1.5 
column volumes of gel filtration buffer at a speed of 0.5 mL/min. 0.5 mL 
fractions were analysed by SDS PAGE and pooled accordingly. The purified 
protein was concentrated by centrifugation to the desired concentration for 
crystallisation experiments or biophysical characterisation. 
2.5.8 Removal of 6xHis tag by thrombin cleavage 
Thrombin cleavage was required to remove the 6xHis tag from protein expressed 
by a pET 15b vector. This step was carried out either after IMAC or gel filtration 
depending on requirement. 0.26 units of thrombin (Novagen) per mg tagged 
protein were added to the sample which was then dialysed against 5 L 20 mM 
Tris pH 7.5, 200 mM NaCl. To remove the thrombin, the sample was loaded by 
peristaltic pump at 1 ml/min, in 5 mL batches, onto a 1mL benzamidine column 
(GE Healthcare) which was pre equilibrated with BC elution buffer (Table 2.8).   Chapter 2 Materials and methods   
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The protein was eluted with 10 column volumes of BC elution buffer at 1 
ml/min. It was then loaded onto a 1 mL HisTrap HR column (GE Healthcare), 
pre equilibrated with IMAC wash buffer, to remove the cleaved 6xHis tag. The 
cleaved protein, with thrombin removed, was then eluted by 10 CV IMAC wash 
buffer and analysed by SDS PAGE. The cleaved protein was pooled together and 
dialysed against 5 L IEX buffer A and then purified further by IEX to ensure that 
the thrombin was completely removed.   
2.5.9 Removal of 6xHis tag by HRV-3C protease 
Tagged HRV 3C protease was required for removal of 6xHis tag from protein 
expressed from the OPINF vector. This step was carried out either after IMAC or 
gel filtration depending on requirement. 5  L of HRV 3C (from a 1 mg/mL stock) 
was used per mg of protein for efficient tag cleavage. The protease was added 
along with 10 mM DTT and 1 mM EDTA and the sample was dialysed against 5L 20 
mM Tris pH 7.5, 200 mM NaCl. It was then loaded on to a pre equilibrated 1 mL 
HisTrap HR column by peristaltic pump at 1 ml/min, 4°C. Protein, with the HRV 
3C protease and 6xHis tag removed, was eluted with 10 column volumes of IMAC 
wash buffer and analysed by SDS PAGE. 
2.5.10  Mass spectrometry 
MALDI TOF and ESI mass spectrometry was performed by Kenneth Beattie, Finger 
Prints Proteomics, University of Dundee, UK. Purified protein was provided as a 1 
mg/mL solution in 20 mM Tris HCl pH 7.5, 50 mM NaCl. Additional small 
molecule ESI MS was carried out by Jim Tweedie, University of Glasgow, UK. 
2.5.11  Cofactor extraction 
Approximately 15 mg of protein was concentrated to a volume of 200  L (over 
100 mg/mL). 100  L MeOH was added resulting in the precipitation of the 
protein. The sample was centrifuged at 13,000 rpm for 30 minutes and the 
supernatant was extracted. This supernatant was analysed by ESI MS.   Chapter 2 Materials and methods   
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2.5.12  Amino acid sequence determination by Edman 
degradation 
Edman degradation was carried out by David Campbell, University of Dundee, 
UK. In preparation, the purified protein was transferred onto PVDF membrane by 
the method described in Section 2.4.8 and stained with Coomassie R 250 for 1 
min. The membrane was then de stained and air dried at room temperature. 
The single band was excised and placed in a sterile eppendorf tube for analysis.  
2.6 Crystallisation experiments 
2.6.1 JBS solubility screen and dynamic light scattering (DLS) 
experiments 
Optimisation of the final protein purification buffer composition prior to 
crystallisation trials was investigated using the JBS Solubility kit (Jena 
Bioscience) [173]. The manufacturer’s protocol was followed [173] to investigate 
the effect of 24 different buffers and 14 different additives on protein solubility 
and aggregation behaviour. The monodispersity of each sample was analysed by 
dynamic light scattering using a Dynapro 801 (Protein Solutions). All samples 
were centrifuged at 13,000 rpm and filtered through a 0.2  m filter before 
testing. The protocol suggested a sample size of 20  L, however, the Dynamo 
801 needed a minimum sample size of 200  L and therefore the experiments 
were scaled up as follows.  
Purified protein was concentrated to over 20 mg/mL by centrifugation. 40  L 
sitting drops (20  L protein: 20  L reservoir buffer) were set up in a 24 well 
sitting drop tray with 0.5 mL of each buffer solution (24) in individual reservoirs. 
The vapour diffusion experiment was incubated overnight at 20°C. After 24 
hours, the drops were investigated for precipitation under a light microscope. 
The clear drops (no precipitation) were pipetted into individual eppendorfs and 
diluted to 200  L with the corresponding buffers resulting in a concentration of 
approximately 1 mg/mL. Each sample was centrifuged at 13,000 rpm for 10 
minutes before DLS experiments were carried out at room temperature. The 
buffer which yielded the most monodispersed DLS reading was selected and the   Chapter 2 Materials and methods   
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protein (at 2 3 mg/mL) was dialysed into a 50 mM concentration of this buffer. 
150  L of protein was added to each of 14 additives, mixed, and then incubated 
for 2 hours at room temperature. DLS experiments were carried out and the best 
additive was selected. The protein was dialysed against the selected buffer and 
additive and concentrated for crystallisation experiments. 
2.6.2 Pre-crystallization test (PCT™) 
After purification to greater than 90 % homogeneity, as estimated by SDS PAGE, 
and in some cases, determination of the optimum crystallisation buffer, target 
protein was concentrated to 20 mg/mL by centrifugation. In order to determine 
the optimum protein concentration for crystallisation experiments a pre 
crystallization test (PCT™) (Hampton Research) was carried out. This was done 
for concentrations of 20, 15, 10 and 5 mg/ml following the manufacturer’s 
protocol [174]. The concentration of the stock target protein was adjusted 
according to PCT™ results.  
2.6.3 Initial sparse matrix crystallisation screening 
Initial sparse matrix crystallisation screening was carried out at 20°C using the 
sitting drop vapour diffusion method. The MICROLAB
® STAR liquid handler 
(Hamilton Life Science Robotics) was used to distribute 50  L reservoir volumes 
of commercial screens into 96 well MRC plates (Innovadyne). The Cartesian™ 
Dispensing System (Genomic Solutions
®) was then used to aliquot a protein drop 
volume of 0.5  L followed by a 0.5  L reservoir drop for each of the 96 
conditions in the plate. Fifteen commercial sparse matrix screens were used and 
are listed with (Table 2.10). Each tray set up was bar coded and stored in a 
Rhombix™ Imaging System (Thermo Electron Corporation) at 20°C which allowed 
crystal growth to be monitored for three months. Photos were taken every day 
for the first week of incubation and once per week thereafter. 
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Crystal screen name  Manufacturer 
Crystal Screens 1 and 2  Hampton Research 
Cryo Screens 1 and 2  Emerald Biosystems 
PACT Screens 1 and 2  Molecular Dimensions 
JCSG plus Screens 1 and 2  Molecular Dimensions 
Peg/Ion Screens 1 and 2  Hampton Research 
Structure Screens 1 and 2  Molecular Dimensions 
Wizard Screens 1, 2 and 3  Emerald Biosystems 
Table 2.10: Commercial sparse matrix crystallisation screens 
2.6.4 Testing X-ray diffraction quality of initial crystals 
Before testing, the crystals were soaked in a range of cryoprotectants. Crystals 
were initially tested in house on a MicroMax™   007 X ray generator (Rigaku) 
equipped with a Cryo cooling system (Oxford Cryo Systems) and a Mar345 
detector. Synchrotron radiation sources (SRS) at ESRF, Grenoble, France and 
Diamond, Oxford, UK were also used to assess crystal diffraction. CrystalCap 
Copper Magnetic™ bases and Mounted CryoLoops™ were purchased from Hampton 
Research. 
2.6.5 Optimisation of initial crystal hits 
Attempts at reproducing and optimising initial crystallisation conditions were 
carried out by varying the pH and precipitant/salt type and concentration. 
Optimisation experiments were designed using Screen Designer software and 
executed using the MICROLAB
®STAR liquid handler. Drop set up and tray 
incubation was carried out as describe in Section 2.6.3.  
2.7 Biophysical characterisation 
2.7.1 Cofactors used for biophysical characterisation 
The cofactors riboflavin, riboflavin 5’ monophosphate sodium salt dihydrate 
(FMN), and flavin adenine dinucleotide disodium salt hydrate (FAD) were 
purchased form Sigma Aldrich and were used in biophysical characterisation 
experiments without further purification. Their structures are depicted in Figure 
2.1.   Chapter 2 Materials and methods   
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Figure 2.1: Structures of cofactors used for ITC experiments: riboflavin, riboflavin 5'-
phosphate sodium salt (FMN) and flavin adenine diphosphate disodium salt (FAD) 
2.7.2 Isothermal Titration Calorimetry (ITC) 
ITC was performed by Margaret Nutley, BBSRC/EPSRC Biological Microcalorimetry 
Facility, University of Glasgow, UK. ITC experiments to measure protein – 
cofactor complexation thermodynamics were done at 25°C using a VP ITC 
titration microcalorimeter (MicroCal) following standard instrumental procedures 
[175, 176]. Purified protein was dialysed extensively against 20 mM Tris pH 7.5, 
150 mM NaCl. The same buffer was used to prepare the cofactors. Samples were 
degassed gently immediately before use. A typical binding experiment involved 
an initial 1  L pre injection followed by 28 x 10  L sequential injections of 
cofactor solution (typically 0.2 0.4 mM concentration, determined using  = ε  
12,200 M
 1cm
 1 at 445 nm) into the ITC cell (1.4 mL active volume, 310 rpm 
stirring) containing protein solution (typically 18 21  M). Control experiments 
were performed under identical conditions by injection of cofactor into buffer   Chapter 2 Materials and methods   
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alone to correct for heats of cofactor dilution. Integrated heat effects, after 
correction for heats of dilution, were analysed by non linear regression in terms 
of a sequential single site binding model using the standard Origin 5.0™ 
(MicroCal) software package in order to determine the stoichiometry of binding 
(N), the association/dissociation constants (KA = 1/ KD) and the enthalpy of 
binding ( ° H   ). Other thermodynamic quantities were calculated using standard 
expressions shown in Equation 2.1.  
o o o S   . T H   = K ln . RT = G   -   - (1 cal = 4.184 J).        Equation 2.1      
2.7.3 Fluorescence Spectroscopy (FS) 
Fluorescence emission and excitation spectra were determined on protein FMN 
samples in an aqueous buffer of 20 mM Tris HCl, 150 mM NaCl. A Spex Fluoromax 
instrument with 5 nm slits was used with 1 cm pathlength quartz cuvettes, 
thermostatted at 25°C. Excitation was induced at 445 nm, with emission 
recorded at 520 nm. The FMN cofactor was prepared in buffer at a concentration 
of 10  M, giving an absorbance of less than 0.12 at  exc l to avoid inner filter 
effects. Fluorescence titration curves were obtained by adding 10  L volumes of 
protein stock solutions (made up in the cofactor solution to avoid dilution 
effects) to 2.5 mL of FMN. The dissociation constant (KD) and number of binding 
sites per mole of protein in solution (N) for the protein FMN complex was 
determined using the quenching of FMN fluorescence upon binding to the 
protein. Data were fitted to standard hyperbolic binding curves using Origin 5.0™ 
software. Data analysis was carried out by Professor Alan Cooper, Department of 
Chemistry, University of Glasgow. 
Fluorescence emission and excitation spectra for the addition of protein to 10 
 M FMN solution were recorded as described above.  
2.7.4 Differential Scanning Calorimetry (DSC) 
DSC experiments were carried out by Margaret Nutley, Biophysical Chemistry, 
University of Glasgow. DSC experiments on protein cofactor complexes were 
conducted on a VP DSC calorimeter and thermal transitions were analysed using 
MicroCal Origin 5.0™ software following the subtraction of the instrumental   Chapter 2 Materials and methods   
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buffer buffer baseline. The sample cell in each experiment contained a pre 
mixed solution of 92  M protein and varying concentrations of cofactor (0 2 mM) 
prepared in 20 mM Tris HCl pH 7.5, 150 mM NaCl, with identical buffer (ensured 
by dialysis) in the reference cell. Samples were briefly degassed before loading 
and scanned over a 20 120°C temperature range at a scan rate of 60°C/h. 
To assess how well the protein refolds after temperature denaturation, samples 
were cooled to room temperature and the DSC scan was repeated. The resulting 
data were compared with that gained from initial experiments. 
2.7.5 Circular Dichroism (CD) 
CD experiments and data analysis were carried out by Dr. Sharon Kelly, Protein 
and Nucleic Acid Characterisation Facility, University of Glasgow, UK. 
CD spectra were recorded for 6xHis tagged and untagged DR_1146 in 50 mM 
phosphate buffer pH 7.5, 150 mM NaCl, in the presence and absence of FMN, 
using a Jasco 810 spectropolarimeter at 20°C. Spectra were recorded in the far 
UV region (187 260 nm) at a typical concentration of 0.5 mg/mL using 0.02 cm 
path length quartz cuvettes. Experiments in the near UV region (320 250 nm) 
were recorded using 0.5cm pathlength cuvettes and a protein concentration of 1 
mg/mL. Data were collected using the following instrument parameters: 
bandwidth 1 nm; scanning rate 50 nm/min; response time 0.5 s and data pitch 
0.2 nm. 
CD peptide backbone conformations can be estimated from spectral 
contributions in the far UV region (240 180 nm). Data were submitted to 
Dichroweb, an online server hosting various secondary structure deconvolution 
algorithms [177]. Estimates of secondary structure content were obtained using 
both the CONTIN procedure and the CDSSTR algorithm [178].  
The unfolding of DR_1146, using guanidine hydrochloride (0 to 6 M) or a 
temperature gradient (5 to 80°C), in the presence and absence of two equimolar 
amounts of FMN, was monitored by CD in the near and far UV regions. The 
experimental set up, sample preparation and procedure was identical to that for   Chapter 2 Materials and methods   
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initial CD experiments (described above). Graphs displaying experimental data 
were produced using Origin software. 
2.7.6 Analytical Ultracentrifugation (AUC) 
Analytical ultracentrifugation (AUC) experiments and data analysis were carried 
out in collaboration with Dr. Olwyn Byron, Division of Infection and Immunity, 
Faculty of Biomedical and Life Science, University of Glasgow, UK.  
Purified protein, at a concentration of 35 mg/mL, was dialysed against a buffer 
of 5 mM FMN, 50 mM Tris HCl pH 7.5, 200 mM NaCl. The dialysate was used in 
the solvent channels of the AUC cells. The concentration dependent 
oligomerisation behaviour of the protein was determined using sedimentation 
equilibrium (SE) and sedimentation velocity (SV) AUC. 
2.7.6.1  Sedimentation velocity (SV)  
A SV experiment was performed using a Beckman Coulter (Palo Alto, CA, USA) 
Optima XL I AUC and an AN 60 Ti rotor. 380  L samples (0.35, 1, 3.5, 10, 22 and 
35 mg/mL) were loaded into 12 mm double sector centrepieces and the 
dialysate was loaded into the second sector. Experiments were performed at 
4°C, at a rotor speed of 49 krpm. A series of 480 scans, 1 minute apart, was 
obtained for each sample, using interference optics. Sedimentation profiles were 
analysed with SEDFIT software [179], which allows the subtraction of systematic 
noise and direct modelling of the sedimentation boundary as a continuous 
distribution of discrete non interacting species (c(s) analysis). The sedimentation 
coefficients that best fitted the Lamm equation were found by finite element 
analysis in SEDFIT [179].  
Buffer density (ρ), viscosity (η) and the partial specific volume (ν) of the 
protein at 4°C and 20°C were calculated using SEDNTERP software [180].  
Apparent sedimentation coefficients (s b , 4 ) for protein species at 4°C in buffer, 
were determined by integration of corresponding peaks. Subsequent true 
sedimentation coefficients (s w , 20 ), corrected for solvent viscosity and density 
were calculated using Equation 2.2:   Chapter 2 Materials and methods   
  - 42 -   
( )
( )
s ×
η
η
×
ρ ν 1
ρ ν 1
= s b , 4
w , 20
b , 4
b , 4
w , 20
w , 20 -
-
      Equation 2.2 
where, 20 = 20°C, w = water, 4 = 4°C and b = buffer. 
Values of s w , 20  were then plotted against protein concentrations (mg/mL) to 
establish the apparent sedimentation coefficient for a given protein species at 
zero concentration (s
o
w , 20 ).    
A theoretical estimate of sedimentation coefficient for the protein, if assumed 
to be a hydrated sphere, was calculated using the following sequence of 
equations (Equation 2.3 to 2.7). 
Anhydrous volume 
A N
ν M
= V         Equation 2.3 
If the protein is spherical, spherical radius R can be determined from 
rearrangement of  
3
3
4 R π = V             Equation 2.4 
The frictional coefficient,  0 f , of the anhydrous sphere of radius R  
R πη = f 6 0             Equation 2.5 
The sedimentation coefficient for an anhydrous sphere ( anhyd s ) with the same 
molar mass as the protein is calculated from 
( )
0
- 1
=
f N
ρ ν M
s
A
            Equation 2.6 
Using a conversion factor of 0.86 (determined using buffer density, partial 
specific volume and a hydration level of 0.4 g/g protein), the sedimentation 
coefficient for a hydrated sphere ( hyd s ) is equal to  
( ) anhyd hyd s . s 86 0 =             Equation 2.7   Chapter 2 Materials and methods   
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Comparison of  hyd s  with experimentally determined s
o
w , 20  can indicate if the 
protein is more extended in shape than a regular sphere. 
2.7.6.2  Sedimentation equilibrium (SE) 
A SE experiment was carried out in a Beckman Coulter (Palo Alto, CA, USA) 
Optima XL I analytical ultracentrifuge, using interference optics. Experiments 
were conducted at 4°C and at rotor speeds of 20, 30 and 40 krpm. Scans were 
obtained at each speed until satisfactory overlay of traces separated by 3 h was 
obtained, indicating attainment of equilibrium. 80  L of the same seven samples 
and buffer used for the SV experiment were loaded into the same counterpieces. 
The data collected were analysed by global modelling using SEDPHAT [181] 
software (http://www.analyticalultracentrifugation.com/sedphat/).  
The apparent weight average molecular weights ( app , w M ) were determined by 
fitting data obtained at 20, 30 and 40 krpm both individually and globally with a 
species analysis model.  
To determine association constants (KA) for the self association of the protein 
datasets were fitted with several different self association models. SE data 
acquired with interference optics generate KA values with units of fringes
 1. It 
was essential to convert this to units of M
 1 using a numerical conversion factor 
established by plotting fringes (obtained from SV analysis) against molar protein 
concentration to give a linear gradient (Figure 2.2 and Table 2.11). 
[Protein] (mg/mL)  [Protein] ( M)  Fringes 
0.35  19.0   1.5 
1  54.2   3 
2  108.5   4 
3.5  189.8   7 
10  549.8  11 
22  1193.2  36 
35  1898.3  60 
Table 2.11: The number of interference fringes generated by the seven protein 
concentrations used in the SV experiment.   Chapter 2 Materials and methods   
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Figure 2.2: Plot of fringes against molar protein concentration to give a numerical 
conversion factor of 30733 fringes M
-1. 
The subsequent relationship between fringes and molar concentration is 
described in Equations 2.8, 2.9 and 2.10. 
M 30733 = fringes             Equation 2.8 
( )
1 5 1 M 10 / 25 . 3 fringes
- - - =          Equation 2.9 
So KA (M
 1) = KA (fringes
-1)/(3.25/10
-5)        Equation 2.10 
Hence, to convert from units of fringes
 1 to M
 1, the value of KA (in fringes
 1) was 
divided by 3.25/10
 5. KA in units of M
 1 was then used to determine the molar KD 
for self association (KA = 1/KD).  
2.7.7 Nuclear Magnetic Resonance (NMR) 
NMR experiments and data analysis were carried out by Dr. Brian Smith, 
Structural Biology, University of Glasgow, UK. 
2.7.7.1  One-dimensional, non-labelled NMR experiments 
Recombinant, T_ DR_1146 was expressed in LB media (Table 2.5) from a pET 15b 
vector in E. coli BL21 Star(DE3) cells as described in Section 2.4.5. The protein 
was purified as in Section 2.5.4 – 2.5.6 and samples, with and without the 6xHis 
tag, were eluted from a S200 10/300 HR Global gel filtration column in a buffer 
of 50 mM Tris pH 7.5, 150 mM NaCl, 0.01% NaN3. An additional T_DR_1146_clvd   Chapter 2 Materials and methods   
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sample was purified in the presence of 1 µM FMN. The samples were typically 
concentrated to 0.6 mM in a volume of 600  L.  
All NMR measurements were performed using a 600 MHz Bruker Avance 
spectrometer equipped with a TCI CryoProbe™ (Bruker BioSpin), at a proton 
frequency of 14.1 T and a temperature of 25 °C. 
For non labelled experiments the sweep width, number of complex points and 
number of scans were 8993 Hz, 4608 points and 8 scans respectively. A method 
of excitation sculpting for water suppression was employed [182]. 
2.7.7.2  Two-dimensional 
15N-
1H Heteronuclear Single Quantum Correlation 
Spectrum (HSQC) 
15N labelled T_DR_1146_clvd was produced by expression in M9 minimal media 
(Table 2.5) using 
15NH4SO4 glucose (Spectra Stable Isotopes) as the sole nitrogen 
source. The sample was purified as in Sections 2.5.4 – 2.5.6 with a final gel 
filtration step into a buffer of 50 mM sodium phosphate pH 7.5, 150 mM NaCl, 
0.01% NaN3. The purified 
15N labelled protein was concentrated to 0.9 mM and a 
sample volume of 600 L.  
15N 
1H HSQC experimental parameters included a sweep width of 8389 Hz and 
896 complex points for 
15N F1, and a sweep width of 1642 Hz and 64 complex 
points for 1H F2.   
After initial HSQC experiments on the T_DR_1146_clvd sample, aliquots of FMN 
from a 50 mM stock solution (high concentration to avoid dilution affects) were 
added to investigate the amount needed to saturate the protein.   
- 46 - 
3  Cloning, expression and purification of DR_1146  
3.1 Expression and purification of dr_1146 from pDEST17 
3.1.1 Construct design 
A full length form of the dr_1146 gene (nucleotide residues 1 to 582), cloned 
into a pDEST17 vector (Table 2.1), was kindly provided by Protein’eXpert, 
Grenoble, France. The nucleotide and putative amino acid sequence for DR_1146 
is annotated on the Comprehensive Microbial Resources database [6] which can 
be accessed on the web page of The J. Craig Venter Institute [7]. 
3.1.2 Recombinant expression of dr_1146 from pDEST17 
1  L plasmid DNA (dr_1146 in pDEST17) was used to transform BL21 Star(DE3) 
competent cells by the method described in Section 2.2.6. 20  L of the 
transformation reaction mixture gave an even spread of single colonies after 20 
hrs incubation at 37°C. 
Recombinant dr_1146 was expressed in LB media (Table 2.5) from the pDEST17 
vector (Table 2.1) as described in Section 2.4.5. A 100 x dilution of starter 
culture was used to initiate cell growth in a 500 mL culture which was incubated 
at 37 °C until an OD600 of 0.6 was reached. The cells were then induced with 
IPTG and incubated for 20 hrs at 22°C. SDS PAGE analysis of cell extracts taken 
after this incubation period determined that DR_1146 was expressed in both 
soluble and insoluble forms in equal amounts.  
Expression was scaled up to 4 x 500 mL cultures as described in Section 2.4.5. 
This resulted in sufficient yield of soluble protein in order to set up 
crystallisation experiments, thus no efforts were made to reduce the amount of 
insoluble protein production.   Chapter 3 Cloning, expression and purification of DR_1146   
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3.1.3 Optimised IMAC purification of DR_1146 
Cell pellet from 2 L of culture was re suspended in 30 mL of lysis buffer (Table 
2.8) and the cells were lysed by French press as described Section 2.5.3. After 
centrifugation the soluble lysate was loaded on to a 5 mL HiTrap HR column as 
described in Section 2.5.4. and flushed with 10 CV of IMAC wash buffer to 
remove unbound proteins. 
IMAC was carried out on an AKTA Purifier FPLC as described in Section 2.5.4.and 
the program employed is depicted in Table 3.1.  
Step number  Number of 
column volumes 
(1 CV = 5 mL) 
% IMAC Wash 
Buffer (20 mM 
imidazole) 
% IMAC Elution 
Buffer (500 mM 
imidazole) 
Effective 
imidazole conc. 
(mM) 
1  10  100  0  20 
 
2  20  90  10  68 
 
3  12  80  20  116 
 
4  10  0  100  500 
Table 3.1: Optimised IMAC protocol 
Figure 3.1 shows the resultant A280 elution profile for the optimised purification 
of DR_1146. Peaks 1, 2 and 3 correspond to protein eluted with 10, 20 and 100 % 
IMAC elution buffer respectively.   Chapter 3 Cloning, expression and purification of DR_1146   
  - 48 -   
 
   0 
 500 
1000 
1500 
2000 
mAU 
  0   50  100  150  200  ml 
F2  A1  A2  A4  A5  A6  A7  A8  A9 A11 B1  B2  B3  B4  B5  B6  B7  B8  B9  B11  C1  C2  C3  C4  C5  C6  C7 C9  C11  D1  D2  D3  D4  D5  D6  D7  D8  D11  E1  E2  E3  E4  E5  E6  Waste 
A280 elution profile 
Fractions collected 
% IMAC elution buffer 
Peak 1  Peak 2 
Peak 3 
10 % IMAC elution buffer 
20 % IMAC elution buffer 
100 % IMAC elution buffer 
 
Figure 3.1: A280 elution profile for optimised IMAC purification of DR_1146. Contaminant 
proteins are eluted with 10 and 20 % IMAC elution buffer steps. Peak 3 corresponds to the elution 
of SP_1651 with 100 % IMAC elution buffer. 
An SDS PAGE analysis of the fractions collected for each peak is shown in Figure 
3.2. A large proportion of impurities present in the initial lysate (lane 1) did not 
bind to the column and thus were eluted in the column flow through (lane 2). 
Subsequent 0, 10 and 20 % IMAC elution buffer washes (lanes 3, 4 and 5 
respectively) removed further impurities. A strong 24 kDa band which 
corresponds to DR_1146 (lane 6) was eluted in the large peak 3 (2400 mAU) of 
Figure 3.1. The strong affinity of the 6xHis tag for the Ni
2+ column matrix 
allowed efficient purification of the target protein by IMAC.  
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When pooling together fractions D10 to E3 (corresponding to peak 3 of Figure 
3.1) for further purification, a pale yellow colour was observed. A yield of 50 mg 
protein was calculated via measurement of absorption at 280 nm (Section 2.5.5).  
A faint band below the main DR_1146 band (lane 6) in Figure 3.2 was observed 
from the time of cell lysis (lane1). During initial purification trials, an ion 
exchange purification step (Section 2.5.6) was carried out in an attempt to 
separate these two entities. Although partial separation was possible, continued 
monitoring of the higher molecular weight separated band showed a decrease in 
intensity with the reappearance of the lower molecular weight band. This 
observation confirmed that proteolysis of DR_1146 was occurring.  
3.1.4 Gel filtration of DR_1146 and subsequent crystallisation 
experiments 
The IMAC purified DR_1146 was dialysed against a gel filtration buffer of 50 mM 
Tris HCl pH 7.5, 200 mM NaCl and was concentrated by centrifugation to 10 
mg/mL. It was then purified further by size exclusion chromatography (SEC) 
using an analytical S200 10/300 HR Global gel filtration column. This was carried 
out in 500  L batches as described in Section 2.5.7. Figure 3.3 shows the 
resultant A280 elution profile from the SEC experiment. The large single peak 2 
was eluted in a buffer volume of 14.93 mL. Comparison with the column 
calibration profile suggests a molecular weight of 46.5 kDa, which indicates that 
DR_1146 exists as a dimer in solution. Although not within the column void 
volume (7.77 mL) a very small peak seen at 12.61 mL was thought to be due to 
aggregation of the concentrated protein.   Chapter 3 Cloning, expression and purification of DR_1146   
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Figure 3.3: A280 elution profile for analytical gel filtration experiment to increase purity and 
determine oligomeric state of DR_1146. It shows a peak eluted in a buffer volume of 14.93 mL 
suggesting a dimeric conformation in solution. The small peak at 12.61 mL could be attributed to 
protein aggregation. 
While lanes 7 and 8 of Figure 3.2 illustrate further purification of DR_1146 by gel 
filtration, the increase in intensity of the lower molecular weight band shows 
the extent of protein degradation. This experiment was carried out two days 
after cell lysis.  
The resulting elution from gel filtration (lanes 7 and 8 of Figure 3.2) was 
concentrated to 20 mg/mL and crystallisation experiments with all commercial 
and in house screens listed in Table 2.10 were set up as described in Section 
2.6.3. Trays were stored at 20°C and monitored using a Rhombix Imaging System 
for duration of three months. The complete experimental process, consisting of 
IMAC, gel filtration and crystallisation set up was performed in a minimum time 
period of two days in an attempt to minimise the extent of protein degradation.   
After a three month period of monitoring crystallisation experiments, no protein 
crystal growth occurred. It was thought that this may be due to either (a) the 
presence of the 6xHis tag (b) the proteolysis of the target protein or (c) possible 
aggregation during concentration for crystal trials.   Chapter 3 Cloning, expression and purification of DR_1146   
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On concentration of the protein for crystal trials an increase in intensity of the 
yellow colour of DR_1146 was observed. 
3.1.5 Non-reduced SDS-PAGE analysis of DR_1146 
Lanes 2 and 4 of Figure 3.4 show SDS PAGE analysis of non reduced DR_1146 
samples, prepared without the addition of 0.3 mM DTT. In comparison with 
reduced samples (lanes 3 and 5) a strong band at approximately 48 kDa can be 
seen. The intensity of this band is significantly reduced on addition of 0.3 mM 
DTT. In combination with the gel filtration result previously described, this mass 
shift suggests that DR_1146 exists as a dimer.  
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Figure 3.4: SDS-PAGE analysis of non-reduced and reduced samples of purified DR_1146 
MALDI TOF analysis of these samples was inconclusive due to degradation of 
DR_1146. There were a number of masses in the 23000 Da region that could give 
rise to a dimer with a molecular mass of about 47000 Da. 
3.1.6 Investigating degradation of DR_1146  
In an attempt to slow or prevent the observed degradation, the following 
modifications to the purification protocol were made: (a) additional Complete 
EDTA free Protease Inhibitor Cocktail Tablets were added both before and after 
cell lysis and (b) EDTA was added after IMAC. Neither of these changes resulted 
in retardation of degradation and subsequently had no impact on crystallisation. 
20 µL samples of purified DR_1146 were incubated at 37°C to investigate the 
extent of proteolysis. The resultant samples were analysed by SDS PAGE and 
western blot.   Chapter 3 Cloning, expression and purification of DR_1146   
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In total, five degraded bands were imaged by SDS PAGE. Three of the five bands 
could be seen on both the SDS PAGE gel and the developed film from the 
western blot. For these bands, this result suggested that the N terminal 6xHis 
tag was still intact after degradation. This implied that the proteolysis reaction 
was occurring at the C terminus. 
The other two degraded bands could be seen only on the SDS PAGE gel 
suggesting that the 6xHis tag needed for detection by western blot was no longer 
intact. This indicated that some proteolysis was also occurring at the N terminal 
of the construct resulting in the removal of the 6xHis tag. 
In conclusion proteolysis is probably occurring at both the N and C terminal of 
DR_1146.   
3.2 Re-cloning of dr_1146 into pET-15b  
3.2.1 Aims and reasoning behind construct design 
In order to investigate the impact of controlled 6xHis tag removal on protein 
crystal growth a full length (FL) and truncated (T) form of the dr_1146 gene 
were cloned into a pET 15b vector with a thrombin cleavable, N terminal 6xHis 
tag.  
Throughout this chapter, protein encoded from the full length gene with the N 
terminal 6xHis tag still intact will be referred to as FL_DR_1146. The protein 
with the 6xHis tag cleaved using thrombin will be referred to as 
FL_DR_1146_clvd.  
The full length insert (fl_dr_1146) consisted of nucleotide residues 1 to 582, 
taken from the Comprehensive Microbial Resources database (CMR) [6, 7] and is 
shown in Appendix 1.  
An N terminal truncated version of the dr_1146 gene (t_dr_1146) was created in 
an attempt to diminish possible occurrence of N terminal proteolysis observed 
for the pDEST17 construct. This gene consisted of nucleotide residues 88 to 582 
taken from the CMR database [6] and is shown in Appendix 2. The reasoning   Chapter 3 Cloning, expression and purification of DR_1146   
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behind the design of this insert was based on the analysis of the following results 
and observations: 
(a) The RONN server [183 185] predicted disorder in the first 37 residues of the 
amino acid sequence of full length DR_1146. Figure 3.5 shows the trace 
generated by the RONN server, which maps the predicted probability of disorder 
in the amino acid sequence. The probability of disorder for the first 37 residues 
(marked in red) is displayed by a probability greater than 0.5. As disorder is 
considered to be unfavourable for ordered nucleation and subsequent protein 
crystal growth, it was decided to remove this mobile region. 
 
1  MCGLAHSPDM SDNKNAGQSSDSQGNGAPQMSRDEAVKTVAGLVKGIKFAM 
 
51  LVSVNDAGHIHSRPMTTQETEFDGDIWFIGAKDSEVVHDVRSRPQVNVSY 
 
101  ADTGSNNYVSVHGTAELIEDRAKLDELWSDMYNMYFEGGKEDPNVQLIKI 
 
151  NAEGAEYWESGGKVRTLFAFAKNLIPGQRADASELGKNDTVNL 
   
Figure 3.5: RONN [183-185] disorder prediction and amino acid sequence of DR_1146. 
RONN plot shows that the first 37 amino acid residues (red) are predicted to be disordered 
(probability > 0.5). Residue Met30 (blue) is thought to encode the true nucleotide sequence start 
codon. 
(b) Figure 3.5 also shows the predicted full length amino acid sequence of 
DR_1146, taken from the CMR database [6, 7]. It can be seen that residue 30 of 
the amino acid sequence is a methionine (marked in blue). It is a possibility this 
methionine could be encoded by the true start codon of the nucleotide 
sequence, with the original full length sequence being wrongly annotated on the 
CMR database [6].    Chapter 3 Cloning, expression and purification of DR_1146   
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(c) A NCBI BLAST [58, 59] search was carried out in an effort to identify proteins 
with amino acid sequence homology to DR_1146. Comparisons of the top five 
homologous proteins begin at around residue 30 of the full length sequence of 
DR_1146. This information contributes to the hypothesis that the sequence 
depicted by the CMR database [6, 7] may have been wrongly annotated.  
As a result of the above findings, primers were designed to produce an N 
terminal truncated construct that would facilitate transcription at the ATG 
codon (nucleotide residues 88, 89 and 90) encoding amino acid residue 30, the 
third methionine of the full length sequence.  
An NdeI recognition site was incorporated into the FL and T forward primers, and 
a BamHI recognition site was included into the FL and T reverse primers in order 
to allow insertion into a pET 15b vector. The complete composition of the 
designed FL and T forward and reverse primers are shown in Table 2.2.   
3.2.2 Cloning of full length and truncated dr_1146 into pET-15b 
using restriction enzymes 
The construct DNA of dr_1146 in pDEST17 was used as the DNA template in the 
PCR step of the re cloning experiment. The master mix recipe and temperature 
cycle used are shown in Section 2.2.3 and Table 2.3.  
An optimum annealing temperature of 68°C was established by preliminary 
experiments resulting in successful amplification of both fl_dr_1146 and 
t_dr_1146 as shown in Figure 3.6. The strong bands in lanes 1 4 correspond to 
successful amplification of the full length gene fragment of 582 bp and those in 
lanes 6 9 to that of the N terminal truncated gene fragment of 495 bp.   Chapter 3 Cloning, expression and purification of DR_1146   
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Lanes 1 4: fl_dr_1146 (582 bp) 
 
Lane 5: BenchTop 1 kb DNA ladder 
 
Lanes 6 9: t_dr_1146 (495 bp) 
 
Figure 3.6: PCR amplification of fl and t_ dr_1146 gene fragments imaged by agarose gel 
electrophoresis. 
These bands were extracted and purified then were inserted into the pcR Blunt 
II TOPO vector (Table 2.1) via the protocol outlined in Section 2.2.5 [151]. The 
success of the insertion reaction was confirmed by an even spread of colonies on 
an LB Agar plate after transformation of DH5a cells. Two single colonies for 
each construct were picked and prepared by Miniprep.  
Double digestions of both the TOPO reaction products and the pET 15b vector 
were carried out following the protocol outlined in Section 2.2.8. Agarose gel 
electrophoresis confirmed successful digestion of the TOPO reaction products 
and successful linearisation of pET 15b (Figures 3.8 and 3.9). 
Successful linearisation of pET 15b can be seen in lane 1 of Figure 3.7. This is 
shown by a decrease in size compared to an undigested pET 15b sample in lane 
2. It was extracted from the gel and purified as described in Section 2.2.4.  
 
  1                  2                   3                  4 
Lane 1: Linearised pET 15b with BamHI and NdeI 
Lane 2: Negative control – pET 15b with no  
BamHI or NdeI 
Lane 3: pET 15b with BamHI only 
Lane 4: pET 15b with NdeI only 
Figure 3.7: Linearisation of pET-15b with BamHI and NdeI restriction enzymes. 
Lanes 1 3 of Figure 3.8 show the successful release of the full length fragments 
from the TOPO reaction product after digestion with NdeI and BamHI restriction 
enzymes.    Chapter 3 Cloning, expression and purification of DR_1146   
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Figure 3.8: Restriction digestion of full length TOPO reaction product resulting in release of 
fl_dr_1146 insert. 
Lanes 1 and 3 of Figure 3.9 show release of the truncated fragment from the 
TOPO reaction product after digestion with NdeI and BamHI restriction enzymes.    
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Figure 3.9: Restriction digestion of truncated TOPO reaction product resulting in release of 
t_dr_1146 insert 
The two inserts for each construct were extracted and purified then ligated into 
the linearised pET 15b vector as described in Section 2.2.9. All four reactions 
gave single colonies after transformation into DH5a  cells confirming a positive 
ligation reaction. The newly cloned full length and truncated DNA constructs 
were prepared by Miniprep. 
A successful restriction digestion with NdeI and BamHI restriction enzymes 
confirmed the presence of inserts in the vector for both full length and 
truncated constructs. DNA sequencing and comparison of results with the CMR 
database [6, 7] sequence (Appendices 1 and 2) confirmed the correct identity 
and codon distribution of the inserts.   Chapter 3 Cloning, expression and purification of DR_1146   
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3.2.3 Expression of fl_ dr_1146 from pET-15b 
1  L fl_dr_1146 plasmid DNA (fl_dr_1146 in pET 15b) was used to transform BL21 
Star(DE3) competent cells and resulted in an even spread of single colonies after 
a 20 hr incubation at 37°C.  
A 100 x dilution of starter culture was used to initiate cell growth in two 500 mL 
cultures which were incubated at 37°C until an OD600 of 0.66 and 0.7 was 
reached. The cells were then induced with IPTG and one of the flasks was 
incubated for at 37°C and one at 22°C for duration of 20 hrs. At 2, 4, 5, 6 and 20 
hr time points, an OD600 reading was taken and a 1 mL sample from each culture 
was taken. Theses samples were then normalised to an OD600 of 5 and the 
soluble fractions were analysed by SDS PAGE as shown in Figure 3.10. 
Comparison of the bands in lane 6 indicates that a larger amount of protein was 
produced after 20 hr expression at 22°C rather than at 37°C.  
    22 °C 
 
 
  37 °C 
1    2      3      4       5      6  
Lane 1: 0 hrs    Lane 2: 2 hrs 
Lane 3: 4 hrs    Lane 4: 5 hrs 
Lane 5: 6 hrs    Lane 6: 20 hrs 
   
Figure 3.10: SDS-PAGE analysis of time point samples taken during expression trials for 
FL_DR_1146. 
A 3.45 g pellet was harvested from the 22°C 500 mL culture by centrifugation. 
Expression was scaled up using 500 mL LB cultures in 2 L flasks with 20 hr 
incubation at 22°C after induction with IPTG. 
3.2.4 Optimised purification of FL_DR_1146  
Cells from 2 L of culture were lysed by French press and the resulting soluble 
lysate purified by IMAC using a 5 mL HiTrap HR column. This was attached to the 
AKTA purifier FPLC as described in Section 2.5.4 and an analogous protocol to 
that outlined in Table 3.1 was followed. To ensure optimum removal of   Chapter 3 Cloning, expression and purification of DR_1146   
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impurities with each increase of % IMAC elution buffer, the gradient was held 
until the A280 elution profile returned to baseline after each peak.  
A high yield of 70 mg of protein was eluted with 100 % IMAC elution buffer 
resulting in a large, broad peak of 2500 mAU. As with purified DR_1146 
expressed from pDEST17, a yellow colour was observed. Analysis of the protein 
eluted by SDS PAGE showed a strong single band corresponding to FL_DR_1146 at 
approximately 24 25 kDa.  
During initial purification trials it was established that exceeding the binding 
capacity of the 5 mL HiTrap HR column greatly improved the purity of target 
protein by reducing the amount of non specific binding of competing proteins. 
Binding lysate from 2 L of cell culture resulted in a high level of purity conducive 
to crystallisation trials.  
The purified protein was concentrated by centrifugation and a PCT test was 
carried out as described in Section 2.6.2. As a result, a full set of commercial 
and in house crystallisation screens (Table 2.10) were set up at 20 and 10 
mg/mL. They were incubated at 20°C and monitored by the Rhombix Imaging 
System. 
After a period of three months, no protein crystals were found and therefore an 
additional SEC purification step was employed. This was carried out in 500 µL 
batches using a S200 10/200 HR Global column following the method described 
in Section 2.5.7. Figure 3.11 is an SDS PAGE analysis of FL_DR_1146 elutant from 
the gel filtration run.    Chapter 3 Cloning, expression and purification of DR_1146   
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Figure 3.11: SDS-PAGE analysis of purification of DR_1146 by SEC. 
Although the gel is highly overloaded, it highlights the high level of purity 
obtained. The band that can be seen at approximately 49 kDa represents the 
protein as a dimer; also described for the pDEST17 construct.  
The A280 profile of the gel filtration purification showed a single peak eluted in a 
volume of 14.95 mL. Comparison with the column calibration profile suggests a 
molecular weight of 46.1 kDa, which indicates that FL_DR1146, like the pDEST17 
construct, exists as a dimer in solution. In contrast to analytical SEC experiments 
for the pDEST17 construct, the previously observed aggregation peak was 
absent. This suggests that the occurrence of protein aggregation before SEC may 
have been eliminated by changing the expression vector from pDEST17 to 
pET15b.   
Although the purity of FL_DR_1146 was very high, subsequent crystallisation 
experiments were still unsuccessful. Although less rapid than for the FL_DR_1146 
pDEST17 construct, proteolysis was still evident after a period of 3 days.     
3.2.5 Removal of N-terminal 6xHis tag by Thrombin cleavage 
Small scale experiments established that 0.25 units of thrombin were sufficient 
to effectively cleave 1 mg of fusion protein after overnight incubation at 4°C. 
The cleavage reaction was carried out as outlined in Section 2.5.8. Small scale 
experiments showed that the presence of imidazole resulted in a retardation of   Chapter 3 Cloning, expression and purification of DR_1146   
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the cleavage reaction. In order to overcome this problem, the cleavage reaction 
mixture was dialysed against 20 mM Tris pH 7.5, 200 mM NaCl overnight.  
Lane 2 of Figure 3.12 shows a decrease in the MW of the FL_DR_1146 band as a 
result of a successful cleavage reaction. The cleaved 6xHis tag can be seen in 
lane 2 at approximately 4 kDa. 
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Figure 3.12: SDS-PAGE analysis of FL_DR1146_clvd purified by IMAC. 
After the completion of the cleavage reaction, a Complete EDTA Free Protease 
Inhibitor Cocktail Tablet was added to the cleavage mixture to stop further 
thrombin proteolysis. In order to remove the cleaved tag, it was passed through 
a 1 mL HisTrap column as described in Section 2.5.4. Figure 3.12 shows that the 
majority of cleaved FL_DR_1146 (FL_DR_1146_clvd) was eluted from the column 
after 0, 10, 20 and 30 mM imidazole washes. The 6xHis tag, traces of un cleaved 
protein and impurities (lane 9) were successfully separated from the target 
protein by this procedure. 
After dialysis to remove NaCl and traces of imidazole, the eluted 
FL_DR_1146_clvd was purified further by ion exchange chromatography to 
remove the remaining thrombin. This technique (Section 2.5.6) relied on a   Chapter 3 Cloning, expression and purification of DR_1146   
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difference in isoelectric point (pI) between FL_DR_1146_clvd (predicted pI of 
4.90) and that of thrombin (pI = 7.1).  
A PCT and subsequent crystallisation experiments were carried out on the 
purified FL_DR_1146_clvd as described in previous Sections. However, again no 
credible protein crystals were obtained.  
The FL_DR_1146_clvd bands in Figure 3.12 again show evidence of degradation 
after tag removal. Attempts to prevent or slow this, as described for the 
FL_DR_1146 pDEST 17 construct, were unsuccessful. 
It was concluded that the change of vector and subsequent removal of 6xHis tag 
had no impact on the crystallisation of FL_DR_1146. This lead to the hypothesis 
that either (a) proteolysis was continuing to occur at the N terminal of the 
protein after 6xHis tag removal, (b) it was occurring at the C terminal of the 
protein or (c) a combination of proteolysis at both terminals was occurring. 
3.2.6 Expression and purification of t_ DR_1146 from pET-15b 
After successful transformation of BL21 Star(DE3) cells using t_dr_1146 pET15 b 
construct DNA, soluble protein was expressed following the protocol established 
for the fl_dr_1146 pET 15b construct. This included 20 hr incubation at 22°C, in 
LB media, after induction with IPTG. 
2 L of cell pellet was lysed by French press and the resulting lysate was purified 
by IMAC following the same method employed for the full length protein 
expressed from pET 15b. However, 6xHis tagged T_DR1146 had a lower affinity 
of the Ni
2+ matrix incorporated in the 5 mL HiTrap column. This resulted in 
elution of the majority of the tagged protein with 10 and 20 % IMAC elution 
buffer rather than with 100 % IMAC elution buffer as seen for the previous 
construct. This is shown in Figure 3.13 where peaks 1 (2400 mAU) and 2 (950 
mAU) are very broad in comparison with peak 3.    Chapter 3 Cloning, expression and purification of DR_1146   
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Figure 3.13: A280 elution profile for optimised IMAC purification of T_DR_1146. Peaks 1 and 2 
correspond to the elution of T_DR_1146 with 10 and 20 % IMAC elution buffer. 
SDS PAGE analysis (Figure 3.14, lanes 4 and 5) confirmed the strong presence of 
T_DR_1146 in peaks 1 and 2 of Figure 3.13.  
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Figure 3.14: SDS-PAGE analysis of purification of T_DR_1146 by IMAC and SEC. 
By exceeding the binding capacity of the 5 mL HiTrap HR column, non specific 
binding was prevented, resulting in very pure protein elution for protein 
corresponding to peaks 1 and 2. Unlike previous IMAC purifications, the 
T_DR_1146 protein eluted in peak 3 (lane 6) was less abundant and impure. 
When pooled, the protein shown in lanes 4 and 5 of Figure 3.14, gave a yellow 
solution. A total yield of 120 mg of protein was calculated by measuring 
absorbance at 280 nm.   Chapter 3 Cloning, expression and purification of DR_1146   
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An additional SEC step was employed in an effort to further increase purity. The 
resultant protein purity is illustrated in lanes 7, 8 and 9 of Figure 3.14. The 
resulting A280 profile (Figure 3.15) shows a single peak eluted with 15.13 mL of 
gel filtration buffer. Comparison with the column calibration profile suggests a 
molecular weight of 42.2 kDa, which again indicates that T_DR_1146 exists as a 
dimer in solution.  
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Figure 3.15: A280 elution profile for analytical gel filtration experiment to determine 
oligomeric state of T_DR_1146 shows a single peak eluted in a buffer volume of 15.13 mL 
suggesting that the protein exists as a dimer in solution. 
It is evident from lanes 7, 8 and 9 of Figure 3.14 that a small amount of 
degradation had occurred after a three day period. Although still a problem, it 
appeared to be less rapid than for the FL constructs. 
Following PCT, crystallisation experiments were set up for two concentrations of 
28 and 9 mg/mL. They were stored and monitored as described in Section 2.6.3. 
After three months no protein crystal were found in any of the wells. However, 
precipitation appeared more crystalline and less amorphous at both 
concentrations compared to experiments set up for the FL protein.    Chapter 3 Cloning, expression and purification of DR_1146   
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3.2.7 Removal of 6xHis tag from T_DR_1146 
The 6xHis tag was cleaved following the same method established for the FL 
protein. Again 0.25 units of thrombin per mg of fusion protein enabled efficient 
tag removal after overnight dialysis at 4°C. 
It was decided that the second IMAC step included in the purification of 
FL_DR_1146_clvd was unnecessary and therefore both the tag and thrombin 
were removed by ion exchange. 
The difference in molecular weight between the bands in lanes 2 and 3 of Figure 
3.16 demonstrates effective removal of the 6XHis tag after the overnight 
incubation at 4 °C. In lanes 3 and 4, the cleaved 6xHis tag is represented by two 
close bands seen at approximately 4 kDa. Lanes 6 9 show the T_DR_1146_clvd 
protein after ion exchange and the absence of the double band at 4 kDa confirms 
successful removal of the 6xHis tag by this method. 
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Figure 3.16: SDS-PAGE analysis of thrombin cleavage of T_DR_1146 and removal of 6xHis 
tag and thrombin by ion exchange chromatography (IEX). 
Crystal trials were again compiled, using 18 and 9 mg/mL protein 
concentrations. After the three months there was no evidence of protein crystal 
growth, however, as with the tagged T_DR_1146, the precipitate, where it 
occurred in the crystallisation drops, was more crystalline and less amorphous 
than for previous experiments. The N terminal truncation appeared more 
favourable in terms of protein crystallisation and nucleation. 
After five days of incubation at 4°C, faint signs of degradation of the 
T_DR_1146_clvd protein was observed. Although, the onset of proteolysis 
appeared to be less rapid than for the other constructs, its occurrence still   Chapter 3 Cloning, expression and purification of DR_1146   
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proved problematic for successful crystallisation. It was proposed that 
proteolysis was occurring at either or both the C and N terminals after tag 
removal.  
As T_DR_1146 appeared to undergo less degradation than FL_DR_1146, the 
truncated construct was selected for biophysical characterisation. 
- 66 - 
4  Biophysical characterisation of T_DR_1146 
Throughout the remaining Chapters, protein encoded from the t_dr_1146 gene 
with the N terminal 6xHis tag still intact will be referred to as T_DR_1146. 
Protein samples with the 6xHis tag removed using thrombin will be referred to as 
T_DR_1146_clvd. Protein samples with FMN added during purification will be 
referred to as ‘holo’ and those without, as ‘apo’.   
4.1 Introduction and research aims 
Throughout the purification processes discussed in Chapter 3, DR_1146 was 
observed to be pale yellow in colour. It was therefore postulated that the 
protein was binding to a yellow prosthetic group that was present in the LB 
media or alternatively, that was produced by either E. coli enzymes or the 
target DR_1146 protein during expression. 
A UV absorption spectrum of yellow T_DR_1146_clvd at 0.275 mg/mL shows 
small absorbance maxima at 375 and 461 nm (Figure 4.1) which are indicative of 
flavin as a substrate in flavin binding proteins [94].  
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Figure 4.1: UV absorption spectrum for T_DR_1146_clvd (at 0.275 mg/mL) showing small 
absorbance maxima at 375 and 461 nm, which are characteristic of flavin present in a flavin 
binding proteins [94]. 
Addition of an excess of the flavin compound riboflavin 5' phosphate dihydrate 
sodium salt to a sample of T_DR_1146_clvd resulted in a bright yellow solution. Chapter 4 Biophysical characterisation of T_DR_1146 
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After overnight dialysis and gel filtration, fractions identified as containing 
T_DR_1146_clvd remained bright yellow. Absorbance spectra of the gel filtered 
sample showed an increase in maxima at 375 and 461 nm, and a shift in spectral 
maxima from 279 nm to 272 nm. These observations suggested that (a) the flavin 
was binding to T_DR_1146_clvd and (b) that in the native state the protein was 
not fully saturated by flavin. 
In an attempt to confirm the identity of the yellow compound bound to the 
protein during expression, the chromophore was extracted as described in 
Section 2.5.11.  Analysis by electrospray ionisation mass spectroscopy (ESI MS) 
showed a peak at 508.30 m/z (Figure 4.2). 
 
m/z = 508.30
m/z
arb
m/z = 508.30
m/z
arb
 
Figure 4.2: Positive ion ESI-MS of yellow prosthetic group extracted from T_DR_1146 
showing a peak at 508.30 m/z. 
In comparison with molecular weights of various flavin compounds (Table 4.1) 
the m/z value was closest to that of riboflavin 5' phosphate dihydrate sodium 
salt at 514.36 g/mol. A sample of this compound was prepared using methanol 
and analysed by ESI MS for comparison. The spectra (not shown) showed a 
comparable peak at 508 m/z suggesting that the extracted chromophore to be 
more than likely a hydrated form of riboflavin 5' phosphate sodium salt. 
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Flavin compound  Molecular weight (g/mol) 
Riboflavin   376.36  
Riboflavin 5' phosphate   456.34 
Riboflavin 5' phosphate sodium salt  478.33 
Riboflavin 5' phosphate dihydrate sodium salt  514.36 
Flavin adenine dinucleotide   785.55 
Flavin adenine diphosphate disodium salt  829.51 
Table 4.1: Molecular weights of various flavin compounds. 
Throughout this study the abbreviations FMN and FAD will be used to represent 
Riboflavin 5' phosphate dihydrate sodium salt and Flavin adenine diphosphate 
disodium salt respectively. 
A BLAST search [58, 59], using the predicted amino acid sequence of T_DR_1146 
from the CMR database [6, 7], identified 58 % sequence homology with a 
putative pyridoximine 5' phosphate oxidase related FMN binding protein from 
Deinococcus geothermalis. A search of the Protein Data Bank [79, 80] found the 
structure of a putative general stress protein (COG3871) from Nostic 
punctiforme PCC 73102 (PDB ID: 2I02) [81] which shares 32 % sequence identity 
with T_DR_1146. This dimeric protein was crystallised in the presence of a single 
FMN molecule bound in a hydrophobic pocket at the dimer interface (discussed 
in more detail in Chapter 5). The FMN binding ability of these homologues 
fuelled further investigation into the flavin binding capacity of T_DR_1146, and 
the subsequent effects on protein stabilisation, structure and crystallisation. 
In this Chapter the investigation of flavin binding to T_DR_1146 and 
T_DR_1146_clvd using isothermal titration calorimetry (ITC) and fluorescence 
spectrometry is discussed. The effect of FMN on thermal stability was assessed 
using differential scanning calorimetry (DSC), and circular dichroism (CD) 
experiments were used to monitor the effects of FMN binding on chemical 
stability and protein structure. The oligomerisation behaviour of holo 
T_DR_1146_clvd in solution was investigated by analytical centrifugation (AUC) 
and preliminary NMR experiments were carried out to assess the feasibility of 3 
D structure determination in solution.  Chapter 4 Biophysical characterisation of T_DR_1146 
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4.2 Isothermal Titration Calorimetry (ITC) 
4.2.1 Experimental aims 
The aims of ITC experiments carried out on T_DR_1146 and T_DR_1146_clvd 
were (a) to confirm that the protein binds to a flavin cofactor (FMN), (b) to 
investigate the effect of 6xHis tag removal on association (KA) and dissociation 
(KD) constants and (c) to compare binding affinities and stoichiometries (N 
values) for three flavin compounds, riboflavin, FMN and FAD.  
4.2.2  ITC experiments on T_DR_1146 and T_DR_1146_clvd with 
FMN 
Experiments were carried out as described in Section 2.7.2 with injections of 
T_DR_1146 (18.5 mM) and T_DR_1146_clvd (18.7 mM) samples into 0.35 mM FMN 
buffer solutions held in the ITC cell. The resulting data showed typical heat 
pulses consistent with exothermic binding of the FMN cofactor to the protein 
(Figure 4.3).  
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Figure 4.3: ITC data for binding of (a) non-cleaved T_DR_1146 and (b) T_DR_1146_clvd to 
FMN at 25° ° ° °C. The upper panel shows the raw data (exothermic heat pulses) for protein-cofactor 
binding. The lower panel shows the differential binding curve derived from the integration of heat 
effects (with dilution heats subtracted), fitted to a standard one-site binding model.  Chapter 4 Biophysical characterisation of T_DR_1146 
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The binding parameters determined for both T_DR_1146 and T_DR_1146_clvd are 
listed in Table 4.2. 
Parameters  T_DR_1146  T_DR_1146_clvd 
 
N (no. of sites per mole of protein) 
 
0.87 ± 0.02 
 
0.95 ± 0.02 
 
KA/10
5 M
 1 
 
2.51 ± 0.19 
 
1.33 ± 0.06 
 
KD/10
 6 M 
 
3.98 ± 0.30 
 
7.55 ± 0.34 
 
° H   kcal/mol 
 
 9.67 ± 0.27 
 
 8.99 ± 0.20 
Table 4.2: Comparison of ITC binding parameters for the addition of T_DR_1146 and 
T_DR_1146_clvd to FMN (0.35 m m m mM) in 20 mM Tris pH 7.5, 150 mM NaCl buffer at 25 ° ° ° °C. 
The data extracted for both T_DR_1146 and T_DR_1146_clvd fitted well to a 
standard one site binding model giving no significant difference in KD values 
suggesting that the presence of the 6xHis tag causes no significant change in 
binding affinity.  
N values of 0.87± 0.02 and 0.95± 0.02 for non cleaved and cleaved samples 
respectively, are consistent with 1:1 binding stoichiometry with one FMN 
molecule bound per monomer (two per dimer). This result suggests that, unlike 
the homologous dimeric structure of 2I02 (PDB ID) [81] which has only one FMN 
molecule bound at the dimer interface, T_DR_1146 has two FMN molecules 
bound per dimer.     
4.2.3 ITC experiments on T_DR_1146_clvd with riboflavin, FMN 
and FAD  
After establishing that FMN binds to T_DR_1146, it was decided to investigate 
binding to other flavin compounds, namely riboflavin and FAD. Experiments were 
carried out as described in Section 2.7.2, with separate injections of FMN, 
Riboflavin and FAD (dissolved in a buffer of 20 mM Tris pH 7.5, 150 mM NaCl) 
into samples of T_DR_1146_clvd held in the cell. The experimental 
concentrations of protein and cofactors used are shown in Table 4.3. Due to low 
aqueous solubility, the concentration of riboflavin (and that of the protein 
sample) had to be halved. This allowed comparisons to be made with results 
gained for FMN and FAD. Chapter 4 Biophysical characterisation of T_DR_1146 
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Parameters/cofactor  Riboflavin  FMN  FAD 
 
T_DR_1146_clvd 
concentration (mM) 
 
0.01 
 
0.02 
 
0.02 
 
Cofactor 
concentration (mM) 
 
0.27 
 
0.38 
 
0.43 
 
N (no. of sites per 
mole of protein) 
 
1.24 ± 0.03 
 
0.95 ± 0.03 
 
1.02 ± 0.06 
 
KA /10
5 M
 1 
 
2.10 ± 0.13 
 
1.17 ± 0.09 
 
1.21 ± 0.20 
 
KD/10
 6 M 
 
4.75 ± 0.30 
 
8.57 ± 0.66 
 
8.24 ± 1.37 
 
° H   kcal/mol 
 
 11.14 ± 0.34 
 
 11.72 ± 0.46 
 
 7.49 ± 0.60  
Table 4.3: Comparison of ITC binding parameters for the addition of Riboflavin, FMN and 
FAD to T_DR_1146_clvd in 20 mM Tris pH 7.5, 150 mM NaCl buffer at 25 ° ° ° °C. 
The ITC results for riboflavin and FAD showed very similar heat pulse patterns 
(consistent with exothermic binding) to that of FMN (Figure 4.4).  Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.4: ITC data for binding of FMN, FAD and riboflavin cofactors to T_DR_1146_clvd at 
25° ° ° °. The upper panel shows the raw data (exothermic heat pulses) for cofactor-protein binding. The 
lower panel shows the differential binding curve derived from the integration of heat effects (with 
dilution heats subtracted), fitted to a standard one-site binding model with parameters shown in 
Table 4-3. Patterns of heat pulses, binding curves and calculated parameters are very similar for all 
three flavin cofactors suggesting there is no significant difference in binding affinity for 
T_DR_1146_clvd. 
The values of KA, KD and N determined for each flavin cofactor are compared in 
Table 4.3. KD parameters for all three flavins were very close within the 
micromolar range thus no significant difference in binding affinity could be Chapter 4 Biophysical characterisation of T_DR_1146 
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concluded. The KD value determined for FMN was very close that determined in 
initial experiments thus showing consistency for different T_DR_1146_clvd 
preparations.  
Values of N for all three flavins are close to 1, again confirming 1:1 binding 
stoichiometry. 
The structures of all three flavins consist of an aromatic isoalloxazine ring 
system and a ribityl hydroxyl chain ending with a prosthetic group ( X), which 
differs for each cofactor (Figure 4.5).   
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Figure 4.5: Structures of riboflavin, FMN and FAD cofactors used for ITC experiments on 
T_DR_1146_clvd. All three structures include an isoalloxazine ring system and ribityl chain with a 
prosthetic group (–X) for each flavin. 
ITC experiments indicated that there is no significant discrimination between KD 
values determined for riboflavin, FMN and FAD, which suggests that the 
presence, identity and size of the prosthetic –X group has no effect on binding 
affinity. It can therefore be postulated that the protein may have a binding Chapter 4 Biophysical characterisation of T_DR_1146 
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pocket in which the isoalloxazine ring and ribityl hydroxyl components of the 
flavins are bound, whilst the prosthetic –X group remains free. 
4.2.4 ITC experiments on T_DR_1146_clvd with PLP  
It has been shown that the pyridoximine 5' phosphate oxidase protein from E. 
coli is able to bind one or two molecules of pyridoxal 5'—phosphate (PLP) in both 
its apo and holo (with FMN) forms [186]. As T_DR_1146_clvd shares amino acid 
sequence homology with a putative pyridoximine 5' phosphate oxidase FMN 
binding protein (discussed in Section 1 1), it was decided to investigate PLP 
binding in order to give an insight into functionality.  
In a separate ITC experiment, 0.344 mM PLP buffer solution was injected into 
18.7 mM apo T_DR_1146 as described in Section 2.7.2. Figure 4.6 shows the raw 
data extracted from the experiment.  
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Figure 4.6: ITC data for addition of (a) FMN injected into T_DR_1146, (b) PLP injected into 
buffer, (c) PLP injected into T_DR_1146 and (d) FMN injected into PLP + T_DR_1146. Results 
indicate that apo T_DR_1146 does not bind PLP and that the presence of PLP does not affect 
FMN binding. 
In contrast to the pattern of exothermic heat pulses gained for binding of FMN to 
T_DR_1146 (Figure 4.6a), addition of PLP to the protein (Figure 4.6c) resulted in 
(a) 
(b) 
(c) 
(d) Chapter 4 Biophysical characterisation of T_DR_1146 
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a pattern similar to that gained from injection into buffer only (Figure 4.6b). It 
was therefore concluded that unlike E. coli pyridoximine 5' phosphate oxidase, 
apo T_DR_1146 does not bind PLP. This suggests that T_DR_1146 does not 
function as a pyridoximine 5' phosphate oxidase like protein, although a 
functional assay would be required to corroborate this. The protein sample with 
PLP added was then titrated against FMN (Figure 4.6d). A typical exothermic 
binding pattern was obtained suggesting that the presence of PLP does not 
affect FMN binding. 
4.3 Fluorescence Spectroscopy (FS)  
4.3.1 Experimental aims 
The aims of FS experiments on T_DR_1146 and T_DR_1146_clvd samples were (a) 
to confirm binding to FMN and compare KD and N values with those gained from 
ITC experiments and (b) to establish if the pale yellow colour of the apo protein 
observed during initial purification trials (before the addition of excess FMN) is 
due to a bound flavin or ‘FMN like’ compound. 
4.3.2 Fluorescence quenching of FMN on binding to T_DR_1146 
Fluorescence emission and excitation spectra for the addition of T_DR_1146 and 
T_DR_1146_clvd to 10  M FMN solution were recorded as described in Section 
2.7.3.  
After recording the intrinsic fluorescence of the FMN solution alone, six 10  L 
aliquots of T_DR_1146 stock solution (1.14 mM) were added to the solution. The 
immediate effect on addition of T_DR_1146, was a decrease or quenching of FMN 
fluorescence intensity confirming that the non cleaved protein binds to the 
flavin cofactor (Figure 4.7).  Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.7: Quenching of FMN intrinsic fluorescence (excitation wavelength = 445nm) by 
increasing concentrations of T_DR_1146. 10 ml aliquots of protein (1.14 mM) added to 2.5ml 
FMN (10 mM) in 20 mM Tris-HCl, 150 mM NaCl buffer at room temperature. 
A KD of 7.95  M ± 1.48 was determined by fitting data to standard hyperbolic 
binding curve (Figure 4.8). The number of binding sites (N) was established as 
0.65± 0.14, which is lower than the expected 1:1 molar binding ratio obtained 
from ITC experiments.  Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.8: Data fitted to standard hyperbolic binding curve to determine KD (7.95 m m m mM ± 1.48) 
and N (0.65± 0.14) values for quenching of FMN fluorescence by increasing concentrations 
of T_DR_1146. 
4.3.3 Fluorescence quenching of FMN on binding to 
T_DR_1146_clvd 
Two 10 mL aliquots, followed by seven 50 mL aliquots of T_DR_1146_clvd stock 
solution (0.25 mM) were added to 10 mM FMN solution to investigate the effect of 
6xHis tag removal on FMN binding. As for the non cleaved protein, quenching of 
the FMN fluorescence intensity was observed after addition of T_DR_1146_clvd 
samples confirming binding to the flavin cofactor (Figure 4.9).     Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.9: Quenching of FMN intrinsic fluorescence (excitation wavelength = 445nm) by 
increasing concentrations of T_DR_1146_clvd. 10 or 50ml aliquots of protein (0.25 mM) added 
to 2.5ml FMN (10 mM) in 20 mM Tris-HCl, 150 mM NaCl buffer at room temperature. 
The constants KD and N for the cleaved protein were determined as 11.48 mM 
± 1.86 and 0.84± 0.17 respectively (Figure 4 10). As the binding parameters 
determined for T_DR_1146 and T_DR_1146_clvd are in the micromolar range, 
they are comparable to those determined by ITC. It was therefore concluded 
that the protein binds flavin cofactors within a range of 4 11.5 mM at a ratio of 1 
molecule of FMN per monomer of protein. Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.10: Data fitted to standard hyperbolic binding curve to determine KD (11.48 m m m mM 
± 1.86) and N (0.84± 0.17) values for quenching of FMN fluorescence by increasing 
concentrations of T_DR_1146_clvd. 
4.3.4 Fluorescence spectra for non-cleaved and cleaved 
T_DR_1146 without the addition of FMN 
As described in Section 3.1.3, during purification of DR_1146, a pale yellow 
colour was observed. As ITC and fluorescence results confirmed that the protein 
binds flavins, it was thought that the observed yellow colour could be due to 
binding to trace amounts of a flavin cofactor during expression. To investigate 
this hypothesis, fluorescence emission spectra (445 nm excitation) for the initial 
T_DR_1146 and T_DR_1146_clvd samples were recorded without the addition of 
excess FMN. 
In Figure 4.11, a small fluorescence peak at approximately 520nm can be seen 
for both T_DR_1146 and T_DR_1146_clvd samples. This suggests the presence of 
an "FMN like" species in the recombinant protein sample.       Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.11: Fluorescence emission spectra (445nm excitation) of T_DR_1146 and 
T_DR_1146_clvd before addition of FMN. The small fluorescence peaks at about 520nm suggest 
the presence of bound "FMN-like" species in the recombinant protein. 
4.3.5 Comparison of T_DR_1146_clvd dissociation constants with 
other flavin binding proteins 
Table 4.4 compares KD values gained for T_DR_1146_clvd with those reported for 
other recombinant flavin binding proteins.  
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Protein  Method  KD Riboflavin (M)  KD FMN (M)  KD FAD (M) 
T_DR_1146_clvd 
 
ITC  4.75 x 10
 6  8.57 x 10
 6  8.24 x 10
 6 
General NAD(P)H Flavin 
Oxidoreductase FRG/FRase I 
from Vibrio fischeri [187] 
 
FS  3.70 x 10
 5  5.00 x 10
 7  1.20 x 10
 5 
WrbA from Escherichia coli 
[188] 
 
FS     2.00 x 10
 6 
(approx.) 
 
  
Flavodoxin from 
Desulfovibrio desulfuricans 
[189] 
 
FS     1.00 x 10
 10    
Dodecin from Thermus 
thermophilus [190] 
 
FS  2.33 x 10
 7  3.11 x 10
 7  5.89 x 10
 7 
Riboflavin Transporter RibU 
from Lactococcus lactis 
[191] 
 
ITC  1.80 x 10
 9       
  FS  6.00 x 10
 10  3.60 x 10
 8  No binding 
 
PNPOx from rabbit liver 
[105] 
FS     1.10 3.00 x 10
 8    
 
Table 4.4: Comparison of KD values established for T_DR_1146_clvd with those reported for 
other flavin binding bacterial proteins show some binding in the same micromolar range 
and some stronger binding in the nanomolar range. 
The General NAD(P)H Flavin Oxidoreductase FRG/FRase I from Vibrio fischeri 
binds Riboflavin, FMN and FAD in the same micromolar range as T_DR_1146_clvd. 
WrbA, a flavodoxin like protein from Escherichia coli also binds FMN within this 
range. The KD values for three other bacterial flavo proteins and a PNPOx from 
rabbit liver are within the nanomolar range signifying stronger flavin binding 
than for T_DR_1146_clvd. 
4.4 Differential Scanning Calorimetry (DSC) 
4.4.1 Experimental aims 
The aims of DSC experiments were (a) to determine Tm values for the apo forms 
of T_DR_1146 and T_DR_1146_clvd and therefore investigating the effect of tag 
removal on thermal stability (Tm values) and (b) to investigate the effect of FMN 
binding on thermal stability. Chapter 4 Biophysical characterisation of T_DR_1146 
  - 82 -   
4.4.2 DSC experiments to assess the thermal stability of 
T_DR_1146 and T_DR_1146_clvd   
Experiments were carried out as described in Section 2.7.4 with 19 mM 
concentrations of apo non cleaved and apo cleaved protein in a buffer of 20 mM 
Tris HCl pH 7.5, 150 mM NaCl. 
The normalised experimental data in Figure 4.12 shows sharp endothermic 
transition peaks for both T_DR_1146 and T_DR_1146_clvd protein samples 
corresponding to similar Tm values of 50.7 and 51.35°C respectively. This 
suggests that removal of the 6xHis tag has negligible effect on thermal stability. 
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Figure 4.12: DSC thermogram showing Tm values of 50.70° ° ° °C and 51.35° ° ° °C determined for 
non-cleaved T_DR_1146 and T_DR_1146_clvd respectively indicating no significant 
difference in thermal stability on 6xHis tag removal. 
After complete denaturation, the two samples were cooled back down to room 
temperature and the DSC experiments were repeated. In Figure 4.13 it can be 
seen that for the rescan of the non cleaved sample the sharpness and intensity 
of the transition peak was greatly reduced with frequent fluctuations. This 
suggests that on cooling the protein sample did not refold very well possibly due 
to aggregation on initial heating. In contrast, the rescan of the cleaved protein Chapter 4 Biophysical characterisation of T_DR_1146 
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sample showed only a small decrease in transition intensity and sharpness 
suggesting that it refolded relatively well on cooling. It was concluded from this 
result that the 6xHis tag might obstruct refolding. 
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Figure 4.13: DSC thermogram comparing transition peaks from repeat DSC scans (dotted 
lines) with initial DSC data (solid lines) for T_DR_1146 (upper section) and T_DR_1146_clvd 
(lower section). The rescan for T_DR_1146_clvd is much closer to the initial DSC data suggesting 
that for non-cleaved T_DR_1146 the 6xHis tag may obstruct the refolding process. 
 
4.4.3 DSC experiments to assess the increase in thermal stability 
of T_DR_1146_clvd on binding to FMN 
Further DSC experiments were carried out to investigate the effect on thermal 
stability on addition of increasing concentrations of FMN. The experiments were 
carried out as described in Section 2.7.4 using 0.092 mM samples of 
T_DR_1146_clvd and 0.02, 0.2 and 2.0 mM concentrations of FMN in 20 mM Tris 
HCl pH 7.5, 150 mM NaCl buffer. 
The normalised DSC thermogram (Figure 4.14) shows a large increase in Tm on 
addition of FMN confirming that binding of the ligand to the protein increases 
thermal stability.  Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.14: DSC thermogram for the addition of increased concentrations of FMN (0-2.0 
mM) to a 0.092 mM sample of T_DR_1146_clvd shows increased intensity/sharpness of 
melting transitions and Tm values on increasing concentrations of FMN. 
A 2:1 ratio of FMN to protein increased the Tm from 51.2°C to 60.2°C. A further 
increase of FMN concentration (20:1) gave a higher Tm of 67.4°C, with a melting 
transition of increased intensity and sharpness. In conclusion, the binding of FMN 
to T_DR_1146_clvd results in greater thermal stability and stabilisation of the 
protein. 
The overall results of the DSC experiments suggest that (a) the 6xHis tag may 
obstruct protein refolding and thus may affect overall stability and (b) addition 
of a two fold molar excess of FMN increases thermal stability significantly. Due 
to the correlation between protein stability and crystal growth, it was decided 
that for future crystallisation experiments, the 6xHis tag would be removed and 
that at least a two equimolar excess of FMN would be added during purification.  Chapter 4 Biophysical characterisation of T_DR_1146 
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4.5 Circular Dichroism (CD) 
4.5.1 Experimental aims 
The aims of the CD experiments were (a) to establish whether T_DR_1146 and 
T_DR_1146_clvd are folded in the presence and absence of FMN, (b) to monitor 
any changes in secondary and tertiary structure on binding to FMN, (c) to 
estimate the secondary structure of apo and holo T_DR_1146_clvd, (d) to 
monitor the temperature denaturation of apo and holo T_DR_1146_clvd, (e) to 
monitor the chemical unfolding of apo and holo T_DR_1146_clvd using increasing 
concentrations of guanidine hydrochloride and (f) to establish if the FMN 
cofactor remains bound to holo T_DR_1146_clvd after unfolding. 
4.5.2 CD experiments to assess the structural effects of FMN 
binding on T_DR_1146 and T_DR_1146_clvd  
CD experiments were carried out as described in Section 2.7.5 using T_DR_1146 
and T_DR_1146_clvd samples in the presence and absence of 1mM FMN. 
Overall, results show changes in protein conformation on binding FMN as judged 
by spectra obtained in the far UV (260 190 nm) and the near UV (320 250 nm) CD 
regions, which correspond to secondary and tertiary elements respectively. 
Changes in intensity around 300 250 nm in the near UV regions for both 
T_DR_1146 and T_DR_1146_clvd (Figure 4.15) suggest that the environments of 
the aromatic amino acids change as a result of FMN binding. It is possible that 
the structure of the protein becomes more rigid as flavin binds or that the 
aromatics are stacking with the flavin rings giving increased signal intensity in 
this spectral region. Higher resolution techniques would be required to ascertain 
the atomic detail of these spectral changes since CD is insufficient to resolve 
such fine detail.  Chapter 4 Biophysical characterisation of T_DR_1146 
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(b) T_DR_1146_clvd 
 
  
(a) non cleaved T_DR_1146 
 
Figure 4.15: Near UV spectra of apo (blue) and holo (red) (a) non-cleaved T_DR_1146 and (b) 
T_DR_1146_clvd. Both in 50 mM phosphate buffer pH 7.5 with 150 mM NaCl. 
In the far UV region (Figure 4.16), corresponding to secondary structural 
conformation, there is a marked decrease in spectral intensity following binding 
of FMN suggesting changes in the overall secondary structure of the protein upon 
ligand binding. These results are consistent with the changes observed in the 
near UV region. It is probable that the protein undergoes gross secondary and 
tertiary conformational changes in the presence of FMN. Some of the differences Chapter 4 Biophysical characterisation of T_DR_1146 
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observed in the far UV region may also reflect contributions from the aromatic 
groups. When aromatic rings align, such contributions are often positive around 
220nm which would result in a decrease in the overall negative ellipticity [192]. 
 
 
 
 
  
(a) non cleaved T_DR_1146 
 
  
(b) T_DR_1146_clvd 
 
Figure 4.16: Far UV spectra of apo (blue) and holo (red) (a) non-cleaved T_DR_1146 and (b) 
T_DR_1146_clvd in a buffer of 50 mM phosphate buffer pH 7.5 with 150 mM NaCl. Chapter 4 Biophysical characterisation of T_DR_1146 
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4.5.3 Secondary structure prediction  
The secondary structure compositions for full length apo and holo T_DR_1146 
and T_DR_1146_clvd and holo T_DR_1146_clvd were estimated using data 
obtained from the far UV CD spectral region (240 190nm). These data were 
submitted to Dichroweb, an online server hosting various secondary structure 
deconvolution algorithms [177]. Average values obtained from the CONTIN and 
the CDSSTR algorithms [178] were used to estimate secondary structural 
content. The estimates obtained for percentage contribution from helices, 
sheets and turns are shown in Table 4.5.  
Protein  % Helix  % Sheet  % Turns  % Unordered  Total % 
Apo T_DR_1146 
 
16  29  21  34  100 
Holo T_DR_1146 
 
10  34  23  33  100 
Apo T_DR_1146_clvd 
 
16  28  21  35  100 
Holo T_DR_1146_clvd 
 
10  33  23  34  100 
Table 4.5: CD secondary structure estimate for apo and holo T_DR_1146 and 
T_DR_1146_clvd. 
On analysis of the tabulated data, it was concluded that T_DR_1146_clvd is a 
mixed alpha beta protein and that FMN binding causes significant changes in 
secondary structure. No notable difference can be seen as a result of 6xHis tag 
removal. 
4.5.4 CD experiments to monitor the thermal unfolding of 
T_DR_1146_clvd using a temperature gradient 
Figure 4.17 shows the decrease in percentage of native ellipticity at 208 nm of 
apo and holo T_DR_1146_clvd over a temperature gradient of 5 80°C. At 
approximately 50°C the ellipticity of the apo protein begins to decline more 
rapidly than that of the holo protein. This data correlates approximately with a 
Tm value of 51.35°C established for the apo protein by DSC (Section 4.4.2). At a 
temperature of 80°C the final percentage of remaining native ellipticity for the 
apo protein (46.2 %) was much lower than that of the holo protein (69.3 %) 
confirming that the presence of FMN increases thermal stability.  Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.17: CD data collected from the thermal unfolding of apo (unbroken line) and holo 
(broken line) T_DR_1146_clvd monitored at 208 nm. 
4.5.5 CD experiments to monitor the chemical unfolding of 
T_DR_1146_clvd using guanidine hydrochloride 
Figure 4.18 shows the decrease in percentage of native ellipticity at 222 nm of 
apo and holo T_DR_1146_clvd as a result of adding increasing concentrations   
(0 6 M) of guanidine hydrochloride (GuHCl).  
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Figure 4.18: CD data collected from the chemical unfolding of apo and holo T_DR_1146_clvd 
monitored at 222 nm using increasing concentrations of GuHCl. Chapter 4 Biophysical characterisation of T_DR_1146 
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The apo protein was found to be slightly less stable than the holo protein. 
Incubation of apo protein in 1M GuHCl resulted in an ellipticity value which was 
44.7 % of the native protein whereas the holo protein remained at 77.5 %. This 
shows that T_DR_1146_clvd is more chemically stable when FMN is bound. 
Estimates of the midpoint of denaturation for apo and holo T_DR_1146_clvd 
were gained by plotting the total percentage change in native ellipticity against 
GuHCl concentration (Figure 4.19).  
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Figure 4.19: Plot of the total percentage change in native ellipticity at 222 nm against GuHCl 
concentration (1-6 M) for the chemical unfolding of apo and holo T_DR_1146_clvd. 
The apo protein is 50 % unfolded at a GuHCl concentration of approximately 0.9 
M. However, a higher concentration of approximately 1.4 M is needed to unfold 
50 % of the holo protein.  
By monitoring the FMN contributions in the visible near UV region (Figure 4.20) it 
is evident that the FMN cofactor added to produce the holo protein is 
subsequently removed on chemical unfolding with GuHCl, with a concentration 
of 2 M required for complete dissociation. This is shown by reduced peak 
intensities at 470 nm on addition of increasing concentrations of guanidine 
hydrochloride. The ease at which the FMN dissociates suggests that the 
intermolecular interactions between the added cofactor and the protein are 
non covalent.   Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.20: Visible-Near UV spectrum for holo T_DR_1146_clvd showing decreased FMN 
contributions (monitored at 470 nm) on increasing concentrations of GuHCl. 
4.5.6 NMR 
4.5.7 Experimental aims 
The aim of preliminary non labelled and labelled NMR experiments was to 
investigate the feasibility of using this technique to determine the 3 D structure 
of T_DR_1146 in solution. 2 D 
15N 
1 H HSQC experiments were used to establish 
the amount of FMN needed to saturate cofactor binding sites.   
4.5.8 One-dimensional, non-labelled NMR experiments 
Well dispersed methyl and amide regions of 1 D spectra for the apo and holo 
forms of T_DR_1146_clvd show that the protein is folded and structured both 
with and without FMN. This is shown in Figure 4.21, which is a spectrum of holo 
T_DR1146_clvd showing defined peaks in the amide (8.5 ppm) and methyl (0 
ppm) spectral regions. Chapter 4 Biophysical characterisation of T_DR_1146 
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 Amide region (8.5 ppm) 
Methyl region 
(0 ppm) 
Figure 4.21: 1D NMR spectrum of non-labelled T_DR_1146_clvd with 1µM FMN. Well-
dispersed methyl and amide spectral regions suggest T_DR_1146 is folded and structured. 
Overall, from 1 D experiments, it was concluded that the addition of FMN has an 
effect on the structure of T_DR_1146. However, in the absence of the FMN 
cofactor, the quality of the spectra is increased with sharper peaks in the down 
field methyl region (0 ppm) (Figure 4.22).  
 
With FMN 
Without FMN 
 
Figure 4.22: Methyl region of 1D NMR spectra for apo (red) and holo (blue) T_DR_1146_clvd 
shows sharper methyl peaks in the absence of the FMN cofactor. 
On comparison of spectra for apo T_DR_1146 and apo T_DR_1146_clvd, it was 
apparent that spectral quality is also improved by removal of the 6xHis tag; a 
result which influenced sample preparation for 2 D 
15N labelled experiments.  Chapter 4 Biophysical characterisation of T_DR_1146 
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4.5.9 Two-dimensional 
15N-
1H HSQC experiments 
Figure 4.23 (a) to (d) shows the resulting 2 D 
15N HSQC spectra for titrations of 
increasing concentrations of FMN (0 to 2.7 mM) into a 0.9 mM sample of apo 
T_DR_1146_clvd in order to determine the [protein]:[FMN] ratio needed to fully 
saturate the protein. 
(d) 2.7 mM FMN
(1:3 protein:ligand)
(b) 0.9 mM FMN
(1:1 protein:ligand)
1H
1H 1H
1H
(a) Apo T_DR_1146_clvd 
(1:0 protein:ligand)
(c) 1.8 mM FMN
(1:2 protein:ligand)
15N
15N
15N
15N
(b) 0.9 mM FMN
(1:1 protein:ligand)
(d) 2.7 mM FMN
(1:3 protein:ligand)
 
Figure 4.23: 2-D 
15N HSQC spectra for titrations of increasing concentrations of FMN (0-2.7 
mM) into a 0.9 mM sample of T_DR_1146_clvd: (a) 0.9 mM Apo T_DR_1146_clvd (1:0 
protein:ligand ratio), (b) 0.9 mM FMN added to 0.9 mM T_DR_1146_clvd (1:1 protein:ligand ratio), 
(c) 1.8 mM FMN added to 0.9 mM T_DR_1146_clvd (1:2 protein:ligand ratio) and (d) 2.7 mM FMN 
added to 0.9 mM T_DR_1146_clvd (1:3 protein:ligand ratio). 
Comparison of Figures 4.23 (a) and (b) show that significant chemical shift 
changes occur on the addition of a 1:1 ratio of FMN to apo T_DR_1146_clvd. 
Further changes occurred when increasing the protein:FMN concentration ratio 
to 1:2 (Figure 4.23c) signifying that 1:1 does not fully saturate binding sites. 
Adding another 0.9 mM aliquot of FMN (1:3 [protein]:[FMN] ratio) produced only 
slight changes (Figure 4.23d) suggesting that binding sites are virtually saturated 
at a 1:2 ratio.  
This result confirms that a 2:1 excess of FMN:protein is required to ensure that 
the binding sites of T_DR_1146_clvd are completely saturated with the cofactor. Chapter 4 Biophysical characterisation of T_DR_1146 
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Based on this result and on data gained from DSC experiments (Section 4.4.3), it 
was decided that at least a two equimolar excess of FMN would be added to the 
protein during purification to ensure that all binding sites are saturated and 
hence that the protein sample is homogenous for crystallisation experiments. 
Figure 1.22 is a superimposition of Figures 1.21 (a) and (d) showing the overall 
pattern of chemical shift changes on addition of 2.7 mM FMN. Such significant 
peak movements show that global structural changes are induced by FMN 
binding.  
1H
15N
0.9 mM apo T_DR_1146_clvd
0.9 mM apo T_DR_1146_clvd
+ 2.7 mM FMN
 
Figure 4.24: Superimposed 2-D 
15N HSQC spectra for apo T_DR_1146_clvd without FMN 
(blue) and apo T_DR_1146_clvd titrated against 2.7 mM FMN (green) showing the pattern of 
chemical shift changes as a result of FMN binding. 
The transition between apo (blue) and holo (green) peaks in Figure 4.24 
occurred through the disappearance of the apo peak and reappearance in a 
different position after addition of FMN. This is suggestive of system in slow 
chemical exchange on the NMR timescale and is typical for protein ligand 
systems with high binding affinity and low dissociation constants (mM or lower) 
[193]. Chapter 4 Biophysical characterisation of T_DR_1146 
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The overall quality of both non labelled and 
15N 
1H HSQC spectra suggests that 
structure determination by NMR would be feasible for T_DR_1146_clvd.  
4.6 Analytical ultracentrifugation (AUC) 
The solution behaviour of holo T_DR_1146_clvd was investigated by 
sedimentation velocity (SV) and sedimentation equilibrium (SE) analytical 
ultracentrifugation (AUC) as described in Section 2.7.6. 
Buffer density and viscosity and the partial specific volume of the protein at 4°C 
were calculated as 1.00968 g/mL, 0.016197 (Poise) and 0.720 mL/g (0.727 mL/g 
at 20°C) respectively, using SEDNTERP software [180]. These parameters were 
utilised for analysis of SV and SE datasets using the SEDFIT [179] and SEDPHAT 
[181] programmes.  
4.6.1 Sedimentation velocity (SV) 
The aim of the SV experiment was to gain insight into the concentration 
dependent oligomerisation behaviour of holo T_DR_1146_clvd and to determine 
a sedimentation coefficient for the protein. 
Seven concentrations of holo T_DR_1146_clvd (0.35, 1, 2, 3.5, 10, 22 and 35 
mg/mL) were analysed in the SV experiment. The resulting size distribution c(s) 
profiles for SV data analysed by SEDFIT [179] are shown in Figures 4.25 to 4.27.  Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.25: Individual size distribution c(s) profiles from SV data analysed with SEDFIT 
[179] for holo T_DR_1146_clvd at (a) 0.35 mg/mL: showing two main species present in 
solution (b) 1 mg/mL: shows peaks for Species 1 and 2 merge closer together suggesting 
self-association (c) 2 mg/mL: two species have merged completely leaving only one main 
peak. The small peak seen close to zero S is thought to be buffer. Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.26: Individual size distribution c(s) profiles from SV data analysed with SEDFIT 
[179] for holo T_DR_1146_clvd at (a) 3.5 mg/mL: shows species 2 begin to migrate back to 
the left (non-ideal) (b) 10 mg/mL and (c) 22 mg/mL: further migration of species 2 to the left. 
 Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.27: Individual size distribution c(s) profile from SV data analysed with SEDFIT [179] 
for holo T_DR_1146_clvd at 35 mg/mL showing non-ideal behaviour of species 2 (migration 
to the left). 
At a concentration of 0.35 mg/mL, two main species (Species 1 and 2) were 
observed within the protein solution (Figure 4.25a). At 1 mg/mL, the two peaks 
corresponding to Species 1 and 2 merged closer together (Figure 4.25b). Such 
behaviour is suggestive of self association in solution.  
A further increase in protein concentration to 2 mg/mL resulted in complete 
merging of the two species to form a single peak (Figures 4.25c). At this 
concentration the protein exists as only species 2 in a single conformation. At 
concentrations of 3.5 and above, Species 2 is shown to migrate back to the left 
again (Figures 4.26b and c). It is thought that the reported decrease in 
sedimentation coefficient (s) of the Species 2 occurred as a result of non ideal 
concentration effects caused by overcrowding of protein molecules at the base 
of the AUC cell. 
Figure 4.28 shows an overlay of size distribution c(s) profiles for the seven 
protein concentrations, which illustrates the overall migration of species 2. Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.28: Normalised (species 2) comparison of size distribution c(s) profiles for 
increasing concentrations of holo T_DR_1146_clvd showing migration of species 2. 
The apparent sedimentation coefficients (s b , 4 ) for species 2 of holo 
T_DR_1146_clvd at 4°C in buffer, and subsequent true sedimentation 
coefficients (s w , 20 ), corrected for solvent viscosity and density were calculated 
as described in Section 2.7.6.1 and are listed in Table 4.6. 
[T_DR_1146_clvd] 
(mg/mL) 
Apparent sedimentation 
coefficient at 4˚C in buffer 
s4,b (S) 
True sedimentation coefficient at 
20˚C in water 
s20,w  (S)  
0.35  1.70± 0.17  2.76± 0.28 
1  1.81± 0.10  2.95± 0.18 
2  1.81± 0.05  2.94± 0.09 
3.5  1.63± 0.05  2.65± 0.08 
10  1.68± 0.02  2.73± 0.03 
22  1.54± 0.03  2.51± 0.05 
35  1.36± 0.03  2.21± 0.04 
Table 4.6: Apparent sedimentation coefficients determined for species 2. Errors for s20,w 
values were estimated using the percentage error calculated for s4,b.  
A plot of sw, 20 against concentration of holo T_DR_1146_clvd (mg/mL) (Figure 
4.29) was used to determine (
0
20 w , s ) (sedimentation coefficient independent of 
concentration) value of 2.87 S. The 
0
w , 20 s  for Species 1 was taken to be equal to 
that of s w , 20  at 0.35 mg/mL (1.72 S) as this concentration is close to zero and 
Species 1 was not resolved at higher concentrations. Chapter 4 Biophysical characterisation of T_DR_1146 
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Figure 4.29: Plot of s w , 20 20 20 20 vs concentration for species 2 of holo T_DR_1146 giving 
0 0 0 0
20 20 20 20 w , s = 
2.87 S.  
Overall, SV results suggest that holo T_DR_1146_clvd undergoes self association 
to form a single species (Species 2) at concentrations above 2 mg/mL. As gel 
filtration elution profiles suggest that the protein exists as a dimer in solution, it 
is proposed that the observed change in quaternary structure with increasing 
concentration is from monomer to dimer, with Species 2 representing holo 
T_DR_1146_clvd in a dimeric conformation.  
The theoretical sedimentation coefficient for dimeric holo T_DR_1146_clvd, if 
assumed to be a hydrated sphere ( hyd s ), was calculated as 3.47 S by the method 
described in Section 2.7.6.3. The 
0
w , 20 s  experimentally determined for Species 2 
(2.87 S) is significantly lower than  hyd s , which suggests that the dimer is not a 
sphere.  A lower than expected value of 
0
w , 20 s  is attributable either to excessive 
hydration or, more probably, to asymmetry or elongation of the protein. It is 
therefore reasonable to speculate that dimeric holo T_DR_1146 is slightly 
elongated in solution. 
Comparison of theoretical and experimentally determined sedimentation 
coefficients for monomeric holo T_DR_1146_clvd, (2.18 S and 1.72 S Chapter 4 Biophysical characterisation of T_DR_1146 
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respectively) infers a similar arrangement to that reported for the dimer; the 
monomer is more extended than a sphere of the same molar mass.      
To confirm the proposed monomer dimer self association of holo 
T_DR_1146_clvd and to establish the concentration dissociation constant; KD, an 
SE experiment was performed.  
4.6.2 Sedimentation equilibrium (SE) 
A SE experiment was carried out at three rotor speeds (20, 30 and 40 krpm) 
using the same seven sample concentrations used for SV AUC (0.35, 1, 2, 3.5, 10, 
22 and 35 mg/mL). The resulting datasets were analysed using SEDPHAT 
software [181] as described in Section 2.7.6.2. Unfortunately the quality of data 
collected decreased over time, resulting in the exclusion of some 20 and 30 
krpm datasets, and hence accounts for the absence of several points in graphs 
generated for data analysis.  
4.6.2.1  Molecular weight determination for holo T_DR_1146_clvd 
Datasets for each rotor speed were separately fitted with a ‘species analysis’ 
model which required values of predicted dimeric mass (36875 Da) and 
0
20 w , s  
(2.87 S). Individual experiment fits were obtained for each of seven 
concentrations corresponding to 20, 30, and 40 krpm rotor speeds. The quality of 
the fit was judged by inspection of generated SE profiles, residuals of the fit and 
root mean squared deviation (rmsd) values. A typical experimental SE profile, 
demonstrating a good fit with the species analysis model, is shown in Figure 
4.30. Chapter 4 Biophysical characterisation of T_DR_1146 
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is indicative of a good fit to experimental data. 
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Figure 4.30: Typical SE profile for holo T_DR_1146-clvd at 0.35 mg/mL, 30 krpm, displaying 
a good fit of the chosen model to experimental data. Characteristics of a good fit include (a) 
almost complete superimposition of data (red solid curve) and fit (red, broken curve) lines (b) small, 
well-dispersed residuals and (c) low rmsd values. 
The apparent weight average molecular weights (M app , w ) determined for the 40, 
30 and 20 krpm data are presented alongside rmsd values in Table 4.7. 
Rotor speed (krpm)  [Protein] (mg/mL)   Mw,app  (Da)  Rmsd (fringes) 
20 
 
0.35 
1 
2 
3.5 
10 
22 
35 
 
19389 
40698 
62831 
38456 
36225 
30907 
30425 
0.28 
0.03 
0.24 
0.04 
0.03 
0.94 
0.03 
30  0.35 
1 
2 
3.5 
10 
22 
35 
 
37751 
38701 
40471 
33145 
31095 
19597 
23976 
0.02 
0.02 
0.20 
0.16 
0.03 
1.04 
0.06 
40  0.35 
1 
2 
3.5 
10 
22 
35 
34201 
36501 
33509 
31568 
28704 
26421 
25688 
0.04 
0.03 
0.06 
0.06 
0.11 
0.14 
0.06 
Table 4.7: Values of M app , w  (with rmsd) determined by fitting to the species analysis model 
for all datasets using SEDPHAT [181]. The values highlighted in bold were excluded from 
analysis due to the poor data quality.  Chapter 4 Biophysical characterisation of T_DR_1146 
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M app , w  values for well fitted data were plotted against protein concentration 
(Figure 4.31) to illustrate the effect of increasing protein concentration. 
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Figure 4.31: Plot of M app , w  against concentration of holo T_DR_1146_clvd (mg/mL). 
The distribution of points in Figure 4.31 reflects the non ideal behaviour of the 
protein at significant concentrations as shown by the reduction in mass on 
increasing protein concentration for all three rotor speeds. The anomalous 
decrease in molecular weight could be attributed to overcrowding of protein 
molecules towards the base of the AUC cell, which limits the ability of the 
protein to form steep concentration gradients. 
On comparison with predicted dimeric molecular weight of the protein (36,875 
Da), the trend depicted in Figure 4.31 shows that the molecular weight of holo 
T_DR_1146_clvd tends towards that of the dimeric protein at concentrations 
close to 0 mg/mL.  
Individual global fits of all smooth experimental data sets for each rotor speed 
resulted in the M app , w  values tabulated below (Table 4.8). A global fit of smooth 
data sets for all three speeds gave an overall molecular weight of 31,572 Da. It is 
thought that this value is lower than the predicted dimeric molecular weight of 
36,875 Da due to non ideal concentration effects. Chapter 4 Biophysical characterisation of T_DR_1146 
  - 104 -   
Rotor speed 
(krpm) 
Global Mw, app for each 
rotor speed (Da) 
Global Mw, app for all 
smooth datasets 
(Da) 
20 
 
34663.35 (rmsd = 0.77)   
30 
 
30593.07 (rmsd = 0.08)         31572.09 
      rmsd = 0.05 
40 
 
29073.25 (rmsd = 0.07)   
Table 4.8: Global M app , w  values determined for 20, 30 and 40 krpm rotor speeds using 
SEDPHAT software [181]. 
4.6.2.2  Investigating different models for self-association 
A global fit of all smooth experimental data sets was performed using three 
different self association models: monomer dimer (1 2), monomer trimer (1 3) 
and monomer tetramer (1 4). The model that best globally represented the 
analysed datasets was the 1 2 model, as shown by almost complete 
superimposition of data and fit lines and small, well dispersed residuals (Figure 
4.32). In addition, the rmsd value for the 1 2 model, was lower than those 
determined for the 1 3 and 1 4 models, a characteristic indicative of the best 
fit. Chapter 4 Biophysical characterisation of T_DR_1146 
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(a) Monomer dimer self association model 
 
rmsd value for fit = 0.036 fringes  
Small, well dispersed residuals of the fit (approx –0.05 to 0.1)  
Good fit: almost complete superimposition of data 
and fit lines 
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Figure 4.32: Representative SE profiles and residuals of the fits for holo T_DR_1146-clvd 
(0.35 mg/mL, 40 krpm) for self-association models (a) 1-2 (b) 1-3 and (c) 1-4. Data are best 
fitted by the 1-2 model confirming that a change from monomer to dimer as concentration 
increases. Chapter 4 Biophysical characterisation of T_DR_1146 
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4.6.2.3  Determination of dissociation (KD
1-2) constant for 1-2 self-association 
By globally fitting all smooth datasets (concentrations 0.35 to 3.5 mg/mL) with 
the 1 2 model, a dissociation constant (KD
1 2) of 7.67  M was obtained. This value 
is consistent with the results obtained from SV experiments, which showed that 
self association was underway at 0.35 mg/mL (19  M), and hence must be 
beginning at a concentration below this. The KD
1 2 obtained by SE AUC confirms 
that at concentrations below 7.67  M, holo T_DR_1146_clvd exists 
predominantly as a monomer and, above 7.67  M, mostly as a dimer. From these 
data, it can be postulated that the structure of holo_T_DR_1146_clvd, derived as 
a result of high concentration crystallisation experiments, would be dimeric.    
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5  Crystallisation of degraded T_DR_1146 with FMN 
5.1  Research aims 
The aim of work described in this Chapter was to gain a stable, homogeneous 
T_DR_1146 sample for crystallisation experiments. This work involved 
attempting to saturate protein binding sites with the FMN cofactor and 
investigating the extent of proteolysis with the objective of isolating a stable 
protein fragment.   
5.2 Purification of T_DR_1146 in the presence of FMN 
The following three experiments were performed to investigate the effect of 
FMN binding on the prevention of proteolysis and the impact on crystallisation of 
T_DR_1146. 
(1) Cell lysis in the presence of FMN 
A final concentration of 2 mM of FMN was added to the standard lysis buffer 
shown in Table 2.8. After cell lysis, the lysate was purified by IMAC and SEC 
(Sections 2.5.4 and 2.5.7). Following 6xHis tag cleavage, crystallisation 
experiments were set up. No protein crystals were obtained. 
SDS PAGE analysis of the purified protein showed that although degradation was 
slowed by the presence of FMN, it was not stopped completely. 
Throughout the purification process, the yellow colour attributed to FMN, 
became paler. This was thought to be due to either the removal of unbound FMN 
or due to dissociation of bound FMN due to high NaCl concentrations in 
purification buffers. 
It was concluded that partial saturation of binding sites and the occurrence of 
degradation gave an inhomogeneous sample, which was unfavorable for 
crystallisation.        Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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(2) Addition of FMN throughout purification 
Two equimolar equivalents of FMN were added to T_DR_1146 samples after each 
purification step to compensate for reversible binding. The last addition was 
made after concentration for SEC. Any excess FMN was removed by passage 
through a S200 10/300 HR Global gel filtration column (Section 2.5.7). 
Subsequent crystallisation experiments were again unsuccessful. 
(3) Attempted co crystallisation with FMN 
Purified T_DR1146_clvd was concentrated to 20 mg/mL (0.98 mM) and FMN was 
added to a final concentration of 2 mM. The mixture was incubated at 4°C for 2 
hrs then crystal trials were set up. No credible protein crystals were obtained. 
As the protocols followed in experiments (2) and (3) ensured complete 
saturation of binding sites with FMN, it was thought that sample inhomogeneity 
due to protein degradation was a major factor in the inability to grow protein 
crystals. 
5.3 Investigating degradation of T_DR_1146 
To investigate the extent of protein degradation, concentrated samples of 
cleaved and non cleaved T_DR_1146 were stored at 4°C for a maximum time of 
two months. SDS PAGE analysis of these degraded samples showed that in 
general, proteolysis resulted in formation of a stable fragment of approximately 
15 kDa (Figure 5.1, lanes 2 4, 8 & 9).    Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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Lane 1: Apo T_DR_1146 
Lane 2: Apo T_DR1146 degraded 
Lane 3: Apo T_DR1146 degraded 
Lane 4: Apo T_DR1146 degraded 
Lane 5: MW Marker 
Lane 6: Apo T_DR_1146_clvd 
Lane 7: Apo T_DR_1146_clvd partially degraded 
Lane 8: Apo T_DR_1146_clvd degraded 
Lane 9: Apo T_DR_1146_clvd degraded 
Lane 10: MW Marker 
Lane 11: Halo T_DR_1146 with tag  
Lane 12: Halo T_DR_1146 degraded (stored for five weeks) 
Lane 13: Halo T_DR_1146_clvd 
Lane 14: Halo T_DR_1146_clvd degraded (stored for weeks) 
Lane 15: MW Marker 
 
   1      2      3     4      5      6     7      8      9     10    11     12   13     14   15 
Stored for two months 
Stored for two 
months 
Proteolysis of 
T_DR_1146 samples 
to form stable 
fragments of 
approx. 15 kDa 
Figure 5.1: SDS-PAGE analysis of degraded T_DR_1146 samples. Lane 1: non-cleaved apo 
T_DR_1146 sample before proteolysis. Lanes 2-4: non-cleaved apo T_DR_1146 samples after 2 
months showing degradation to a stable fragment. Lane 6: cleaved apo T_DR_1146 sample before 
proteolysis. Lane 7: partial degradation of cleaved apo T_DR_1146 sample after 2 months. Lanes 
8&9: cleaved apo T_DR_1146 sample after 2 months showing degradation to a stable fragment. 
Lanes 11&12: non-cleaved holo T_DR_1146 before and after proteolysis showing formation of 
stable fragment after 5 weeks. Lanes 13&14: cleaved holo T_DR_1146 before and after proteolysis 
showing formation of stable fragment after 5 weeks. 
Samples of non cleaved and cleaved holo T_DR_1146 were stored at 4°C for five 
weeks. The extent of degradation of theses samples is shown in lanes 12 and 14 
respectively, confirming that the addition of FMN in the protein sample does not 
prevent proteolysis. Comparison of lanes 11 and 12 with 13 and 14 shows that 
non cleaved T_DR_1146 degrades to the same level as T_DR_1146_clvd 
suggesting that the tag is removed by proteolysis without the addition of 
thrombin. This can also be seen for apo T_DR_1146 (no additional FMN added) by 
comparing lanes 1 4 (tagged) with 6 9 (cleaved). 
The degraded samples shown in lanes 2, 8, 12 and 14 were purified by anion 
exchange to remove degraded peptides. Crystallisation experiments were then 
set up however, no protein crystals resulted.   Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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The degraded non cleaved holo T_DR_1146 sample (lane 12) was analysed by N 
terminal sequencing, establishing the first eight residues of the amino acid 
sequence to be Ser1, His2, Met3, Ser4, Arg5, Asp6, Glu7 and Ala8. Residue 3 
(Met3) matches residue 1 of the T_DR_1146 sequence confirming that the 6xHis 
tag is removed without the addition of thrombin. The residues Ser1 and His2, 
which were encoded from vector nucleotides, remain intact after N terminal 
proteolysis.  
ESI MS analysis of the degraded non cleaved holo T_DR_1146 sample showed 
numerous peaks in the 15,700 15,800 Da region with two main peaks at 15,694 
and 15,710 Da (Figure 5.2). 
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0 
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% 
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15487.00 
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15725.00 
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15767.00 
15781.00 
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15858.00 
16082.00 
16006.00 
15931.00 
15946.00 
16015.00 
16160.00 16143.00 
Mass (Da)   
Figure 5.2: ESI-MS analysis of degraded non-cleaved holo DR_1146 showing two main 
peaks at 15,694 Da (Peak 1) and 15,710 Da (Peak 2). 
The reported N terminal sequencing and ESI MS results were used in conjunction 
with the ProtParam tool [171] from the ExPASy proteomics server [172] to 
predict a possible C terminal cleavage site for T_DR_1146. A method of 
subtracting the MWs of individual amino acids from the theoretical MW of 
DR_1146 (18,380 Da including vector residues Ser1 and His2) was used in order to   Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
  - 111 -   
match the masses determined by ESI MS (15,694 and 15,710 Da). Figure 5.3 
shows the predicted C terminal cleavage site, which is located between the 
residues Phe139 and Ala140.     
For these calculations, it was assumed that FMN was removed during ESI MS as 
the technique involves use of acetonitrile, which dissociates non covalent 
intermolecular forces between the cofactor and protein during the experiment.  
 
  2I02 C terminal 
Predicted C terminal cleavage site for 
T_DR_1146 
Predicted trypsin 
cleavage site  
2RE7 
C terminal 
 
Figure 5.3: Residues 124-164 of the amino acid sequence of T_DR_1146 with the predicted 
C-terminal cleavage site marked between Phe139 and Ala140. The predicted secondary 
structure is shown above the amino acid sequence of T_DR_1146 (determined by Network Protein 
Sequence Analysis[194, 195]). C-terminal sites for PDB structures 2RE7 and 2i02 are also 
indicated by vertical black lines. The PeptideCutter tool [171] from the ExPASy proteomics server 
[171, 172] was used to predict a C-terminal trypsin cleavage site between residues K135 and 
V136. Figure 5.3 was generated using the program Aline [196]. 
5.4 Analysis of FMN binding in the crystal structures of 
two T_DR_1146 homologues from the PDB 
A search of the RCSB PDB [79, 80] using the predicted amino acid sequence of 
T_DR_1146 gave the 3 D crystal structures of 10 homologues with between 47 to 
21 % sequence identity with the target T_DR_1146 protein. Amino acid sequence 
alignment (performed using Multalin [197]) of 7 of theses homologues (Figure 
5.4) shows complete conservation of four residues (red) and partial conservation 
of several regions. One of the conserved residues is a methionine that is involved 
in FMN binding of structure 2I02 (described later in this Section). 
   Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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Figure 5.4: Amino acid sequence alignment of T_DR_1146 with homologous PDB structures 
including 2RE7 and 2IO2 using MultAlin [197]. Figure and secondary structure of 2I02 
generated by ESPript 2.2 [198, 199] using data from the PDB. 
The structure 2RE7 (PDB ID) is a putative general stress protein (COG3871) from 
Psychrobacter arcticus 273 4 solved at 2.50 Å resolution [200]. The amino acid 
sequence of 2RE7 shows 47 % identity with that of T_DR_1146 and it was 
crystallised in the absence of a FMN cofactor (Figure 5.5a). 
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Figure 5.5: 3-D schematic ribbon representation of (a) 2RE7 complexed with four SO4
2- ions 
[200] and (b) 2IO2 complexed with one molecule of FMN, two molecules of PEG 330 and a Cl
- 
ion [81] taken from the RCSB PDB [79, 80]. Β-strands are represented as arrows, α-helices as 
coiled ribbons and random coils as thin tubes. Bound prosthetic molecules and ions are 
represented by ball and stick diagrams. The direction of the polypeptide chains are depicted by the 
following colour ramps: (a) both chains of 2RE7 go from blue (N-terminus) to red (C-terminus) and 
(b) Chain A of 2I02 goes from blue (N-terminus A) to green (C-terminus A) and Chain B of 2I02 
goes from green (N-terminus B) to red (C-terminus B). 
Each peptide chain is 133 amino acids long ending with Gly133. However, the 
predicted UniProt [201] amino acid sequence was 164 residues in length 
suggesting that, like T_DR_1146, the protein underwent C terminal proteolysis 
before crystallisation. The C terminal cleavage site (after Gly133) is marked on 
the equivalent T_DR_1146 sequence in Figure 5.3.  
The structure of a putative general stress proteins (COG3871) from Nostoc 
punctiforme PCC 73102 (PDB ID: 2I02), solved at 1.80 Å resolution has 32 % 
identity with T_DR_1146. In contrast to 2RE7, the dimeric structure of 2I02 was 
crystallised with one molecule of FMN bond in a hydrophobic pocket positioned 
at the dimer interface (Figure 5.5b). The Structural Classification of Proteins 
database (SCOP) [202] classified Chains A and B of 2I02 to have a split barrel like 
fold, which is characteristic of the FMN binding split barrel superfamily. This 
fold is shared with 47 of the 421 FMN binding proteins entered on the PDB. 
In order to predict which T_DR_1146 residues are involved in FMN binding, the 
interactions of 2I02 with the bound FMN were examined using the programs Coot 
[203] and Relibase 2.2.1 [204, 205].   Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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The single FMN molecule is involved in extensive hydrophobic and hydrogen bond   
interactions with 2I02. Most of the interactions involve Chain A however two 
residues from Chain B bind to the ribityl hydroxyl region of FMN. 
The isoalloxazine moiety of the FMN molecule forms hydrophobic contacts (of 
less than 3.8 Å) with Trp111, Phe55 and Mse40 residues of Chain A. Only an 
unmodified Methionine residue is conserved in the T_DR_1146 and 2RE7 
sequences with Tyr and Ile (T_DR_1146) and Phe and Ile (2RE7) in place of 
Trp111 and Phe55. In addition to hydrophobic interactions, the isoalloxazine ring 
and 2I02 are involved in hydrogen bonded interactions (Figure 5.6). The ring 
atoms O4 and N3 make direct hydrogen bonds with Ser41(N) and Phe55(O) of 
Chain A. Neither of theses two amino acids are conserved in the sequences of 
T_DR_1146 or 2RE7. 
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Ser41 
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N3 
    O3' 
    O5' 
      O1P 
       
    O2P 
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Figure 5.6: Direct hydrogen bond interactions between Chain A (yellow) and Chain B 
(magenta) of 2I02 and a single FMN molecule. Nitrogen, oxygen and phosphate atoms are 
coloured blue, red and orange respectively and hydrogen bonds indicated by dotted black lines. 
Figure generated using PyMOL [206]. 
The hydroxyl groups of the ribityl chain form three direct hydrogen bonds with 
Pro39(O) of Chain A, and Trp134(NE1) and Phe140(O) of chain B of which Pro39 
(Chain A) and Trp134 (Chain B) are conserved.    Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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His61(N) and Lys62(NZ and N) form direct hydrogen bonds to the prosthetic 
phosphate moiety of FMN (O2P and O1P), and to the ribityl atom O5'. It can be 
seen in the sequence alignment (Figure 5.4) that neither His61 nor Lys62 are 
conserved in the sequences of T_DR_1146 or 2RE7. ITC results suggest that the 
phosphate moiety of FMN (which is part of a prosthetic group that differs 
between flavins) plays no part in binding to T_DR_1146. It is therefore possible 
that the absence of Lys62 and His 61 could have a negative impact on the FMN 
binding affinity of T_DR_1146. As 2RE7 is also deficient of Lys62 and His61, this 
may explain why this particular protein was crystallised in the absence of FMN. 
Only biophysical characterisation of 2I02 and 2RE7 and structure determination 
of T_DR_1146 will confirm such hypotheses.   
A summary of the atoms of FMN and amino acid residues involved in hydrogen 
bonding is given in Table 5.1. 
Amino acid 
residue 
Atoms involved 
in hydrogen 
bond 
Chain of 2I02  Bond length (Å)  FMN atoms 
Phe55  Backbone 
carboxyl O 
A 
 
 
2.8  Ring N3'  
Ser41  Backbone N   A 
 
3.3  Ring O4 
Pro39  Backbone 
carboxyl O 
A 
 
 
2.8  Ribityl O2'  
Trp134  Cyclic N in side 
chain (NE1) 
B 
 
 
3.1  Ribityl O3'  
Phe140  Backbone 
carboxyl O 
B 
 
 
2.7  Ribityl O3'  
Lys62  Side chain N (NZ)  A 
 
2.9  Ribityl 05'  
Lys62  Backbone N  A 
 
2.8  O1P  
His61  Backbone N  A 
 
3.2  O2P  
Table 5.1: Summary of the hydrogen bonds formed between 2I02 and FMN  
In conclusion, as the 2I02 FMN binding residues Mse40, Pro39 and Trp134 are 
conserved in the amino acid sequence of T_DR_1146, it is thought that they may 
be involved in binding of the protein to the isoalloxazine ring system and ribityl 
chain of the FMN cofactor. It is unknown whether the replacement residues for 
un conserved amino acids will interact with FMN in the same way as in 2I02. 
However, it is thought that the absence of a Lys62 and His61 in T_DR_1146 may   Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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prevent hydrogen bonding to the phosphate moiety and explain predicted 
redundancy of the prosthetic –X group of flavins in binding to the protein.     
5.5 Construct design and cloning of t_DR_1146 with a C-
terminal truncation 
To investigate crystallisation of the stable T_DR_1146 fragment, attempts were 
made to clone a C terminal truncated form of the t_dr_1146 gene (c_t_dr_1146) 
into pOPINF. The c_t_dr_1146 construct was designed to encode a protein of 132 
residues ending at Gly132. This was based on the C terminal cleavage site of the 
homologous 2RE7 crystal structure, which is thought to have degraded to this 
point. This C terminal site was chosen for construct design because of its close 
proximity to a predicted trypsin cleavage site (determined by PeptideCutter 
[171, 172]) in a region with no predicted secondary structure (determined by 
Network Protein Sequence Analysis [194, 195]) (Figure 5.3). 
Primers were designed as described in Section 2.2.1 and are listed in Table 2.2. 
The construct DNA of t_dr_1146 in pET15b was used as the DNA template in the 
PCR step and the master mix recipe and temperature cycle shown in Section 
2.2.3 and Table 2 3 were used. 
An optimum annealing temperature of 58°C resulted in successful amplification 
of the c_t_dr_1146 gene fragment (396 bp) shown in Figure 5.7.  
 
        1                  2 
 
 
Lane 1: Amplified c_t_dr_1146 (396 bp) 
 
Lane 2: 1 Kb Plus DNA Ladder 
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Figure 5.7: PCR amplification of c_t_ dr_1146 gene fragment imaged by agarose gel 
electrophoresis. 
This band was excised and purified as described in Section 2.2.4. The purified 
PCR product was added to the InFusion reaction mixture as described in Section   Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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2.2.5 and the reaction was immediately quenched with TE buffer and 5  L of the 
reaction mixture was used to transform DH5a  cells. The absence of colonies 
after overnight incubation at 37°C proved to be a negative result. The 
competency of the DH5α cells was confirmed by a positive control. 
This work could not be continued due to time constraints.    
5.6 Purification and crystallisation of degraded 
15N 
labelled T_DR_1146 sample 
A 0.9 mM sample of T_DR_1146, produced for NMR experiments, was incubated 
at 4°C for three months in a buffer of 50 mM phosphate buffer pH 7.5, 150 mM 
NaCl, 0.01 % NaN3 and 2 mM FMN. NMR experiments repeated over the three 
month period determined that proteolysis was complete due to no further 
changes in 
15N HSQC spectra. 
The sample was purified by SEC using the same buffer but without 2 mM FMN. 
The resulting A280 elution profile (Figure 5.8) showed a single peak (Peak 1) 
eluted in 15.97 mL of buffer which corresponds to a dimer of 27.9 kDa (including 
FMN contributions). Later peaks correspond to removal of degradation products 
and un bound FMN.   
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Figure 5.8: A280 elution profile for SEC purification of degraded T_DR_1146 shows a single 
peak eluted with 15.97 mL of buffer corresponding to a dimer.   Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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A high level of purity was confirmed by SDS PAGE analysis of the degraded 
T_DR_1146 eluted in Peak 1 (Figure 5.9, lanes 4 6).  
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Lane 1: MW Marker 
Lane 2: Halo T_DR_1146 partially degraded 
Lane 3: Halo T_DR_1146 degraded before SEC 
Lane 4: Halo T_DR_1146 degraded 
Lane 5: Halo T_DR_1146 degraded 
Lane 6: Halo T_DR_1146 degraded 
 
Purified by SEC 
 
Figure 5.9: SDS-PAGE analysis of degraded T_DR_1146 after purification by SEC. 
The purified protein was concentrated to 15 mg/mL and crystal trials were set 
up following the minimalistic approach described in Section 6.11. This involved 
the use of PACT 1 & 2 and JCSG+ crystallisation screens with site 1 containing 
degraded T_DR_1146 (15 mg/mL) and site 2 containing a negative control (gel 
filtration buffer).  
After 3 days, small yellow microcrystals formed in site 1, condition B1 (0.1 M MIB 
buffer pH 4.0, 25 % w/v PEG 1500) of the PACT screen (Figure 5.10). 
 
Figure 5.10: Crystals of degraded T_DR_1146 in 0.1 M MIB buffer pH 4.0, 25 % w/v PEG 1500. 
The composition of MIB buffer pH 4.0 (Molecular Dimensions) is shown in Table 
5.2.   Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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Chemical Name and source  Molar 
ratio 
Formula 
weight 
Mass 
(g) 
Final 
buffer 
volume 
(mL) 
Final 
buffer 
conc. 
(M) 
Comment 
Sodium malonate  2  266.00  4.15  100  1  Adjust to pH 
4.0 with 10 
M NaOH 
Imidazole 
 
3  68.08  2.55       
Boric acid  3  61.83  2.32       
Table 5.2: Composition of MIB buffer pH 4.0 provided by Molecular Dimensions. 
The microcrystals displayed no birefringent properties and in most cases were 
fused together. The observed yellow colour of the crystals was more intense 
than the pale yellow background drop. 
After two weeks of incubation the crystals grew to approximately 50  m in 
diameter with more defined edges. 
The crystals were mounted into 0.1 mm loops before being immersed in two 
different cryoprotectants (Table 5.3).  
Cryoprotectant   Composition  Comments 
A  0.1 M MIB buffer pH 4.0 
25 % PEG 1500 
25 % Glycerol 
 
MIB buffer taken from 1 M 
stock made following recipe in 
Table 5.1 
B  0.1 M MIB buffer pH 4.0 
40 % PEG 1500 
 
 
MIB buffer taken from 1 M 
stock made following recipe in 
Table 5.1  
Table 5.3: Composition of experimental cryoprotectants. 
Initial in house X ray diffraction experiments resulted in no diffraction. 
However, on exposure to synchrotron radiation, a diffraction pattern with a 
resolution limit of 7.3 Å (Figure 5.11) was observed, confirming analysis of 
protein crystals rather than FMN or salt. The most defined spots were gained 
using cryoprotectant A, resulting in some lunar patterns (Figure 5.11, zoomed). 
The presence of rings or merged spots suggests that diffraction resulted from a 
cluster of single microcrystals rather than a single crystal.      Chapter 5 Crystallisation of degraded T_DR_1146 with FMN   
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Figure 5.11 - Diffraction pattern for degraded T_DR_1146 crystals. Zoomed region shows lunar 
patterns as a result of diffraction using cryoprotectant A. The presence of rings or merged spots 
suggests that diffraction resulted from a cluster of single microcrystals rather than a single crystal. 
It was concluded that crystallisation of degraded T_DR_1146 occurred due to 
sample homogeneity achieved by isolating a stable fragment and saturating 
binding sites with FMN. As T_DR_1146 shares high sequence homology with the 
apo protein 2ER7, it is thought it may be possible to crystallise an apo form of 
degraded T_DR_1146 in the absence of FMN. 
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6  Expression, purification and crystallisation of 
SP_1651 
6.1 Project aims 
The aim of this project was to investigate the expression, purification and 
crystallisation of SP_1651 from S. pneumoniae with the objective of obtaining 
the 3 D crystal structure. This would allow structural and functional comparisons 
to be made with a homologue from D. radiodurans (DR_2242), for which the 
structure has been solved by Dr. Dave Hall as part of the ESRF’s structural 
genomics project.  
6.2 Construct design  
A full length form of the sp_1651 gene (residues 1 to 519) cloned into a pOPINF 
vector (Table 2.1) was kindly provided by Dr. Alan Riboldi Tunnicliffe, University 
of Glasgow. The cloning work was carried out at the Oxford Protein Production 
Facility, Oxford, using the In Fusion™ PCR Reaction system (Clontech).    
Throughout this chapter, protein encoded from the full length gene with the N 
terminal 6xHis tag still intact will be referred to as SP_1651. The protein with 
the 6xHis tag cleaved using HRV 3C protease will be referred to as SP_1651_clvd.  
6.3 Recombinant expression of sp_1651 from pOPINF 
2  L plasmid DNA (sp_1651 in pOPINF) was used to transform B834(DE3) 
competent cells by the method described in Section 2.2.6. 5  L of the 
transformation reaction mixture gave an even spread of single colonies after 20 
hrs incubation at 37°C. 
Recombinant sp_1651 was expressed in Overnight Express™ Autoinduction Media 
(Table 2.5) from the pOPINF vector as described in Section 2.4.6. A 100 x 
dilution of starter culture was used to initiate cell growth in a 500 mL culture 
which was incubated at 37°C for 4 hrs, followed by 20 hrs at 25°C at which an   Chapter 6 Expression, purification and crystallisation of SP_1651   
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OD600 of 7.05 was reached. A cell pellet of 6.18 g was harvested by 
centrifugation of the 500 mL culture. 
6.4 Initial purification trial 
The pellet was re suspended in 35 mL of lysis buffer (Table 2.8) with the 
addition of 0.2 % Tween 20. The cells were lysed by French press and loaded on 
to a 1 mL HisTrap HR column as described in Sections 2.5.3 and 2.5.4. IMAC was 
carried out on the bench, with the lysate incubated on ice, using a peristaltic 
pump at a flow rate of 1 mL/min. The loaded column was flushed with 12 
column volumes (CVs) of IMAC wash buffer followed by 10 CVs of IMAC elution 
buffer. The composition of buffers used for purification of SP_1651 are shown in 
Table 2.8.  
Successful expression of sp_1651 is evident in lane 3 of Figure 6.1 which shows a 
defined band at approximately 21 kDa (ringed). The presence of SP_1651 in this 
lane, and its absence in lanes 1 and 2, corresponding to the column flow through 
and the 12 CV wash respectively, shows that the tagged protein had an affinity 
for the Ni
2+ matrix making purification by IMAC feasible. The significant number 
of impurities as seen in lane 3 of Figure 6.1, indicates further optimisation of the 
IMAC protocol is necessary to obtain pure protein. 
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Figure 6.1: SDS-PAGE analysis of fractions eluted from initial IMAC purification. 
An A280 measurement of the elution fraction containing SP_1651 gave a peak 
maximum at 277.2 nm. A yield of 21.0 mg protein (including impurities) was 
calculated (Section 2.5.5).   Chapter 6 Expression, purification and crystallisation of SP_1651   
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6.5 Initial investigation of 6xHis tag cleavage with HRV-
3C protease 
Cleavage of the 6xHis tag using HRV 3C protease was carried out as described in 
Section 2.5.9. The decrease in molecular weight of the SP_1651 band in lane 4 of 
Figure 6.1 compared to lane 3 confirmed the success of the cleavage reaction. 
6.6 Initial investigation into the removal of cleaved 6xHis 
tag by IMAC 
After dialysis to remove imidazole, the cleaved sample was loaded on to a 1 mL 
HisTrap column and the flow through was collected. The column was flushed 
with IMAC wash buffer plus increasing concentrations of imidazole in 5 column 
volume intervals. The single bands in lanes 3 and 4 of Figure 6.2 show that 
SP_1651 was eluted in the column flow through (lane 3) and with 5 CVs of IMAC 
wash buffer (lane 4).  
 
       1    2    3    4     5    6    7    8    9    10 
Lane 1: After HRV 3C cleavage  
Lane 2: Dialysed to remove precipitate 
Lane 3: Column flow through 
Lane 4: O mM imidazole buffer 
Lane 5: 10 mM  midazole buffer 
Lane 6: 20 mM imidazole buffer (IMAC wash buffer) 
Lane 7: 30 mM imidazole buffer 
Lane 8: 50 mM imidazole buffer 
Lane 9: 100 mM imidazole buffer  
Lane 10: 500 mM imidazole buffer (IMAC elution buffer) 
Figure 6.2: SDS-PAGE analysis of fractions eluted from IMAC purification of SP_1651_clvd 
Lanes 3 and 4 were pooled together and a yield of 6.3 mg protein was 
calculated. The SP_1651 bands were very pure and thus suitable for 
crystallisation experiments. The faint band just below the SP_1651 bands in 
lanes 3 and 4 may either be an impurity or a proteolysis product.  
The purified SP_1651 was concentrated to 9 mg/mL and two sparse matrix 
screens were set up: Hampton 1 and 2, Cryo 1 and 2 and an in house Grid 
Screen. They were stored and monitored at 20°C in a Rhombix Imaging System.   Chapter 6 Expression, purification and crystallisation of SP_1651   
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After six weeks no protein crystals resulted, although crystalline precipitate was 
observed for several conditions.  
6.7 Optimised purification protocol for crystallisation 
experiments 
1 L of cell culture was produced following the protocol outlined in Section 2.4.6. 
Cell lysis was carried out using the Constant Cell Disruption System (Section 
2.5.3). After cell lysis and harvesting an additional Complete EDTA free Protease 
Inhibitor tablet was added to the soluble supernatant to avoid possible 
proteolysis. 
IMAC was carried out using a 5 mL HiTrap HR column to accommodate an 
increased amount of protein. Using an AKTA purifier FPLC, a step gradient 
including two additional imidazole concentrations (10 and 20% IMAC elution 
buffer) and an increased number of CVs was employed in an attempt to remove 
impurities (Table 6.1). 
Step number  Number of 
column volumes 
(1 CV = 5 mL) 
% IMAC wash 
buffer (20 mM 
imidazole) 
% IMAC elution 
buffer (500 mM 
imidazole) 
Effective 
imidazole conc. 
(mM) 
1  12  100  0  20 
 
2  11  90  10  68 
 
3  8  80  20  116 
 
4  8  0  100  500 
Table 6.1: Optimised IMAC protocol. 
Figure 6.3 is the A280 elution profile for the optimised purification of SP_1651. 
Peaks 1 and 2 (approximately 250 mAU) correspond to protein eluted with the 
additional 10 and 20 % IMAC elution buffer steps.   Chapter 6 Expression, purification and crystallisation of SP_1651   
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Figure 6.3: A280 elution profile for optimised IMAC purification of SP_1651. Peak 3 
corresponds to the elution of SP_1651 with 100 % IMAC Elution buffer. 
Lanes 4 8 in Figure 6.4 show the impurities eluted with these buffer 
concentrations. Lane 9 contains a heavy single band corresponding to the protein 
eluted in peak 3 (Figure 6.3) resulting in an absorbance of 2000 mAU.  This single 
band at approximately 21 kDa was SP_1651 at purity sufficient for crystallisation 
trials. A yield of 14.4 mg of pure SP_1651 was calculated and then was 
partitioned onto two aliquots to investigate crystallisation both with and without 
the 6xHis tag.  
 
  1    2    3     4     5     6    7    8     9   10 
kDa 
 
98 
62 
 
49 
38 
 
28 
 
17 
14 
 
6 
 
 
Lane 1: Lysate 
Lane 2: Column flow through 
Lane 3: IMAC wash buffer 
Lane 4:  
Lane 5:      10 % IMAC elution buffer 
Lane 6: 
Lane 7:      20 % IMAC elution buffer 
Lane 8: 
Lane 9: 100 % IMAC elution buffer 
Lane 10: MW Marker 
 
Figure 6.4: SDS-PAGE analysis of optimised IMAC purification of SP_1651.   Chapter 6 Expression, purification and crystallisation of SP_1651   
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6.8 Gel filtration of SP_1651 to analyse oligomeric state 
Half of the purified SP_1651 prep was dialysed against a gel filtration buffer of 
20 mM Tris pH 7.5, 100 mM NaCl as described in Section 2.5.2. It was then 
concentrated to a volume of 500 mL (approximately 14 mg/mL) and analysed by 
size exclusion chromatography using a S200 10/300 HR Global gel filtration 
column as described in Section 2.5.7. The aim of this experiment was to 
determine the oligomeric state of the protein in solution. Figure 6.5 shows the 
resulting A280 elution profile, which comprises a single peak at an elution volume 
of 13.28 mL. Comparison with the column calibration profile suggests a 
molecular weight of 40 kDa, which indicates that SP_1651 exists as a dimer in 
solution. The eluted protein fractions were pooled and concentrated to 16.3 
mg/mL by centrifugation (Section 2.5.6). 
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Figure 6.5: A280 elution profile for analytical gel filtration experiment to determine oligomeric 
state of SP_1651 shows a single peak eluted with 13.28 mL of buffer. 
6.9 HRV-3C cleavage of 6xHis tag 
The second aliquot of the SP_1651 prep was subjected to 6xHis tag removal 
using HRV 3C protease followed by an IMAC step as described previously. The 
cleaved protein (SP_1651_clvd) was dialysed into the same buffer as the non   Chapter 6 Expression, purification and crystallisation of SP_1651   
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cleaved protein (20 mM Tris HCl pH 7.5, 100 mM NaCl) and was concentrated to 
25.3 mg/mL by centrifugation (Section 2.5.6). 
6.10 Pre-crystallization Test (PCT) for SP_1651 and 
SP_1651_clvd 
A Pre crystallization Test (PCT) to establish the optimum protein concentration 
for crystallisation experiments was carried out for SP_1651 and SP_1651_clvd as 
described in Section 2.6.2. The experiments were observed by light microscope 
after 24 hr incubation at 20°C. Concentrations of 16.3 mg/mL and 17.0 mg/mL 
were selected for SP_1651 and SP_165_clvd respectively.  
6.11 Crystallisation trials for SP_1651 and SP_1651_clvd 
When setting up crystallisation experiments the minimalistic approach designed 
by Newman et al. (2005) [207] was employed. This method was designed 
primarily for small academic laboratories where cost and experimental 
monitoring are important considerations. The strategy involved the combination 
of two 96 condition screens; JCSG+   a sparse matrix screen developed by the 
Joint Centre for Structural Genomics, and PACT – a systematic screen which 
tests pH, anionic and cationic additives. The JCSG+ screen allows initial 
screening covering a wide range of conditions selected from other sparse matrix 
screens without redundancy. The PACT screen can be used to gain information 
about the protein even in the absence of crystal growth [207].  
The trays were stored and monitored as outlined in Section 2.6.3, with SP_1651 
(16.3 mg/mL) in drop 1 and SP_1651_clvd (17.0 mg/mL) in drop 2 for each 
condition in both 96 well trays. The remaining protein samples were separated 
into 60 µL aliquots and stored at –20°C to minimise possible proteolysis.  
After 11 days, birefringent crystals were formed in condition A1, site 2 of the 
PACT screen. This corresponded to the SP_1651_clvd sample at a concentration 
of 17 mg/mL. The composition of the A1 well solution was 0.1 M SPG Buffer pH 
4.0, 25 % w/v PEG 1500. The SPG Buffer pH 4.0 (Molecular Dimensions)   Chapter 6 Expression, purification and crystallisation of SP_1651   
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comprised succinic acid, sodium dihydrogen phosphate monohydrate and glycine 
(Table 6.2).  
Chemical Name and source  Molar 
ratio 
Formula 
weight 
Mass 
(g) 
Final 
buffer 
volume 
(mL) 
Final 
buffer 
conc. 
(M) 
Comment 
Succinic acid (Sigma S3674)  2  118.10  1.48  100  1  Adjust to pH 
4.0 with 10 
M NaOH 
Sodium dihydrogen phosphate 
monohydrate (Fluka 71507) 
 
7  137.99  6.04       
Glycine (Fluka 50046)  7  75.07  3.28       
Table 6.2: Composition of SPG Buffer pH 4.0 provided by Molecular Dimensions. 
The crystals had formed as 100  m clusters (Figure 6.6) and were difficult to 
separate without breaking.  
 
Figure 6.6: SP_1651_clvd crystals grown from 0.1 M SPG buffer pH 4.0, 25 % PEG 1500 
No crystals were found in condition A1 for the non cleaved protein. Phase 
separation and possible microcrystals were observed, however after 3 months 
there was no crystal formation suggesting that the presence of the 6xHis tag was 
unfavourable. No further crystals were found in either of the trays for either 
protein over a three month period. 
Analysis of the PACT screens for SP_1651 and SP_1651_clvd after two weeks gave 
an insight into unfavourable crystallisation conditions. Heavy amorphous 
precipitate appeared in the presence of a combination of acetate buffer and 
various cations, with 0.2 M ZnCl2  giving particularly heavy precipitation for both 
SP_1651 and SP_1651_clvd.   Chapter 6 Expression, purification and crystallisation of SP_1651   
  - 129 -   
6.12 X-ray diffraction experiments on SP_1651_clvd 
crystals 
The PACT crystallisation tray containing the initial SP_1651_clvd crystals was 
taken to the Diamond Light Source, South Oxfordshire where crystals were 
mounted into 0.12 mm loops before being immersed in three different 
cryoprotectants (Table 6.3). It was difficult to loop single crystals as they 
formed as fragile clusters, which were easily damaged. 
Cryoprotectant   Composition  Comments 
A  0.1 M SPG buffer pH 4.0 
25 % PEG 1500 
 
Taken directly from well 
 
B  0.1 M SPG buffer pH 4.0 
25 % PEG 1500 
25 % Glycerol 
 
SPG buffer taken from 1 M stock 
made following recipe in Table 6.2  
C  0.1 M SPG buffer pH 4.0 
10 % PEG 600 
SPG buffer taken from 1 M stock 
made following recipe in Table 6.2 
Table 6.3: Composition of experimental cryoprotectants. 
Diffraction confirmed that the crystals were protein and diffraction data with a 
resolution limit of 3.2 Å (Figure 6.7), were collected using a fractured single 
crystal immersed in cryoprotectant B (Table 6.3). 
 
Figure 6.7: Diffraction image of SP_1651_clvd.   Chapter 6 Expression, purification and crystallisation of SP_1651   
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Multiple spots in the diffraction pattern exist due to the crystal being split. 
Although this crystal appears mosaic the diffraction image represents a suitable 
crystal form for optimisation. 
6.13 Attempts to reproduce and optimise SP_1651 
crystals 
Frozen aliquots of SP_1651_clvd were thawed at room temperature and efforts 
were made to reproduce/optimise the initial crystallisation. The experiments 
carried out are listed in Table 6.4. For each experiment the concentrations of 
protein in drops 1 and 2 were 17.0 and 8.5 mg/mL respectively. A drop size of 1 
 L (protein:precipitant ratio of 0.5  L:0.5  L) was used. After 6 weeks there was 
no evidence of crystallisation. It was thought that the protein had been 
damaged, denatured, unfolded or aggregated by the freeze thaw process making 
crystallisation unfavourable.  
Experiment  Conditions/Screen  Number of 
conditions 
Comments 
Reproduction 
Tray 1 
0.1 M SPG buffer pH 4.0 
25 % PEG 15000 
96 x same 
condition in each 
well 
SPG buffer made following 
recipe in Table 6 2.   
Reproduction 
Tray 2 
0.1 M SPG buffer pH 4.0 
25 % PEG 15000 
96 x same 
condition in each 
well 
SPG buffer made using 
sodium dihydrogen 
phosphate dehydrate 
rather than hygroscopic 
monohydrate 
Reproduction 
Tray 3 
0.1 M SPG buffer pH 4.0 
25 % PEG 15000 
96 x same 
condition in each 
well 
SPG buffer purchased from 
manufacturer 
Reproduction 
Tray 4 
PACT tray  96 different 
conditions 
PACT Screen from the 
same batch which 
produced initial crystals 
Optimisation 
Tray 1 
Varied pH between 3.8 4.5 in 
0.1 pH unit increments. 
Varied % PEG 1500 between 
5 30 % in 5 % increments. 
48 different 
conditions 
SPG buffer made following 
recipe in Table 6 2.   
Table 6.4: Experiments set up in attempt to reproduce/optimise SP_1651_clvd crystals. 
Seeding experiments were performed in an attempt to reproduce the initial 
crystals however the drop precipitated destroying any remaining crystals. After 
re sealing and re incubation at 20°C for 24 hrs, some crystals reappeared. 
However, no diffraction was observed despite trying numerous crystals from this 
batch in the previously successful cryoprotectant.   Chapter 6 Expression, purification and crystallisation of SP_1651   
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A fresh batch of SP_1651_clvd was prepared by the same protocol used to obtain 
the initial crystals. The crystallisation experiments listed in Table 6.4 were 
repeated in a second attempt to reproduce the initial crystal hit. No crystals 
grew after continued monitoring of experiments over a period of 3 months.    
6.14 JBS Solubility Screen and DLS experiments  
A study by Zulauf and D’Arcy (1992) [208] showed that the presence of 
aggregates in the protein solution may inhibit crystal nucleation or growth. In 
the past, researchers have tried to overcome such problems by adjusting 
purification protocols, removing fusion and purification tags and adding reducing 
agents, ultimately to provide a suitable environment conducive to complex 
macromolecules. Although these factors are important, buffer composition can 
also impact on aggregation. Jancarik et al. (2004) [173] devised the JBS 
Solubility Kit which tests a panel of buffers and additives to find the condition in 
which the recombinant protein is most homogenous. This method uses DLS 
experiments to assess the monodispersity of the conditions tested. These studies 
resulted in the crystallisation of 9 out of 14 proteins which had previously been 
susceptible to aggregation [173].  
In an attempt to generate new crystal hits, the JBS Solubility kit was used for 
SP_1651_clvd as described in Section 2.6.1. The initial 24 well hanging drop 
experiments resulted in precipitation of the protein in buffers 1 5. This showed 
that the protein was insoluble in these buffer conditions (pH 3 4.5) therefore 
they were excluded from the DLS buffer screen. Table 6.5 shows the results 
gained for Part A: DLS Buffer Screen. The results recorded included the average 
hydrodynamic radius (Rh) (nm), polydispersity (P) (nm), % polydispersity (% P) 
and the predicted molecular weight (MW) (kDa) values gained from DLS 
experiments. These values were analysed in conjunction with the generated 
regularisation histograms and the range of the 12 individual DLS measurements 
for each buffer. 
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Buffer  Composition (100 mM)  R (nm)  P (nm)  % P  % P < 25 %  MW 
(kDa) 
6  Na/K phosphate pH 5.0  2.98  0.51  17.1  Yes  40.9 
7  Sodium citrate pH 5.5  2.69  0.57  21.1  Yes  32.0 
8  Na/K phosphate pH 6.0  3.25  1.66  51.1  No  50.4 
9  Bis Tris pH 6.0  2.78  0.83  29.9  No  34.5 
10  MES pH 6.2  2.98  0.99  33.2  No  41.1 
11  ADA pH 6.5  2.96  0.89  30.0  No  40.4 
12  Bis Tris propane pH 6.5  2.61  0.97  37.0  No  31.2 
13  Ammonium acetate pH 7.0  2.91  0.97  33.2  No  38.7 
14  MOPS pH 7.0  3.03  1.13  37.3  No  42.7 
15  Na/K phosphate pH 7.0  2.84  0.83  29.2  No  36.4 
16  HEPES pH 7.5  2.73  1.10  40.3  No  33.1 
17  Tris pH 7.5  2.96  0.80  27.0  No  40.2 
18  EPPS pH 8.0  2.95  1.12  38.0  No  40.0 
19  Imidazole pH 8.0  3.00  1.04  34.7  No  41.7 
20  Bicine pH 8.5  3.50  1.64  46.9  No  60.8 
21  Tris pH 8.5  2.90  0.96  33.1  No  38.5 
22  CHES pH 9.0  3.02  1.04  34.4  No  42.2 
23  CHES pH 9.5  3.01  1.19  39.5  No  42.3 
24  CAPS pH 10.0  2.85  1.01  35.4  No  36.8 
Table 6.5: Results of DLS Buffer Screen on SP_1651_clvd. 
Jancarik et al. (2004) [173] identified the criteria of a suitable crystallisation 
buffer to be one which gives a radius of less than 5 nm and a percentage 
polydispersity of less than 25%. Buffers 6 (pH 5.0) and 7 (pH 5.5) gave suitable 
monomodal size distributions (< 5 nm) and poydispersity percentages below 25 % 
and thus would be suitable for crystallisation trials. However, it was decided 
that the best result was gained for buffer 7, which was comprised of 100 mM 
sodium citrate pH 5.5. It was chosen because of the combination of a high 
intensity (> 90 %) single peak on the DLS histogram (Figure 6.8), a low 
hydrodynamic radius of 2.69 nm, and a narrow result distribution shown on the 
measurement trace (Figure 6.9).    Chapter 6 Expression, purification and crystallisation of SP_1651   
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Figure 6.8: Dynamic light scattering histogram of SP_1651_clvd in buffer 7, 100 mM Na 
citrate pH 5.5. The high intensity single peak (yellow) demonstrates high monodispersity. Figure 
generated by Dynapro-801 software (Protein Solutions). 
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Figure 6.9: Ranges of the 12 measurements taken for SP_1651_clvd in buffer 7, 100 mM Na 
citrate pH 5.5. Shows a narrow range of results over the 12 measurements taken. Figure 
generated by Dynapro-801 software (Protein Solutions). 
In general, the results gained for SP_1651_clvd were good, with radius values 
ranging between 2.69 to 3.50 nm (all below 5 nm) and percentage polydispersity 
values ranging between 17 to 51 %. The worst result was gained for SP_1651_clvd 
solubilised in buffer 20, which was comprised of 100 mM bicine pH 8.5. The DLS 
histogram (Figure 6.10) shows evidence of a high molecular weight aggregate 
which is undesirable for successful crystallisation.   Chapter 6 Expression, purification and crystallisation of SP_1651   
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Figure 6.10: Dynamic light scattering histogram for SP_1651_clvd in buffer 20, 100 mM 
bicine pH 8.5. Figure shows the presence of high molecular aggregates (red) and anomalous low 
molecular species (blue). Figure generated by Dynapro-801 software (Protein Solutions). 
Although the SP_1651_clvd sample in buffer 7 was deemed suitable for 
crystallisation trials, Part B of the experiment (additive screen) was still carried 
out to investigate the positive and negative effects of commonly used additives 
on homogeneity and monodispersity. The experiment was carried out as 
described in Section 1.6.1 and the results are depicted in Table 6.6.  
  Composition  Stock 
conc. 
Final 
conc. 
R (nm)  P (nm)  % P  Compared 
with initial 
result 
MW 
(kDa) 
1  Sodium chloride  80 mM  20 mM  2.76  0.50  18.3  Slightly better  34.1 
2  Sodium chloride  200 mM  50 mM  2.78  0.75  26.8  Same  34.7 
3  Sodium chloride  400 mM  100 mM  2.75  0.62  22.5  Same  33.6 
4  Glycerol  20%  5%  2.91  0.83  28.6  Slightly worse  38.6 
5  Glycerol  40%  10%  3.27  1.26  38.5  Slightly worse  51.4 
6  CHAPS  8 mM  2 mM  2.71  0.48  17.8  Same  32.5 
7  OG  0.40%  0.10%  2.69  0.51  18.8  Slightly better  31.8 
8  OG  4%  1%  2.66  0.60  22.5  Slightly worse  31.0 
9  DDM  0.40%  0.10%  3.23  0.88  27.2  Slightly worse  49.8 
10  DDM  4%  1%  3.26  0.55  16.8  Slightly worse  51.0 
11  BME  40 mM  10 mM  2.69  0.62  23.0  Slightly worse  31.9 
12  DTT  4 mM  1 mM  2.62  0.44  16.8  Same  30.0 
13  DTT  20 mM  5 mM  2.69  0.36  13.4  Slightly better  31.8 
14  TCEP  120 mM  30 mM                
Table 6.6: Results of DLS Additive Screen on SP_1651_clvd in 50 mM Na citrate pH 5.5. 
A slight improvement on the initial 100 mM odium citrate pH 5.5 buffer was 
gained for additive 1 (20 mM NaCl final conc.), additive 7 (0.1 % octyl 
glucopryanocide final conc.) and additive 13 (5 mM DTT final conc.). In general,   Chapter 6 Expression, purification and crystallisation of SP_1651   
  - 135 -   
no great change was observed. Additive 14, 120 mM TCEP (stock concentration) 
resulted in the sample precipitating before the DLS experiment could be 
performed.  
SP_1651_clvd was dialysed into four subsequent buffers: (a) 50 mM Sodium 
citrate pH 5.5 buffer without any additive, (b) with 20 mM NaCl, (c) with 0.1 % 
octyl glucopryanocide and (d) with 5 mM DTT. Crystallisation experiments were 
set up for 20 mg/mL and 10 mg/mL samples of each, using the PACT/JCSG+ 
strategy described in Section 1.10. 
After 3 months of monitoring the experiments using a Rhombix Imaging System 
(Section 2.6.3), no credible protein crystals were gained. 
In some of the histograms generated throughout these experiments, a low 
molecular weight species of low intensity was present. This anomaly cannot be 
explained; however it is thought to be concentration dependent and disappears 
at higher protein concentrations. The average molecular weight calculated for 
the 24 buffers equalled 33.6 kDa. This correlated with the gel filtration trace 
(Figure 6.5) corresponding to SP_1651 which suggested that it is dimeric in 
solution. Although lower than the expected value of 38.8 kDa this may be due to 
the contribution from the anomalous low molecular weight species.    
The JBS Solubility test was also carried out on non cleaved SP_1651 samples. In 
comparison with SP_1651_clvd results, none of the 24 buffers gave an 
improvement in monodispersity. In the majority of cases, large molecular weight 
aggregates were present resulting in an average molecular weight of 232 kDa, a 
value almost 7 times that calculated for SP_1651_clvd. The best result obtained 
for SP_1651 was for buffer 6, sodium/potassium phosphate pH 5.0. Table 6.7 
contrasts the difference in radius, polydispersity, % polydispersity and MW values 
for SP_1651 and SP_1651_clvd samples for this buffer.  
Protein sample  R (nm)  P (nm)  % P  % P < 25 %  MW (kDa) 
SP_1651  3.26  1.03  31.6  No  51.1 
SP_1651_clvd  2.98  0.51  17.1  Yes  40.9 
Table 6.7: Comparison of DLS Buffer Screen results for SP_1651 and SP_1651_clvd in buffer 
6.   Chapter 6 Expression, purification and crystallisation of SP_1651   
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Although both radial measurements are below the 5 nm criteria, the value for 
SP_1651_clvd is less than half of that gained for the non cleaved SP_1651 
sample. 
Figure 6.11 compares the regularisation histograms for both protein samples in 
buffer 6. For SP_1651_clvd the % polydispersity is below the desired threshold of 
25 %, whereas that for the non cleaved protein is above. For non cleaved 
SP_1651 (Figure 6.11b) there is evidence of a high molecular weight species 
which is absent for SP_1651_clvd (Figure 6.11a). Ultimately, these results 
confirm that the cleaved protein is less aggregated in solution and therefore 
crystallisation is more favourable. This could explain why the initial crystals 
described in Section 6.12 were gained for SP_1651_clvd but not for SP_1651 
using the same condition.     
           
(a) 
  
 
(b) 
 
Figure 6.11: (a) DLS histogram of SP_1651_cvld in buffer 6 shows a monodispersed sample 
(b) DLS histogram of SP_1651 in buffer 6 shows the presence of high molecular aggregates 
(red) and anomalous low molecular species (blue). Figures generated by Dynapro-801 software 
(Protein Solutions). 
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7  Other targets from D. radiodurans and S. 
pneumoniae  
7.1 DR_0463 from D. radiodurans 
7.1.1 Project aims 
The aim of this project was to investigate the expression and purification of 
DR_0463 from D. radiodurans R1 with the objective of crystallising and 
characterising the protein.  
7.1.2 Construct design 
A full length form of the dr_0463 gene (nucleotide residues 1 to 2937), cloned 
into a pDEST17 vector (Table 2.1), was kindly provided by Protein’eXpert, 
Grenoble, France. The nucleotide and putative amino acid sequence for DR_0463 
is annotated on the Comprehensive Microbial Resources (CMR) database [6] 
which can be accessed on the web page of The J. Craig Venter Institute [7]. The 
gene has been assigned the name treY and has been putatively identified as a 
maltooligosytrehalose enzyme, involved in trehalose biosynthesis [122]. 
Throughout this chapter the gene and encoded protein will be referred to by the 
given locus name of DR_0463. 
7.1.3 Recombinant expression of dr_0463 from pDEST17 
Before beginning expression trials, dr_0463 pDEST17 construct DNA was 
sequenced to confirm the same codon distribution of nucleotides as for the 
putative sequence annotated on the CMR database.  
1  L plasmid DNA (dr_0463 in pDEST17) was used to transform B834(DE3), BL21 
Star(DE3), Rosetta(DE3)pLysS and BL21(DE3)pLysS competent cells (genotypes 
given in Table 2.6 of Chapter 2) by the method described in Section 2.2.6. 20  L 
of the transformation reaction mixture gave an even spread of single colonies 
after 20 hrs incubation at 37°C for all four cell lines.   Chapter 7 Other targets from D. radiodurans and S. pneumoniae   
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Preliminary expression trials were performed for each cell line using LB media 
(Table 2.5) as described in Section 2.4.5. A 100 x dilution of starter culture was 
used to initiate cell growth in each of the four 500 mL cultures which were 
incubated at 37°C until an OD600 of 0.6 was reached. They were then induced 
with IPTG and incubated for 20 hrs at 22°C.  
SDS PAGE (Section 2.4.8) and western blot analysis (Section 2.4.9) of 0.5 mL cell 
extracts taken during this incubation period were used to assess the levels of 
soluble and insoluble expression. Table 7.1 gives a summary of the results gained 
for the four cell lines tested. 
Cell line  Soluble expression  Insoluble expression 
B834(DE3)  No  No 
BL21 Star(DE3)  No  No 
Rosetta(DE3)pLysS  No  Weak 
BL21(DE3)pLysS  No   Very strong 
Table 7.1: Results of preliminary expression trials for DR_0463 in four different cell lines as 
judged by SDS-PAGE and western blot. Strong insoluble expression was observed for 
BL21(DE3)pLysS. In addition, a small amount of insoluble DR_0463 was produced by 
Rosetta(DE3)pLysS. No expression was observed for B834(DE3) and BL21 Star(DE3) and no 
evidence of soluble DR_0463 was found for any of the four cell lines. 
The largest quantity of DR_0463 was produced in an insoluble form by 
BL21(DE3)pLysS competent cells. This is shown by the increasing intensity of a 
band at approximately 100 kDa in lanes 7 11 of Figure 7.1.  
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Figure 7.1: SDS-PAGE analysis of soluble (Lanes 2-6) and insoluble (Lanes 7-11) cell 
extracts (normalised to OD600 = 5) taken at time points to assess expression levels of 
DR_0463. Increased intensity of the band at approximately 100 kDa in lanes 7-11 indicates good 
expression of DR_0463 in the insoluble cell fraction. Analysis of soluble cell extracts (lanes 2-6) 
showed several faint bands in the 100 kDa region, however none were recognised by western blot.   Chapter 7 Other targets from D. radiodurans and S. pneumoniae   
  - 139 -   
A small amount of insoluble DR_0463 was produced by Rosetta(DE3)pLysS but no 
expression was identified for B834(DE3) and BL21 Star(DE3) cell lines.  
No soluble protein was produced by B834(DE3), BL21 Star(DE3) or 
Rosetta(DE3)pLysS cells, although several possible bands were observed in the 
100 kDa region of soluble BL21(DE3)pLysS cell extracts (Figure 7.1, lanes 2 6). 
These bands were not detected by western blot and did not show any affinity for 
the HisTrap HR column matrix during initial IMAC purification trials. This 
suggests that either (a) the bands in lanes 2 6 are not DR_0463 and thus no 
soluble target protein was expressed or (b) the 6xHis tag is inaccessible for 
detection and purification. 
It was decided to concentrate efforts on solubilisation and purification of 
insoluble DR_0463 produced by BL21(DE3)pLysS cells. To enable further 
experiments, protein expression was scaled up to 4 x 500 mL cultures as 
described in Section 2.4.5. 
7.1.4 Solubilisation and IMAC purification of DR_0463 
Cell pellet from 2 L of culture was re suspended in 30 mL of lysis buffer (Table 
2 8) and the cells were lysed by French press as described Section 2.5.3. After 
centrifugation the soluble and insoluble fractions were separated. The insoluble 
pellet, containing expressed DR_0463, was solubilised by the procedure 
described in Section 2.5.3, using 20 mL of solubilisation buffer (Table 2.8). After 
further centrifugation at 5700 rcf for 30 minutes, the solubilised supernatant 
was loaded on to a 1 mL HisTrap HR column, pre equilibrated with IMAC wash 
buffer (Table 2.8) containing 8 M urea. The column was flushed with 10 CV of 
this buffer to remove any unbound proteins. 
IMAC was carried out on an AKTA Purifier FPLC as described in Section 2.5.4. 
with 8 M urea added to both wash and elution buffers. The program employed is 
summarised in Table 7.2.  
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Step number  Number of 
column volumes 
(1 CV = 1 mL) 
% IMAC Wash 
Buffer (+8 M 
urea) 
% IMAC Elution 
Buffer (+8 M 
urea) 
Effective 
Imidazole conc. 
(mM) 
1  10  100  0  20 
 
2  20  90  10  68 
 
3  12  80  20  116 
 
4  10  0  100  500 
Table 7.2: IMAC protocol or purification of solubilised DR_0463. 
The eluted fractions were analysed by SDS PAGE as shown in Figure 7.2. 
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Figure 7.2: SDS-PAGE analysis of IMAC purification of solubilised DR_0463 
The large 100 kDa bands in the solubilised supernatant (Lane 2) and the column 
flow through (lane 3) show similar intensities suggesting that on loading, a large 
proportion of the target protein passed through the column without binding. 
Such low affinity for the Ni
2+ matrix resulted in the elution of DR_0463 with IMAC 
wash buffer (Lane 4) and 10 % IMAC elution buffer (Lane 5) alongside many 
impurities. Faint single bands corresponding to target protein eluted with 20 % 
(lane 6) and 100 % (lane 7) IMAC elution buffer showed insufficient yields for re 
folding experiments. 
In an attempt to increase binding of DR_0463 to the column resin, the following 
protocol adaptations were made: 
(a) Increasing the potential binding capacity of the column by using a higher 
volume 5 mL HiTrap column   Chapter 7 Other targets from D. radiodurans and S. pneumoniae   
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(b) Reducing the imidazole concentration of IMAC wash buffer from 20 to 5 
mM in an attempt to prevent the protein passing through the column 
without binding 
(c) Adding 5 % glycerol to the solubilised supernatant before loading onto the 
column in an attempt to ‘loosen’ the protein and make the 6xHis tag 
accessible for binding 
(d) Changing denaturation agent from 8 M urea to 6M guanidine hydrochloride 
SDS PAGE analysis of IMAC purification experiments implementing the above 
changes showed no increase in the amount of DR_0463 binding to the column. 
However, it was found that sequentially repeating IMAC purification with the 
same protein sample resulted in the removal of many unwanted impurities. On 
the second and third passes (Figures 7.3b and c) through the 5 mL HiTrap 
column, DR_0463 was purified to a level and yield deemed acceptable for 
further purification by gel filtration or ion exchange. 
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Figure 7.3: SDS-PAGE analysis of second (a) and third (b) IMAC purifications of DR_0463. 
Lanes 3-6 of (a) and Lanes 3-6 of (b) show that repetitive IMAC cycles produced purity levels and 
yields of DR_0463 acceptable for further purification by ion exchange or gel filtration.   Chapter 7 Other targets from D. radiodurans and S. pneumoniae   
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Future work planned for the DR_0463 project involved optimisation of the 
purification protocol to produce sufficient yields of pure protein for re folding 
trials. 
7.2 SP_1648 from S. pneumoniae and DR_2284 from D. 
radiodurans 
7.2.1 Project aims 
The aim of this project was to investigate the expression and purification of 
homologous genes from S. pneumoniae (sp_1648 or psaB) and D. radiodurans R1 
(dr_2284). Crystallisation of the encoded proteins would allow structural and 
functional comparisons to be made. 
Work on DR_2284 was carried out at within the Macromolecular Crystallography 
Group, ESRF, Grenoble, France.  
7.2.2 Construct design  
A full length form of the sp_1648 gene (residues 1 to 723) cloned into a pOPINF 
vector (Table 2.1) was kindly provided by Dr. Alan Riboldi Tunnicliffe, University 
of Glasgow. The cloning work was carried out at the Oxford Protein Production 
Facility, Oxford, using the In Fusion™ PCR Reaction system (Clontech).    
A full length form of the dr_2284 gene (nucleotide residues 1 to 720), cloned 
into a pET151/D TOPO vector (Table 2.1), was kindly provided by The 
Macromolecular Crystallography Group, ESRF, Grenoble, France.  
The nucleotide and putative amino acid sequence for both sp_1648 and dr_2284 
are annotated on the Comprehensive Microbial Resources database [6] which can 
be accessed on the web page of The J. Craig Venter Institute [7]. 
7.2.3 Recombinant expression and purification of SP_1648  
2  L plasmid DNA (sp_16481 in pOPINF) was used to transform B834(DE3) 
competent cells by the method described in Section 2.2.6. 5  L of the   Chapter 7 Other targets from D. radiodurans and S. pneumoniae   
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transformation reaction mixture gave an even spread of single colonies after 20 
hrs incubation at 37°C. 
Small scale expression trials were carried out in Overnight Express™ 
Autoinduction Media (Table 2.5) as described in Section 2.4.6. A 20 x dilution of 
starter culture was used to initiate cell growth in two 100 mL cultures which 
were incubated at 37°C for 4 hrs. One culture was then incubated at 25°C and 
the other at 22°C for 24 hrs at which OD600 values of 7.0 and 6.8 were reached. 
The respective cell pellets were then harvested by centrifugation. 
SDS PAGE analysis of 0.5 mL samples taken throughout expression trials showed 
similar results for both cultures incubated at 25 and 22°C. Steady expression in 
the insoluble cell fraction was observed 6 hrs after the temperature was 
decreased as shown by the increasing size of the bands at approximately 29 kDa 
(Figure 7.4a and b). In the soluble cell fractions (Figures 7.4c and d), less 
intense bands appeared 10 hrs after the temperature decrease, with those 
incubated at 25°C being more prominent. 
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Figure 7.4: SDS-PAGE analysis of insoluble (a and b) and soluble (c and d) cell extracts 
(normalised to OD600 = 5) taken at time points to assess expression levels of SP_1648 at 25 
° ° ° °C (a and c) and 22 ° ° ° °C (b and d). Overall results were similar for 25°C and 22°C samples. 
Analysis of the insoluble cell fractions (a) and (b) shows a steady increase in intensity of the band 
at approximately 30 kDa indicating good expression of SP_1648. Analysis of soluble cell extracts 
(c) and (d) shows some expression after 9-10 hrs, with more prominent bands for the 25°C sample.   Chapter 7 Other targets from D. radiodurans and S. pneumoniae   
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Although expression appeared greater in the insoluble cell fraction, it was 
decided to investigate purification of the soluble protein before attempting 
solubilisation and re folding of insoluble SP_1648. 
The cell pellets were re suspended in 30 mL of lysis buffer (Table 2.8) with the 
addition of 0.2 % Tween 20. The cells were lysed by French press and the soluble 
lysates were loaded on to separate 1 mL HisTrap HR columns as described in 
Sections 2.5.3 and 2.5.4. IMAC purification was carried out on the bench, with 
the lysate incubated on ice, using a peristaltic pump at a flow rate of 1 mL/min. 
The loaded column was flushed with 12 column volumes (CVs) of IMAC wash 
buffer (Table 2.8) followed by 10 CVs of IMAC elution buffer (Table 2.8).  
SDS PAGE analysis of the resulting elusions indicated that SP_1648 has no affinity 
for the column. Lanes 1 2 and 5 6 of Figure 7 5 show similar band intensities (at 
29 kDa) in the lysate and column flow through, demonstrating that the target 
protein had passed through the column without attaching to the matrix. This 
suggests that the 6xHis tag was unavailable for binding.   
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Figure 7.5: SDS-PAGE analysis of attempted IMAC purification and HRV-3C proteolysis of 
soluble SP_1648 expressed at 25 (lanes 1-3) and 22° ° ° °C (lanes 5-7). The equal intensity of the 29 
kDa band in the cell lysate and column flow through (for both samples) shows that SP_1648 has no 
affinity for the HisTrap HR column matrix suggesting that the 6xHis tag may be inaccessible. 
Attempted cleavage of the 6xHis tag using HRV-3C protease was unsuccessful, as shown by no 
decease in molecular weight (lanes 3 and 7) in comparison to the column flow through (lanes 2 and 
6). This supports the supposition that the 6xHis tag may not be available for binding to the column. 
To assess the accessibility of the 6xHis tag, the protein samples were subjected 
to HRV 3C proteolysis as described in Section 2.5.9. For both samples, 
comparison of SDS PAGE analysis (Figure 7.5) before and after the cleavage 
reaction showed no decrease in molecular weight (comparison of lanes 2 and 3 
for 25°C sample and Lanes 6 and 7 for 22°C). This suggests that the 6xHis tag   Chapter 7 Other targets from D. radiodurans and S. pneumoniae   
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was inaccessible for proteolysis and thus explains lack of affinity for the HisTrap 
HR column matrix. 
Future work planned for the SP_1648 project included purification of soluble 
protein by ion exchange and gel filtration in an attempt to overcome the 6xHis 
tag non affinity problems encountered with IMAC purification. Alternatively, 
experiments to solubilise, purify and refold insoluble SP_1648 could be 
attempted.  
7.2.4 Expression of DR_2284 
1  L plasmid DNA (dr_2284 in pET151/D TOPO) was used to transform BL21 
Star(DE3), Rosetta 2(DE3) and BL21 AI competent cells (genotypes given in Table 
2.6 of Chapter 2) by the method described in Section 2.2.6. 20  L of the 
transformation reaction mixture gave an even spread of single colonies after 20 
hrs incubation at 37°C for all three cell lines. 
Preliminary expression trials were performed for each cell line using LB media 
(Table 2.5) as described in Section 2.4.5. The OD600 values taken for overnight 
starter cultures were used to ensure equal cell densities were achieved on 
inoculation of each 100 mL expression culture. The three cultures were then 
incubated at 37°C until an OD600 of 0.6 was reached upon which the BL21 
Star(DE3) and Rosetta2 (DE3) cultures were induced with IPTG and the remaining 
BL21 AI culture, induced with 0.2 % arabinose. All three cultures were then 
incubated for a further 20 hrs at 22°C after which cells were harvested by 
centrifugation. Cell pellets of 2.7 and 3.8 g were gained for Rosetta2 (DE3) and 
BL21 Star(DE3), with the largest cell growth of 4.3 g obtained for BL21 AI. 
A western blot of 0.5 mL cell extracts taken after this incubation period (Figure 
7.6) showed no soluble expression of the target protein.    Chapter 7 Other targets from D. radiodurans and S. pneumoniae   
  - 146 -   
 
1      2     3    4      5     6        7     8  
Lane 1: Positive control 
Lane 2: MW marker 
Lane 3: BL21 Star(DE3) soluble fraction 
Lane 4: BL21 Star(DE3) insoluble fraction 
Lane 5: BL21 AI soluble fraction 
Lane 6: BL21 AI insoluble fraction 
Lane 7: Rosetta 2(DE3) soluble fraction 
Lane 8: Rosetta 2(DE3) insoluble fraction 
 
  kDa 
 
  62 
 
  49 
  38 
 
  28 
 
DR_2284 from BL21 AI cells   
Figure 7.6: Western blot analysis of soluble and insoluble cell extracts taken during 
expression trials for DR_2284. One faint band appeared in Lane 6, corresponding to insoluble 
expression by the BL21-AI cell line 
This is indicated by the absence of bands in lanes 3, 5 and 7 corresponding to the 
soluble fractions of BL21 Star(DE3), BL21 AI and Rosetta 2(DE3) cell lines. A faint 
band of approximately 30 kDa in lane 6 shows a small amount of insoluble target 
protein expression with the arabinose induced BL21 AI cells which, as reported 
earlier, showed the largest cell growth during expression trials.  
7.2.5 Future work for DR_2284 
As only a very small amount of insoluble DR_2284 was produced, it may be 
beneficial to continue expression trials with variables including temperature and 
induction conditions in an attempt to express either soluble protein or a greater 
yield of insoluble protein. Alternatively, expression of DR_2284 in BL21 AI cells 
could be scaled up for solubilisation experiments. 
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8  Discussion 
8.1 DR_1146 
The dr_1146 gen from D. radiodurans was successfully overexpressed in E. coli 
and purified to a level and yield that was conducive for crystallisation. However, 
despite significant diligence in the purification protocol initial crystal trials were 
unsuccessful; probably due to the inhomogeneity of the sample caused by 
proteolysis of the target protein. Ultimately, it was a combination of rational 
truncation, complete proteolysis and cofactor saturation that lead to the 
successful crystallisation of DR_1146 and although of poor quality, some 
diffraction was achieved. 
On a whole, this study reflects the importance and advantage of incorporating 
information gained from biophysical characterisation into the strategies 
employed for successful protein crystallisation. 
Through the use of biophysical techniques it was established that DR_1146 is a 
flavoprotein, with a capacity to associate with three flavin cofactors, namely 
riboflavin, FMN and FAD.  
Flavoproteins are ubiquitous proteins; known to indulge in a wide range of 
biological functions thanks to the extensive redox capacity of the bound flavin 
molecule [85]. Hence, identification as a flavoprotein, could associate DR_1146 
with a number of essential cellular roles including aerobic respiration [85], 
apoptosis [97, 98] and detoxification [99, 100]. It is likely that whatever system 
it belongs to, DR_1146 bound to flavin, will undergo either one or two electron 
transfers [85]. This could implicate the protein in the production of DNA and 
protein damaging ROS as a result of irradiation. In the future, further 
characterisation and elucidation of a 3 D structure may contribute to a greater 
understanding of how D. radiodurans is able to deal with such oxidising 
conditions in order to maintain viability and prevent cell death.  
It was initially thought that DR_1146 could be a flavoprotein based on a 
combination of information gained from bioinformatics and by the observation   Chapter 8 Discussion   
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that the target protein was yellow during expression and purification. Although 
analysis of the extracted yellow prosthetic group by ESI MS was inconclusive, UV 
and fluorescence spectra suggested that the yellow colour of DR_1146 was due 
to a flavin molecule bound to the protein. UV absorbance spectra of a DR_1146 
sample showed small absorbance maxima at 375 and 461 nm; a characteristic 
that is indicative of flavin binding proteins [94]. The presence of the two 
maxima in this spectral region suggests that the bound flavin cofactor is in an 
oxidised state on comparison with the spectrum of an oxidised glucose oxidase 
flavoprotein shown in Figure 1.5 of Section 1 [85, 108]. Fluorescence emission 
spectra (445 nm excitation) recorded for a sample of DR_1146 displaying a pale 
yellow colour showed a small fluorescence peak at approximately 520nm, which 
also suggests the presence of a ‘flavin like’ species.       
ITC and fluorescence experiments performed to quantify flavin binding, 
established that DR_1146 exhibits similar binding affinities for all three 
cofactors, riboflavin, FMN and FAD. KD values determined were all within the 
micromolar range (4 11  M), which, on comparison with other flavin binding 
proteins suggests moderate binding [187 191]. It is Interesting that DR_1146 is 
able to bind all three flavins with similar affinities, as many other flavoproteins 
show specificity for either FMN or FAD [85]. Results showing that DR_1146 binds 
riboflavin, FMN and FAD within the same micromolar range, suggest that the 
prosthetic –X group (hydrogen atom for riboflavin, phosphate group for FMN, 
adenine diphosphate for FAD) differentiates the three flavin structures but has 
no effect on binding affinity. This finding contrasts the case for the majority of 
flavoproteins where the prosthetic  X group of FMN or FAD is integral to binding. 
This also appears to be the case for the DR_1146 homologue, 2I02, a putative 
general stress protein (GOG3871) from Nostoc punctiforme PCC 73102 [81]. On 
analysis of possible interactions between 2I02 and FMN (using coordinates 
entered into the PDB) it appears that His61 and Lys62 are integral to FMN 
binding by forming hydrogen bonds with the oxygen atoms of the 5' phosphate 
moiety of the prosthetic group. As neither His61 nor Lys62 are conserved in the 
putative amino acid sequence of DR_1146, this may explain why there is no 
increase in binding affinity for FMN and FAD in comparison with riboflavin. Like 
DR_1146, the apo homologue, 2RE7 (a putative general stress protein (COG3871) 
from Psychrobacter arcticus [200]) is also lacking His 61 and Lys62, which may   Chapter 8 Discussion   
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explain why this protein was crystallised in the absence of FMN and could 
support efforts to crystallise an apo form of T_DR_1146.  
The binding stoichiometries established by ITC and FS confirm that DR_1146 
binds two molecules of FMN per dimer. This suggests that the FMN binding 
capacity of DR_1146, differs from that of the homologue 2I02. The structure of 
2I02 entered on the PDB, indicates that the dimeric protein has only one FMN 
molecule bound at the dimer interface. Only biophysical characterisation of 2I02 
and structure determination of T_DR_1146 will allow firm comparisons to be 
made. To date, any work carried out on 2I02 and 2RE7 remains unpublished.  
To complement observed flavin binding, DSC and CD experiments showed 
DR_1146 has higher thermal and chemical stability in the presence of an FMN 
cofactor. An addition of a two equimolar excess of FMN to a sample of DR_1146, 
resulted in a change of Tm from 51.2 to 60.2˚C, signifying a marked increase in 
thermal stability on FMN binding. CD spectra for the chemical unfolding of 
DR_1146 showed that the apo protein is 50 % unfolded at a GuHCl concentration 
of 0.9 M whereas a higher concentration of 1.4 M is needed to unfold 50 % of the 
holo protein. This demonstrated that DR_1146 is chemically more stable when 
complexed with FMN. By monitoring the FMN contributions in the visible near UV 
region of CD spectra, it became apparent that FMN completely dissociates from 
DR_1146 on addition of approximately 2M GuHCl. As for the majority of known 
flavoproteins, the observed ease of dissociation suggests that the flavin 
prosthetic group is non covalently bound. 
Overall changes in near and far CD spectra suggested that DR_1146 undergoes 
gross tertiary and secondary conformational changes in the presence of FMN. An 
increase in intensity in the near UV region suggests that the environments of the 
aromatic amino acids change as a result of FMN binding. Although speculative, it 
is possible that the aromatics are stacking with the isoalloxazine ring system 
making the structure of DR_1146 more rigid. Although many of the residues 
forming hydrophobic contacts in the structure of 2I02 are not conserved in 
T_DR_1146, their putative replacements are aromatic and hence may play a 
similar stabilising role.    Chapter 8 Discussion   
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Data obtained from the far UV spectral region was used to estimate secondary 
structure compositions. It was concluded that DR_1146 is a mixed alpha beta 
protein and that FMN binding causes significant changes in secondary structure. 
No notable difference could be seen as a result of 6xHis tag removal. 
Pronounced chemical shift changes in 
15N 
1H HSQC NMR spectra on addition of 
FMN confirms that global structural changes are induced by flavin binding. Such 
observations, connecting increased structural stability with FMN binding, 
reinforced efforts to crystallise the holo protein due to the strong relationship 
between sample stability and crystal growth. Observation of chemical shifts in 
15N 
1H HSQC NMR spectra on addition of FMN aliquots, also showed that a 2:1 
excess of FMN:protein was required to ensure that the binding sites of DR_1146 
were completely saturated with the cofactor. It was therefore decided that at 
least a two equimolar excess of FMN would be added to the protein during 
purification to ensure that all binding sites were saturated. It was thought that 
this would ensure that the protein samples used for crystallisation experiments 
were homogenous. 
In the absence of any known functional assay for DR_1146, CD 
spectrophotometry and NMR spectroscopy proved to be useful tools in 
establishing that DR_1146 is a highly folded and structured protein in vitro. The 
overall quality of preliminary non labelled and 
15N  
1H HSQC spectra obtained 
confirms that structure determination would be feasible by NMR. NMR spectra 
were a good indicator of quality, purity and homogeneity of DR_1146 
preparations and it was perhaps not coincidental that protein crystals were 
obtained from a sample purified to the high standards required for this 
technique.  
Initial expression trials performed on three different constructs harbouring the 
dr_1146 gene, showed that very high yields of soluble target protein were 
produced in BL21 Star(DE3) competent cells. The resulting 6xHis tagged protein 
was easy to purify, showing good affinity for Ni
2+ resin for IMAC. However, 
homogeneity proved very difficult to attain because of a combination of 
extensive N  and C terminal proteolysis (as determined by N terminal sequencing 
and mass spectrometry) and reversible binding of flavin cofactors. When all 
efforts of prevention or retardation of proteolysis failed, it was decided to   Chapter 8 Discussion   
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investigate the full extent of degradation by storing the protein for three months 
at 4°C. As discussed earlier, it was in fact a NMR spectrum that indicated that 
for a sample of DR_1146, degradation had ceased and that the protein was fully 
saturated with FMN. Subsequent purification by gel filtration isolated a stable 
dimeric fragment of 27.9 kDa from which small yellow crystals were formed. In 
total, a loss of approximately 18.6 kDa had occurred in comparison with the 
original full length protein expressed from pDEST17. Although poor, the resulting 
diffraction pattern indicated protein crystals rather than FMN or salt, and 
promising lunar patterns observed showed potential for optimisation.  
Progression of this work to attain diffraction quality sufficient for structure 
determination using crystallography would primarily include reproduction and 
optimisation of the DR_1146 crystals obtained. To enable these experiments a 
degraded sample would be prepared under identical conditions to those 
employed previously. Meanwhile, it would be beneficial to continue attempts to 
clone an N  and C  terminally truncated gene to encode a protein fragment of 
similar size for recombinant expression. It is thought that initial efforts to do 
this failed as a result of a problematic insertion of the gene into the pOPINF 
vector due to possible deactivation of the essential enzyme needed for the 
pOPINF InFusion cloning reaction. It may be productive to clone the fragment in 
to pET 15b by the method used successfully to clone full length and truncated 
versions of dr_1146 into pET 15b. 
It should be noted that DR_1146 crystals were obtained by following a 
minimalistic approach designed by Newman et al., (2005) [207] involving use of 
only two 96 condition crystal screens, PACT and JCSG+. The small, yellow 
crystals of degraded DR_1146 complexed with FMN were produced by sitting 
drop vapour diffusion, in condition B1 (0.1 M MIB buffer pH 4.0, 25 % w/v PEG 
1500) of the PACT screen. Success of this small scale strategy contrasted 
previous efforts to crystallise non homogenous samples using up to nine sets of 
expensive commercial reagents. This result suggests that it is the quality of the 
protein preparation that impacts on successful crystallisation rather than the 
number of conditions screened. However, the consistency, reliability and speed 
of automating the crystallisation process, whether large, medium or small, is 
unprecedented. Successful crystallisation described in this study, resulted from   Chapter 8 Discussion   
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trays compiled by volume dispensing robotics. In addition, crystal growth was 
identified and monitored using an automated Rhombix system.  
Perhaps high throughput screening would have been better applied to the 
cloning step of the protein production pipeline. It was bioinformatic software, 
namely the RONN Disorder Prediction Server [183 185] that guided the successful 
30 residue N terminal truncation of DR_1146. Perhaps, before starting expression 
trials it would have been beneficial to produce various truncated forms of the 
dr_1146 gene, based upon bioinformatic analysis such as disorder prediction and 
sequence alignment with other successfully crystallised homologues. Parallel 
expression trials could have then saved time in identifying a stable, homogenous 
protein fragment for crystallisation. 
In terms of construct design, a change in expression vector from pDEST17 (non 
cleavable 6xHis tag) to pET 15b, to incorporate a thrombin cleavable 6xHis tag, 
did not directly affect crystallisation of DR_1146. However, DSC experiments 
suggested that when in place, the 6xHis tag may obstruct protein refolding and 
thus may have a negative affect on protein stability. Interestingly, for the final 
DR_1146 sample that gave diffracting crystals, the 6xHis tag had been degraded 
away without intervention by thrombin proteolysis. This suggests that removal of 
the tag would be favourable for crystallisation. Hence for cloning of an N  and C 
terminal truncated construct, a vector with a cleavable 6xHis tag would be 
chosen.                                                                              
The elution profiles from gel filtration purifications performed on DR_1146, 
suggested that the protein exists as a dimer in solution. This information was 
used in conjunction with data obtained from SE AUC experiments to establish 
that the holo protein undergoes monomer dimer self association at a 
concentration of 7.67  M (KD
1 2). This value is consistent with the results 
obtained from SV experiments, which showed that self association was underway 
by a concentration of 19  M. The KD
1 2 obtained by SE AUC confirms that at 
concentrations below 7.67  M, holo T_DR_1146_clvd exists predominantly as a 
monomer and, above 7.67  M, mostly as a dimer. From this data, it can be 
postulated that if a crystal structure solution for DR_1146 were obtained, as a 
result of high concentration crystallisation experiments, its quaternary structure 
would be dimeric.    Chapter 8 Discussion   
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A global fit of SE data was used to determine an overall predicted molecular 
weight of 31,572 Da. It is thought that this value is lower than the dimeric 
molecular weight of 36875 Da (predicted using the ProtParam tool from the 
ExPASy server [171, 172]) because of two possible reasons; (a) that overcrowding 
of protein molecules in the experimental cell at high concentration caused non 
ideal migration of the dimer species or (b) that the lower than expected 
molecular weight reflected proteolysis of DR_1146 throughout the duration of 
the experiment. The most probable scenario would be the former explanation as 
experiments were conducted within two days to avoid significant proteolysis of 
DR_1146.    
Sedimentation coefficients (at zero concentration) of 1.72 and 2.87 S were 
established for the respective monomer and dimer conformations of holo 
DR_1146. This calculation was enabled by analysis of SV data obtained for a 
range of concentrations between 0.35 and 35 mg/mL. Comparison of 
experimental values with theoretical sedimentation coefficients (for a hydrated 
sphere of the same molar mass as the protein) suggest that both monomer and 
dimer have a slightly elongated shape in solution.  
Although this study presents extensive biophysical characterisation of DR_1146, 
its true biochemical and biological function remains unknown. Significant sharing 
of amino acid sequence homology suggests DR_1146 may be a pyridoxine 5'  
phosphate oxidase protein (PNPOx). 
The PNPOx family of enzymes have been shown to catalyse the terminal step in 
the de novo biosynthesis of pyridoxal 5' phosphate (PLP) in bacteria, by the FMN 
dependent oxidation of PNP (pyridoxine 5'  phosphate) or PMP (pyridoxamine 5'  
phosphate) [60, 62, 64, 65, 209, 210]. 
The reaction product, PLP has recently been identified as an effective 
antioxidant, [72 74] able to quench singlet oxygen radicals [75]. Hence, if 
DR_1146 was to be identified as a PNPOx enzyme, it could play a role in stress 
response through scavenging of ROS by its reaction product PLP. Such action may 
prevent the propagation of cell damaging hydroxyl radicals and hence contribute 
to the radioresistance of D. radiodurans.    Chapter 8 Discussion   
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This study presents several similarities in the physical and chemical properties of 
DR_1146 and characterised PNPOx enzymes, beginning with oligomeric state. Gel 
filtration elution profiles and AUC SV and SE analyses showed that DR_1146 
exists as a dimer at concentrations above 7.67  M. The crystal structures of 
bacterial, human, mammalian and yeast PNPOx enzymes are also homodimeric 
with molecular weights (22 29 kDa, monomeric) comparable with those 
determined for full length DR_1146 constructs [61]. Interestingly, like DR_1146, 
PNPOx preparations from E. coli have been shown to be susceptible to 
degradation by proteases as indicated by the presence of similar doublet bands 
on SDS PAGE gels [62]. Controlled trypsin digest resulted in doublet of 
approximately 14 kDa that was shown to retain only 1 % PNPOx catalytic activity.          
The main analogy between DR_1146 and PNPOx enzymes, highlighted by this 
study, is that the target protein has a capacity to bind FMN, the integral 
electron transfer vessel involved in the synthesis of PLP from PNP or PMP. E. coli 
PNPOx has been documented to associate with two molecules of FMN, which are 
bound in hydrophobic cavities approximately 19 Å apart, along the dimer 
interface [61, 62]. This correlates with data obtained from ITC experiments 
performed on DR_1146, which shows 1:1 binding stoichiometry, suggesting that 
the target protein also binds two molecules of FMN per dimer. However that is 
where the similarities end. 
The amino acid residues forming interactions between E. coli PNPOx and FMN 
occur in sequence motifs highly conserved within the PNPOx family [61]. Such 
motifs are not conserved in the amino acid sequence of DR_1146 suggesting that 
the capacity to bind FMN does not signify functional similarities.  
Characterised PNPOx enzymes show high specificity for FMN over riboflavin and 
FAD. Binding affinities for FMN are reported to be within the nanomolar range 
(KD = 11 30 nm) [105] whereas those for FAD and riboflavin are not quantified in 
the literature. FMN has also been shown to be significantly more efficient as a 
catalytic cofactor when complexed with PNPOx in comparison to the other two 
flavins [211] suggesting that binding to the single phosphate prosthetic group of 
FMN may be integral to enzymatic function. In contrast to PNPOx enzymes, 
DR_1146 displays weaker binding affinities for the three cofactors, and does not 
show any specificity for FMN over riboflavin and FAD. As the prosthetic   Chapter 8 Discussion   
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phosphate group of FMN does not appear to be important to binding in holo 
DR_1146, is most likely that it has no effect on catalysis and hence it is probable 
that DR_1146 does not share functional similarities with PNPOx.     
In addition to FMN binding, E. coli PNPOx has also been shown to tightly 
associate two molecules of PLP. The crystal structure shows one molecule of PLP 
to be situated within the active site of the enzyme, in close proximity to a FMN 
molecule, and the other to be stored 11 Å away in a non catalytic site [68]. PLP 
has been shown to be an effective inhibitor of the PNPOx catalysed reaction (Ki = 
1 8  M [60, 65]) when in complex with the enzyme. Quantifiably, PLP has a 
greater affinity for the active site of PNPOx than either PNP or PMP substrates 
which suggests that product inhibition is a mode of regulation for the reaction 
[60, 76]. In contrast, none of the residues reported to be involved in PLP binding 
by E. coli PNPOx [68], are conserved in the amino acid sequence of DR_1146 and 
ITC and FS results suggest that the protein is unable to bind PLP. Of course, it is 
possible that PLP is already bound to the protein and its presence has remained 
undetected due to spectral masking by bound FMN, as both cofactors absorb UV 
light in similar regions [63]. This could be confirmed or disproved by monitoring 
a decrease in absorbance at 388 nm after addition of 0.1 M NaOH to apo 
DR_1146 to remove any bound PLP [186]. However, to date, evidence from this 
study suggests that DR_1146 is unable to bind PLP which appears to be a key 
reaction controlling substrate; hence it is proposed that DR_1146 does not 
function as a PNPOx in D. radiodurans. This postulation could be either 
confirmed or dispelled by performing the enzymatic assay used to confirm 
function for E. coli PNPOx as described by Di Salvo et al. (1998) [62]. 
It has been shown that PNPOx from Arabidopsis thaliana has tolerance to 
oxidative stress by comparing growth of the wild type and a deletion mutant in 
the presence of H2O2. The deletion strain showed a distinct growth defect in 
comparison with the wild type [67]. Independent of whether DR_1146 is shown 
to be a PNPOx or not, this would be a good way of assessing its putative role in 
cellular response to oxidative stress. 
At this time, the function of DR_1146 is unknown, but is thought that it belongs 
to a family of PNPOX like proteins that are able to bind FMN. Some such 
structures, like 2I02, have been entered on the PBD but details and   Chapter 8 Discussion   
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characterisation remain unpublished. This study is the first to look at 
characterisation and crystallisation of this protein or indeed a PNPOx from D. 
radiodurans. 
8.2 Other Targets 
8.2.1 SP_1651 
Expression of the gene sp_1651 (psaD) has previously been shown to encode a 
thiol peroxidase in S. pneumoniae [139]. Its homologue from D. radiodurans, 
DR_2242 is a putative thiol specific antioxidant protein, belonging to the 
Thioredoxin like superfamily [6, 7]. The structure of DR_2242 has been solved by 
Dr. Dave Hall as part of the ESRF’s structural genomics project (unpublished).  
A full length form of the sp_1651 gene was recombinantly expressed from 
pOPINF in sufficient yields for crystallisation experiments. The resulting protein 
was purified to homogeneity by IMAC and gel filtration and the corresponding 
elution profile suggested that SP_1651 is dimeric in solution. After 6xHis tag 
removal by HRV 3C protease, the minimalistic approach to crystallisation 
proposed by Newman et al. (2005) [207] was followed. After 11 days, 
birefringent crystal bunches were formed in 0.1 M SPG Buffer pH 4.0, 25 % w/v 
PEG 1500. Diffraction data with a resolution limit of 3.2 Å was obtained. 
Although mosaic, the image represented a suitable crystal form for optimisation. 
Unfortunately, attempts to reproduce SP_1651 crystals failed and hence, 
structural comparisons with DR_2242 could not be made. 
8.2.2 DR_0463, A maltooligosyltrehalose synthase (MTSase) 
D. radiodurans encodes a large 108 kDa enzyme known as maltooligosyltrehalose 
synthase (MTSase) from the gene treY (locus name dr_0463). This protein, in 
conjunction with its partner protein maltooligosyltrehalose trehalohyrdolase 
(MTHase), catalyses the breakdown of maltooligosaccharide (or starch) into 
trehalose [122]. Trehalose has been shown to protect cell membranes and 
proteins against oxidative stress [123 128] and thus could facilitate the 
extraordinary protection and recovery displayed by D. radiodurans.    Chapter 8 Discussion   
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This study describes the expression of treY in BL21(DE3)pLysS cells to yield large 
amounts of DR_0463. Unfortunately the target protein was expressed in inclusion 
bodies, hence subsequent purification trials required solubilisation in 8 M urea. 
Once unfolded and extracted from the insoluble cell fraction, DR_0463 was 
purified by IMAC with buffers containing 8M urea to maintain a denatured state. 
This step also proved problematic, as the 6xHis tagged MTSase showed weak 
affinity for the Ni
2+ column matrix thus allowing non specific binding of 
contaminant E. coli proteins. In an attempt to increase binding affinity several 
protocol adaptations were made including, use of a higher volume column, 
reducing the imidazole concentration of the IMAC wash buffer, adding glycerol 
to ‘loosen’ the protein and finally, changing the denaturant to 6 M guanidine 
hydrochloride. None of these changes increased in the amount of DR_0463 
binding to the column. 
However, it was found that sequentially repeating IMAC purification up to three 
times with the same protein sample resulted in the removal of many unwanted 
impurities. Purity levels and yield deemed acceptable for further purification by 
gel filtration or ion exchange were obtained.  
In order to progress to crystal trials, the purification protocol described for 
DR_0463 would need to be optimised to produce sufficient yields of pure protein 
for crystal trials. In order to set up crystallisation experiments, DR_0463 would 
first have to be re folded into a structured aqueous state which could be 
assessed by CD or NMR.  
8.2.3 SP_1648 and DR_2284       
SP_1648 is an ATP binding protein that forms part of the Mn ABC transport 
system in S. pneumoniae [145] and its homologue from D. radiodurans, DR_2284 
is predicted to share a similar function [6, 7]. Although Mn is known play a 
pivotal role in preventing oxidative protein damage in D. radiodurans, research 
into the structure of the Mn ABC transport system remains undocumented.   
Expression of the sp_1648 pOPINF construct in B834(DE3) cells, using 
autoinduction media resulted in production of the corresponding protein 
predominantly in inclusion bodies. On attempting to purifying the small amount   Chapter 8 Discussion   
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of soluble protein produced by IMAC, it be came apparent that the 6xHis tag was 
inaccessible for binding to the Ni
2+ matrix of the HisTrap column. In order to 
obtain homogenous SP_1648 for crystal trials, alternative methods of purification 
(ion exchange or gel filtration) would need to be utilised in order to overcome 
6xHis tag non affinity problems. Alternatively, experiments to solubilise, purify 
and refold insoluble SP_1648 could be attempted.  
Small scale trials for the expression of the dr_2284 pET151/D TOPO construct in 
LB media, resulted in the production of only a very small amount of insoluble 
protein in arabinose induced BL21 AI cells. Future work would include 
continuation of expression trials, to investigate variables such as temperature 
and induction conditions in an attempt to express either soluble protein or a 
greater yield of insoluble protein.  
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9  Membrane proteins from D. radiodurans 
9.1 Working with membrane proteins 
To complement information gained from the structures determined for soluble 
proteins, the ESRF’s structural genomics project has been expanded to include 
investigation into the structure determination of target membrane proteins. The 
first 6 months of this CASE award was therefore spent at the protein laboratory 
in Grenoble to gain initial experience in cloning. 
Membrane proteins represent about 30 % of the human genome and are prime 
objectives in the pharmaceutical industry as drug targets. It has been estimated 
that more than half of all drugs currently on the market are directed against 
membrane proteins [212]. They also ubiquitous in their function, ranging from 
proteins involved in complex signalling pathways to basic small molecule 
transport proteins. However, the number of membrane protein structures 
determined to date (approximately 100) remains relatively low in comparison to 
the 30,000 soluble protein structures determined [213 215]. This can be 
attributed to the many difficulties faced during several stages: in cloning, 
expression, purification and finally in the crystallisation pipeline. Over the last 
decade there has been a modicum of success in membrane crystal structure 
determination, but there is still a shortfall between predicted expansion and 
reality of actual structures determined [216]. 
Membrane proteins are notoriously difficult to express by conventional 
expression routes, for example, the expressed product can be toxic to the E. coli 
host cells due to the preponderance of hydrophobic domains [217 219]. Hence, 
careful consideration is required when designing plasmid constructs and when 
selecting systems for recombinant expression. The cell lines C41 and C43, which 
are mutated versions of the E. coli strain BL21, have been shown to overcome 
much of the toxic effects associated with over expression of hydrophobic 
membrane proteins [217]
 and are therefore a good starting point for expression 
trials. Alternatively, successful expression has been reported using yeast, insect 
and mammalian systems [220]. However, these methodologies are more complex   Chapter 9 Membrane proteins from D. radiodurans   
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and expensive than the E. coli route, which has the advantage of being cheap 
and easy to use [221].  
When extracting and purifying a membrane protein after successful cloning and 
expression, it is essential to mimic the native lipid environment of the protein by 
use of a suitable detergent. The detergent functions to maintain the integrity of 
the hydrophobic domains and prevent the protein from collapsing [222]. 
Although there is a considerable number of detergents available the task of 
determining the most suitable for both protein solubilisation and stability can be 
difficult [223, 224]. The necessity to have detergent present in all purifying and 
crystallisation steps can also present a greater challenge for nucleation and 
crystal growth since this substantially increases the number of variables in the 
crystallisation experiment [213]. While there is a whole range of detergents with 
a large variety of critical micelle concentrations (CMC) that would suit most 
requirements it is still very much a trial and error approach to determine which 
detergent will solubilise and stabilise the extracted membrane protein. One 
other, not inconsiderable, factor is the expense involved, particularly with 
detergents with large CMCs. 
It is thought that structural genomic projects may be the way forward in the 
field of membrane protein structural biology [225]. This is due to the availability 
of high throughput methodologies employed at every step of the journey from 
clone to structure, which allows cloning, expression, solubilisation and 
purification experiments to be carried out in parallel [226]. Comparisons can be 
easily made between a large number and range of targets, allowing selection of 
potential candidates for crystallisation and structure determination.  
A range of membrane proteins from D. radiodurans had already been chosen for 
investigation and two of theses protein targets included in the project were an 
undecaprenyl diphosphatase (UDP) and a diacylglycerol kinase (DGKA). This 
study describes the molecular cloning of their corresponding genes bacA and 
dgkA to enable recombinant expression trials.    Chapter 9 Membrane proteins from D. radiodurans   
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9.2 Diacylglycerol kinase (DGKA) 
D. radiodurans is predicted to encode a 13.3 kDa diacylglycerol kinase from the 
384 bp gene, dgkA [6, 7]. The bioinformatics programs TMpred [227] and SOSUI 
[228] have been used to predict DGKA will have 3 transmembrane domains once 
expressed.   
While there is no current 3 D structure for E. coli DGKA, NMR assignments have 
been made [229] and the topology of the protein has been elucidated [230]. It 
exists as a 40 kDa homotrimer consisting of three 13 kDa subunits each with an 
active site. In turn each of the subunits has three transmembrane domains. 
Biochemically, DGKA has been shown to catalyse the conversion of diacylglycerol 
and MgATP to phosphatidic acid and MgADP.
 This pathway has served as a 
valuable model for membrane protein biocatalysis, stability, folding and 
misfolding studies [231], and thus presents DGKA as a potential drug target.  
9.3 Undecaprenyl diphosphatase (UDP)   
In D. radiodurans, undecaprenyl diphosphatase (locus name DR_0454) is a 29.7 
kDa protein predicted to be encoded from the 825 bp gene bacA [6, 7]. Using 
TMpred [227] and SOSUI [228] software, it is predicted that UDP will have 7 8 
transmembrane domains once expressed. UDP derived from E. coli has been 
expressed; extracted from the membrane using detergent and purified to near 
homogeneity in the histidine tagged form. Although, to date the crystal 
structure of UDP has not been solved for any organism, the E. coli enzyme has 
been characterised [232, 233]. It has been shown to function as a phosphatase, 
catalysing the dephosphorylation of undecaprenyl diphosphate to undecaprenyl 
phosphate, which is an important lipid carrier in the synthesis of peptoglycan 
and other cell wall components [232, 233].   
It has also been shown that the over expression of the E. coli bacA gene encodes 
a resistance to the polypeptide antibiotic bacitracin [234]. Further investigations 
into the mechanism employed by UDP to encode such antibiotic resistance could 
be of great interest from a clinical aspect.   Chapter 9 Membrane proteins from D. radiodurans   
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9.4 Materials and methods 
Full length forms of the bacA and dgkA genes were cloned into a pET 28b 
producing both N  and C terminally 6xHis tagged constructs. Primers were 
designed to incorporate BamHI/HindIII (N terminally tagged) and NcoI/XhoI (C 
terminally tagged) restriction enzymes and are depicted in Table 9.1. 
Primer   Sequence  Restriction site 
Full length bacA 
with N terminal 
6xHis tag 
Forward: 5' GAATTCGGATCCGATGGACTGGCTGTA 
TTCGCTG 3' 
 
Reverse: 5' GAATTCAAGCTTATCAGGCGAGCGAGC 
CGT TTTG 3'  
 
BamHI: 5' GˆGATCC 3' 
 
 
HindIII: 5' AˆAGCTT 3'  
Full length bacA 
with C terminal 
6xHis tag 
Forward: 5'GGATCCATGGACTGGCTGTATTCGCTG 3' 
 
Reverse: 5' AAGCTTCTCGAGGGCGAGCGAGCCGTTT 
TGC 3 
 
NcoI: 5' CˆCATGG 3' 
 
XhoI: 5' CˆTCGAG 3' 
Full length dgkA 
with N terminal 
6xHis tag 
Forward: 5' GAATTCGGATCCGGTGAACTCGGCG 
GGCTCGGC 3' 
 
Reverse: 5' GAATTCAAGCTTACTAGAGCCGACTCA 
CCCACGC 3' 
 
BamHI: 5' GˆGATCC 3' 
 
 
HindIII: 5' AˆAGCTT 3' 
 
Full length dgkA 
with C terminal 
6xHis tag 
Forward: 5'  GGATCCATGGGCGTGAACTCGGCGG 
GCTCGGC 3' 
 
Reverse: 5' AAGCTTCTCGAGGAGCCGACTCACCC 
ACGC 3' 
NcoI: 5' CˆCATGG 3' 
 
 
XhoI: 5' CˆTCGAG 3' 
Table 9.1: Oligonucleotide primers for amplification of bacA and dgkA genes. The restriction 
sites incorporated into each primer sequence are shown in bold. 
The required inserts were amplified from D. radiodurans R1 genomic DNA by PCR 
using the master mix and temperature cycles listed in Section 2.2.3. To establish 
the optimum concentration of genomic DNA required, several dilutions of the 
0.375 mg/mL stock were trialled (1:0, 1:10, 1:20 and 1:40 dilutions of genomic 
DNA with sterile deionised H2O). The resulting PCR products were digested with 
the corresponding restriction enzymes (BamHI and HindIII for N terminally 
tagged; NcoI and XhoI C terminally tagged) and separated by agarose gel 
electrophoresis (Sections 2.2.8 and 2.2.4). The required genes were extracted, 
purified and then ligated (Section 2.2.9) into linearised pET 28b (prepared with 
BamHI and HindIII or NcoI and XhoI restriction enzymes). Positive clones were 
identified by digestion with the restriction enzyme EcoR1 which is unable to 
cleave plasmid DNA if the insert has been ligated into place effectively.   Chapter 9 Membrane proteins from D. radiodurans   
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Positive clones were transformed in DH5 α cells for storage (Section 2.2.6) and 
into BL21(C41) and BL21(C43) expression strains for preliminary, small scale 
expression trials using 20 mL LB cultures with IPTG induction (Section 2.2.4). 
BL21(C41) and BL21(C43) cell lines were selected based on evidence that they 
function to overcome the toxic effects associated with over expression of 
hydrophobic membrane proteins [217]
 in order to give sufficient yields of protein 
for characterisation and crystallisation experiments.  
9.5 Results and discussion 
9.5.1 DGK 
Full length forms of the dgkA gene were cloned into pET 28b to produce N  and 
C terminally Hisx6 tagged constructs for expression trials. Critical to the success 
of this process was the optimisation of PCR conditions which produced a yield of 
amplified insert sufficient for ligation into pET 28b. The best amplification was 
achieved using 1:0 and 1:10 concentrations of genomic DNA; an annealing 
temperature of 55°C, and by using the additive, Q solution (Purchased from 
Qiagen, composition not available) to alleviate the possibility of mutation 
caused by high G C content (72.4 % for dgkA [6, 7]). Figure 9.1 illustrates the 
positive PCR of dgkA inserts (384 bp) which are shown as strong bands between 
500 bp and 250 bp marker bands. 
 
 DNA dilutions    1:0    1:10    1:20  1:40      M    1:0    1:10   1:20  1:40 
  N terminal 6xHis tag    C terminal 6xHis tag 
dgkA 384 bp 
   
Figure 9.1: Agarose gel showing successful PCR of dgkA from 1:0, 1:10, 1:20 and 1:40 
dilutions of genomic DNA (stock concentration 0.375 mg/mL). Primers designed to produce N-
terminal and C-terminal 6xHis tagged constructs were used for the PCR reaction. PCR products 
are shown by strong single 384 bp bands between 500 and 250 bp marker bands.   Chapter 9 Membrane proteins from D. radiodurans   
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Successful ligation into linearised pET 28b was achieved for almost all of the 
dgkA inserts (both N  and C  terminally tagged) as shown by ineffective digestion 
with EcoR1 (Figure 9.2). Positive clones are depicted by un cleaved plasmid 
which appears on an agarose gel as three close bands; nicked (top), open coiled 
(middle) and supercoiled (bottom) DNA. Several positive clones were selected 
for sequencing which confirmed the presence of the dgkA insert. The single 
negative clone obtained (marked X in Figure 9.2) was excluded from further 
studies. 
  N terminal 6xHis tag 
 X 
C terminal 6xHis tag 
 
 
  C terminal 6xHis tag 
Nicked DNA 
Open colied DNA 
Supercolied DNA (faint) 
   
Figure 9.2: Agarose gel imaging dgkA-pET-28b plasmids after digestion with EcoRI. Positive 
clones can be identified by three close bands; nicked (top), open coiled (middle) and supercoiled 
(bottom) DNA. This pattern indicates that plasmid DNA was not cleaved by EcoR1, signifying that 
the insert has been ligated into place. The single negative clone obtained is marked X and was 
excluded from further studies. 
Research into the expression of dgkA from pET 28b was continued at the ESRF, 
Grenoble by Dr. Rana Roy and Dr. Dave Hall.     
9.5.2 UDP 
Full length forms of the bacA gene were successfully cloned into pET 28b to 
enable possible expression of N  and C terminally Hisx6 tagged protein. The best 
PCR amplification was achieved by using 1:10, 1:20 and 1:40 dilution of genomic 
DNA and an annealing temperature of 58°C. Positive PCR products are imaged as 
strong 825 bp fragments in Lanes 2 4 and 7 9 of Figure 9.3. No amplification   Chapter 9 Membrane proteins from D. radiodurans   
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occurred from undiluted genomic DNA at 0.375 mg/mL (Figure 9.3, Lanes 1 and 
6). 
 
DNA dilutions     1:0    1:10    1:20    1:40      M    1:0    1:10    1:20   1:40 
N terminal 6xHis tag  C terminal 6xHis tag 
  bacA 825 bp 
   
Figure 9.3: Agarose gel showing successful PCR of bacA from 1:10, 1:20 and 1:40 dilutions 
of genomic DNA (0.375 mg/mL). PCR products are shown by strong 825 bp bands between 1000 
bp and 500 bp marker bands. The absence of bands in lanes 1 and 6 signify that no amplification 
occurred from undiluted genomic DNA. 
The insert amplified from the 1:40 dilution of genomic DNA was selected for 
ligation into linearised pET 28b. Successful incorporation of the bacA gene into 
N terminally tagged pET 28b was confirmed by release of the 825 bp insert from 
the 5.5 kbp vector on digestion with XhoI and NcoI restriction enzymes (Figure 
9.4).  
 
       X                                                      X           X            X 
N terminal 6xHis tag 
pET28b  
5.5 kbp 
 bacA  
825 bp 
   
Figure 9.4: Agarose gel showing release of the 825 bp from the 5.5 kbp vector on digestion 
of bacA-pET28b with XhoI and NcoI restriction enzymes. Release of the insert is indicative of a 
positive clone. Negative clones (marked by X) are indicated by no evidence of insert release and 
were excluded from further studies. 
clones of bacA in pET 28b with residues included to encode an N terminal 6xHis 
tag. Positive clones were also obtained for the C terminal tagged construct as 
shown by no disruption to plasmid DNA on digestion with EcoR1 (Figure 9.5).    Chapter 9 Membrane proteins from D. radiodurans   
  - 166 -   
 
Nicked DNA 
  Open coiled DNA 
Supercoiled DNA 
C terminal 6xHis tag 
   
Figure 9.5: Agarose gel imaging bacA-pET-28b (C-terminal 6xHis tagged) plasmids after 
digestion with EcoRI. All of the clones are positive as shown by three close bands; nicked (top), 
open coiled (middle) and supercoiled (bottom) DNA. This pattern indicates that plasmid DNA was 
not cleaved by EcoR1, signifying that the insert has been ligated into place.  
Several positive clones for both N  and C  terminal tagged bacA were selected 
for preliminary small scale expression trials using BL21(C41) and BL21(C43) cell 
lines. 20 mL LB cultures were incubated until an OD600 of 0.6 was reached, and 
then were induced with 1 mM IPTG. They were then incubated at 16, 20 and 
37°C, with shaking at 200 rpm, for 20 hrs. 1 mL samples, taken every hour 
during cell growth were analysed by SDS PAGE which showed no trace of bacA 
expression. This negative result was confirmed by western blot.      
9.6 Summary and conclusions 
The genes dgkA and bacA are thought to encode the membrane proteins, DGK 
and UDP in D. radiodurans. In order to investigate the enzymes as potential drug 
targets, the genes have been cloned into pET 28b for recombinant expression in 
E. coli strains. This study describes the successful PCR, restriction enzyme 
digestion, purification and ligation of the full length target genes into the 
chosen expression vector. Primers were designed to produce two different 
constructs for each gene, which, on over expression would encode target protein 
with either an N  or a C terminal 6xHis tag.  
Although preliminary expression trials for bacA from pET 28b were unsuccessful, 
there are still avenues to explore in an effort to gain recombinant expression. 
For example, one could vary the IPTG concentration used for inducing protein 
production. Furthermore, different induction methods could be employed, such 
as autoinduction systems or arabinose induction, which is required when using 
the slow promoting strain BL21(AI). Alternatively, a change in the constituents 
of growth media could aid over expression. As the bacA gene consists of many   Chapter 9 Membrane proteins from D. radiodurans   
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rare codons which are not recognised by some typical expression strains, cell 
lines like Rosetta 2(DE3), which can alleviate such codon bias, could be included 
in expression trials [149, 152, 163, 164].  
Ultimately, the cloning of the D. radiodurans genes bacA and dgkA has made an 
important contribution to the extension of the ESRF’s structural genomics 
project to include the study of membrane proteins. Investigation into the 
expression of the cloned genes has been continued at the ESRF, by Dr. Rana Roy 
and Dr. Dave Hall. Access to high throughput methodologies and the synchrotron 
radiation source at the ESRF may contribute immensely to the future of this 
project 
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Appendix 1 – Sequences of full length DR_1146 
 
DNA sequence 
ATGTGTGGTCTGGCCCATTCTCCGGATATGAGCGACAACAAGAACGCCGGACAAAGCAGT 
GACAGCCAGGGCAACGGTGCGCCGCAGATGAGCCGTGACGAAGCCGTGAAGACGGTCGCT 
GGGCTGGTCAAGGGCATCAAATTCGCCATGCTGGTGTCGGTCAACGACGCGGGCCACATC 
CACTCGCGCCCCATGACCACCCAGGAAACCGAGTTCGACGGCGATATCTGGTTTATCGGC 
GCCAAGGACAGCGAGGTCGTTCACGATGTCCGCAGCCGCCCCCAGGTCAACGTGAGCTAC 
GCCGACACCGGCAGCAACAACTACGTGAGCGTGCACGGCACCGCCGAACTGATCGAAGAT 
CGCGCCAAACTCGACGAACTGTGGAGCGACATGTACAACATGTACTTCGAGGGCGGCAAG 
GAAGACCCGAATGTCCAGCTCATCAAGATCAACGCCGAGGGCGCCGAATACTGGGAGAGC 
GGCGGCAAGGTGCGGACCCTCTTCGCCTTCGCCAAGAACCTGATTCCTGGCCAGCGCGCC 
GACGCGAGCGAGCTGGGCAAGAACGACACGGTTAATCTCTAA 
 
Amino acid sequence 
       10                   20                   30                 40                 50                  60  
MCGLAHSPDM  SDNKNAGQSS  DSQGNGAPQM  SRDEAVKTVA  GLVKGIKFAM  LVSVNDAGHI  
 
                   70                80                  90                 100                 110               120  
HSRPMTTQET  EFDGDIWFIG  AKDSEVVHDV  RSRPQVNVSY  ADTGSNNYVS  VHGTAELIED 
  
                  130                 140              150                 160                170               180  
RAKLDELWSD  MYNMYFEGGK  EDPNVQLIKI  NAEGAEYWES  GGKVRTLFAF  AKNLIPGQRA 
  
              190  
DASELGKNDT  VNL       
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Appendix 2   Sequences of truncated DR_1146 
 
DNA sequence 
ATGAGCCGTGACGAAGCCGTGAAGACGGTCGCTGGGCTGGTCAAGGGCATCAAATTCGCCAT 
 
GCTGGTGTCGGTCAACGACGCGGGCCACATCCACTCGCGCCCCATGACCACCCAGGAAACCG 
 
AGTTCGACGGCGATATCTGGTTTATCGGCGCCAAGGACAGCGAGGTCGTTCACGATGTCCGC 
 
AGCCGCCCCCAGGTCAACGTGAGCTACGCCGACACCGGCAGCAACAACTACGTGAGCGTGCA 
 
CGGCACCGCCGAACTGATCGAAGATCGCGCCAAACTCGACGAACTGTGGAGCGACATGTACA 
 
ACATGTACTTCGAGGGCGGCAAGGAAGACCCGAATGTCCAGCTCATCAAGATCAACGCCGAG 
 
GGCGCCGAATACTGGGAGAGCGGCGGCAAGGTGCGGACCCTCTTCGCCTTCGCCAAGAACC 
 
TGATTCCTGGCCAGCGCGCCGACGCGAGCGAGCTGGGCAAGAACGACACGGTTAATCTCTAA 
 
 
Amino acid sequence  
                 11                   21                  31                  41                 51                 61  
M  SRDEAVKTVA  GLVKGIKFAM  LVSVNDAGHI  HSRPMTTQET  EFDGDIWFIG  AKDSEVVHDV   
 
                  71                  81                 91                 101                  111      121 
RSRPQVNVSY  ADTGSNNYVS  VHGTAELIED  RAKLDELWSD  MYNMYFEGGK  EDPNVQLIKI   
 
                  131                141                151                161 
NAEGAEYWES  GGKVRTLFAF  AKNLIPGQRA  DASELGKNDT  VNL  
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